<SEC-DOCUMENT>0001193125-20-018469.txt : 20200129
<SEC-HEADER>0001193125-20-018469.hdr.sgml : 20200129
<ACCEPTANCE-DATETIME>20200129163759
ACCESSION NUMBER:		0001193125-20-018469
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20200129
DATE AS OF CHANGE:		20200129

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DBV Technologies S.A.
		CENTRAL INDEX KEY:			0001613780
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-233651
		FILM NUMBER:		20558664

	BUSINESS ADDRESS:	
		STREET 1:		177-181 AVENUE PIERRE BROSSOLETTE
		CITY:			MONTROUGE
		STATE:			I0
		ZIP:			92120
		BUSINESS PHONE:		33(0)155427878

	MAIL ADDRESS:	
		STREET 1:		177-181 AVENUE PIERRE BROSSOLETTE
		CITY:			MONTROUGE
		STATE:			I0
		ZIP:			92120
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d841346d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:71%; font-size:10pt; font-family:Times New Roman"><B>Filed Pursuant to Rule 424(b)(5)<BR>Registration No. 333-233651 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information contained in this preliminary prospectus
supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where such
offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>SUBJECT TO COMPLETION, DATED JANUARY 29, 2020 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><B>(To prospectus dated
October&nbsp;1, 2019) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>$125,000,000 Ordinary Shares </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>(including in the form of American Depositary Shares) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g841346g31k50.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">We are offering $125,000,000 of our ordinary shares (including in the form of American Depositary Shares, or ADSs) in a global offering. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">We are offering ordinary shares in the form of ADSs in the United States, Canada and certain countries outside of Europe. The ADSs may be evidenced by
American Depositary Receipts, or ADRs, and each ADS represents the right to receive <FONT STYLE="white-space:nowrap">one-half</FONT> of one ordinary share. We are offering ordinary shares in Europe (including France) exclusively addressed to
&#147;qualified investors&#148; (as this term is defined under EU Regulation n&deg;2017/1129), referred to herein as the European offering. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">We have
agreed to issue, at the option of the underwriters, within 30 days from the date of this prospectus, up to an aggregate of $18,750,000 of our ordinary shares in the form of ADSs to be sold to the several underwriters at the applicable offering
price. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">The total number of ordinary shares in the U.S. offering and European offering is subject to reallocation between them. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">Our ADSs are listed on the Nasdaq Global Select Market under the symbol &#147;DBVT.&#148; On January 28, 2020, the last reported sale price of the ADSs on
Nasdaq was $11.20 per ADS. Our ordinary shares are traded on Euronext Paris under the symbol &#147;DBV.&#148; On January 28, 2020, the last reported sale price of the ordinary shares on Euronext Paris was &#128;20.40 per share, equivalent to a price
of $11.23 per ADS, assuming an exchange rate of $1.1005 per euro. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10.5pt; font-family:Times New Roman"><B>Investing in our ordinary
shares and ADSs involves a high degree of risk. You should review carefully the risks and uncertainties referenced under the heading &#147;<A HREF="#suptoc841346_6">Risk Factors</A>&#148; on page S-8 of this prospectus supplement as well as those
contained in the other documents that are incorporated by reference into this prospectus supplement or the accompanying prospectus. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR>Ordinary<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR>ADS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Public Offering Price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Underwriting Commission<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Proceeds to DBV Technologies (before expenses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="left">Total gross proceeds from the global offering, including the European offering, are
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (assuming an exchange rate of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per Euro). Such proceeds less underwriting commissions are $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="left">We refer you to &#147;Underwriters&#148; section of this prospectus supplement for additional information
regarding underwriting compensation and estimated offering expenses. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman"><B>Neither the United States Securities and Exchange Commission
nor any U.S. state securities commission has approved or disapproved of these securities or passed upon the adequacy or the accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal
offense. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">The underwriters expect to deliver the ordinary shares and ADSs to purchasers on or about February&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><I>Joint-Book Running Managers </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top" NOWRAP><B>Goldman&nbsp;Sachs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"><B>Citigroup</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc841346_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc841346_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-iv</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc841346_3">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc841346_4">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc841346_5">SUMMARY CONSOLIDATED FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc841346_6">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc841346_7">MARKET INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc841346_8">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc841346_9">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc841346_10">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc841346_11">DESCRIPTION OF SHARE CAPITAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc841346_12">DESCRIPTION OF AMERICAN DEPOSITARY SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc841346_13">MATERIAL INCOME TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc841346_14">UNDERWRITERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc841346_15">MATERIAL CHANGES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc841346_16">ENFORCEMENT OF CIVIL LIABILITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc841346_17">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc841346_18">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc841346_19">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc841346_20">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suptoc841346_21">EXPENSES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_3">ABOUT DBV TECHNOLOGIES S.A.</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_6">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_7">DESCRIPTION OF SHARE CAPITAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_8">DESCRIPTION OF AMERICAN DEPOSITARY SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_9">LIMITATIONS AFFECTING SHAREHOLDERS OF A FRENCH COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_10">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_11">ENFORCEMENT OF CIVIL LIABILITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_12">TAXATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_13">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_14">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_15">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_16">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc841346_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus are part of an effective &#147;shelf&#148; registration statement that we filed with the U.S.
Securities and Exchange Commission, or the SEC, on September&nbsp;6, 2019. This prospectus supplement provides you with the specific details regarding this offering. The accompanying prospectus provides you with more general information, some of
which does not apply to this offering. You should rely only on the information contained or incorporated by reference in this prospectus supplement, the accompanying prospectus or any free writing prospectus that we have authorized for use in
connection with this offering. To the extent information in this prospectus supplement is inconsistent with the accompanying prospectus or any of the documents incorporated by reference into this prospectus supplement and the accompanying
prospectus, you should rely on this prospectus supplement. You should read and consider the information in both this prospectus supplement and the accompanying prospectus together with the additional information described under the headings
&#147;Where You Can Find More Information&#148; and &#147;Information Incorporated by Reference.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated or the context
otherwise requires, references in this prospectus supplement to &#147;DBV,&#148; &#147;the company,&#148; &#147;our company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to DBV Technologies S.A. and our consolidated subsidiary.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus contain summaries of certain provisions contained in some of the documents described herein,
but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be
incorporated by reference as exhibits to the registration statement of which this prospectus supplement is a part, and you may obtain copies of those documents as described below under the heading &#147;Where You Can Find More Information.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither we, nor any agent, underwriter or dealer has authorized any person to give any information or to make any representation other than those
contained or incorporated by reference in this prospectus supplement, the accompanying prospectus or any related free writing prospectus prepared by or on behalf of us or to which we have referred you. This prospectus supplement, the accompanying
prospectus or any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus supplement, the accompanying
prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. If
anyone provides you with different or inconsistent information, you should not rely on it. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information contained in this prospectus supplement, the accompanying prospectus and any accompanying free writing prospectus is accurate only as of
the date of this prospectus supplement, the accompanying prospectus and any such accompanying free writing prospectus, regardless of the time of delivery of this prospectus supplement, the accompanying prospectus, any such accompanying free writing
prospectus or of any sale of our ordinary shares or ADSs. You should not assume that the information contained in this prospectus supplement, the accompanying prospectus or any related free writing prospectus is accurate on any date subsequent to
the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus supplement, the
accompanying prospectus or any related free writing prospectus is delivered, or ordinary shares or ADSs are sold, on a later date. Our business, financial condition, results of operations and prospects may have changed since those dates. You should
read this prospectus supplement, the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with
this offering, in their entirety before making an investment decision. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For investors outside the United States: We have not done anything that would permit the offering or
possession or distribution of this prospectus supplement and the accompanying prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of
this prospectus supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities described herein and the distribution of this prospectus supplement and the
accompanying prospectus outside the United States. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are incorporated in France, and a majority of our outstanding securities are owned by U.S.
residents. Under the rules of the SEC, we are currently eligible for treatment as a &#147;foreign private issuer.&#148; As a foreign private issuer, we will not be required to file periodic reports and financial statements with the SEC as frequently
or as promptly as domestic registrants whose securities are registered under the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Presentation of Financial Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
maintain our books and records in euros and report under International Financial Reporting Standards as issued by the International Accounting Standards Board. None of the consolidated financial statements incorporated by reference into this
prospectus supplement were prepared in accordance with generally accepted accounting principles in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our financial statements are
presented in euros. All references in this prospectus supplement and the accompanying prospectus to &#147;$,&#148; &#147;US$,&#148; &#147;U.S.$,&#148; &#147;U.S. dollars,&#148; &#147;dollars&#148; and &#147;USD&#148; mean U.S. dollars and all
references to &#147;&#128;&#148; and &#147;euros,&#148; mean euros, unless otherwise noted. Throughout this prospectus supplement and the accompanying prospectus, references to ADSs mean ADSs or ordinary shares represented by ADSs, as the case may
be. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Trademarks </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We own various
trademark registrations and applications, and unregistered trademarks and servicemarks, including &#147;Viaskin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>,&#148;
&#147;EPIT<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>&#148; &#147;DBV Technologies<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>,&#148; &#147;Abyldis<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>&#148; and
our corporate logo. All other trademarks or trade names referred to in this prospectus supplement and the accompanying prospectus are the property of their respective owners. Trade names, trademarks and service marks of other companies appearing in
this prospectus supplement and the accompanying prospectus are the property of their respective holders. Solely for convenience, the trademarks and trade names in this prospectus supplement and the accompanying prospectus may be referred to without
the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the
fullest extent under applicable law, their rights thereto. We do not intend to use or display other companies&#146; trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-iii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc841346_2"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus and the information incorporated by reference in this prospectus supplement and the accompanying
prospectus contain forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that
involve a number of risks and uncertainties. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, these
forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All statements other than present and historical facts and conditions contained in this prospectus supplement, the accompanying prospectus and the information
incorporated by reference in this prospectus supplement and the accompanying prospectus including statements regarding our future results of operations and financial positions, business strategy, plans and our objectives for future operations, are
forward-looking statements. The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;can,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;is designed to,&#148; &#147;may,&#148; &#147;might,&#148;
&#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;objective,&#148; &#147;should,&#148; or the negative of these and similar expressions identify forward-looking statements. Forward-looking statements include, but are not limited
to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory filings and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to continue as a going concern; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress and results of our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies
and clinical trials, and our research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance product candidates into, and successfully complete, clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance our Viaskin manufacturing capabilities, manufacture clinical and commercial supplies of
our product candidates and comply with regulatory requirements related to the manufacturing of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop sales and marketing capabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commercialization of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our business model, strategic plans for our business, product candidates and technology;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our
product candidates and technology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates of our expenses, future revenues, capital requirements and our needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential benefits of strategic collaboration agreements and our ability to enter into strategic
arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain and establish collaborations or obtain additional grant funding; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of our product candidates, if approved by regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments relating to our competitors and our industry, including competing therapies; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties, including those listed under the caption &#147;Risk Factors&#148; in this
prospectus supplement, the accompanying prospectus and the information incorporated by reference in this prospectus supplement and the accompanying prospectus. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-iv </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of these factors, we cannot assure you that the forward-looking statements in this prospectus
supplement, the accompanying prospectus and in the information incorporated by reference in this prospectus supplement and the accompanying prospectus will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate,
the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and
plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read this prospectus supplement, the accompanying prospectus and the information incorporated by reference in this prospectus supplement and the
accompanying prospectus completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus and the information incorporated by reference in this prospectus supplement and the accompanying
prospectus may contain market data and industry forecasts that were obtained from industry publications. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. While we believe
the market position, market opportunity and market size information included in this prospectus supplement, the accompanying prospectus and in the information incorporated by reference in this prospectus supplement and the accompanying prospectus is
generally reliable, such information is inherently imprecise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-v </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc841346_3"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights certain information about us, this offering and selected information contained elsewhere in or incorporated by reference in this
prospectus supplement. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our securities. For a more complete understanding of our company and this offering, we
encourage you to read and consider carefully the more detailed information in this prospectus supplement and the accompanying prospectus, including the information referred to under the heading &#147;Risk Factors&#148; in this prospectus supplement
beginning on page <FONT STYLE="white-space:nowrap">S-8,</FONT> the information incorporated by reference in this prospectus supplement and the accompanying prospectus, and the information included in any free writing prospectus that we have
authorized for use in connection with this offering before making an investment decision. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DBV Technologies S.A. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage specialty
biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. Our therapeutic approach is based on epicutaneous immunotherapy, or EPIT, our proprietary method of delivering
biologically active compounds to the immune system through intact skin using Viaskin. We have generated significant data demonstrating that Viaskin&#146;s mechanism of action is novel and differentiated as it targets specific antigen-presenting
immune cells in the skin, called Langerhans cells, which capture the antigen and migrate to the lymph node in order to activate the immune system without allowing passage of the antigen into the bloodstream, minimizing systemic exposure in the body.
We are advancing this unique technology to address areas of unmet medical need, including in patients suffering from food allergies, for whom safety is paramount as the introduction of the offending allergen into their bloodstream can cause severe
or life-threatening allergic reactions, such as anaphylactic shock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our proprietary platform is based on our epicutaneous Viaskin patch. We have designed
and developed this technology internally, for which we have scalable manufacturing capabilities. Viaskin is an electrostatic patch, which may offer a convenient, self-administered, <FONT STYLE="white-space:nowrap">non-invasive</FONT> immunotherapy
to patients. Once applied on intact skin, Viaskin forms a condensation chamber, which hydrates the skin and solubilizes the antigen allowing it to penetrate the epidermis, where it is captured by Langerhans cells. Based on numerous scientific
publications and our own research, we believe this unique mechanism of action has a favorable safety profile and that it generates a strong immune response that results in allergen desensitization. Our epicutaneous immunotherapy method allows us to
develop product candidates addressing food allergies, as well as other unmet medical needs. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our most advanced product candidates: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g841346g15e30.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>US FDA Breakthrough Therapy and Fast Track designation in children </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>**</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>US FDA Fast Track designation in pediatric patients two and older </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are focused on becoming the leader in discovering, developing and commercializing food allergies products. Our pipeline development strategy is based on
leveraging Viaskin&#146;s scientific profile while taking into consideration a combination of target market characteristics, which include allergen prevalence, persistence and severity. We select our target product candidates with the aim to address
allergies that have high unmet medical needs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, we had cash and cash equivalents of &#128;172.0&nbsp;million, or $193.1&nbsp;million (based on the noon buying rate of the
Federal Reserve Bank of New York of &#128;1.00 to $1.1227 on December&nbsp;31, 2019). The information above is based on preliminary unaudited information and management estimates for the year ended December&nbsp;31, 2019, is not a comprehensive
statement of our financial results, and is subject to completion of our financial closing procedures. Our independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of
assurance with respect to, this preliminary estimate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2020, we announced the appointment of Ramzi Benamar as our Chief Financial Officer,
effective January&nbsp;6, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also in January&nbsp;2020, we announced positive topline results of the three-year, open-label extension of our Phase III
PEPITES trial, or PEOPLE trial, evaluating the long-term efficacy and safety of investigational Viaskin Peanut in peanut-allergic children ages 4 to 11 years.&nbsp;The results demonstrated long-term clinical benefit as shown by an increase in
eliciting dose, or ED, which may decrease the chance of reacting to an accidental peanut exposure. After three years, we observed that 75.9% (107/141) of patients had increased their ED from baseline, and 51.8% (73/141) of patients reached an ED of
at least 1,000 mg peanut protein by year three. The safety profile of Viaskin Peanut was consistent with that observed in the clinical program to date in over 1,000 patients. During the PEOPLE trial, the most common adverse events were mild to
moderate skin reactions localized to the </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
administration site, and there was no epinephrine use deemed related to treatment. No treatment related serious adverse events were reported. One patient experienced one case of mild anaphylaxis
that was determined by the investigator to be possibly related to treatment and resolved without treatment. Treatment compliance remained high throughout the study at a mean of 98% over three years of treatment. Low discontinuations due to adverse
events were observed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
legal and commercial name is DBV Technologies S.A. We were incorporated as a soci&eacute;t&eacute; par actions simplifi&eacute;e (S.A.S.) under the laws of the French Republic on March&nbsp;29, 2002 for a period of 99 years and subsequently
converted on March&nbsp;13, 2003 into a soci&eacute;t&eacute; anonyme. We are registered at the Nanterre Commerce and Companies Register under the number 441 772 522. Our principal executive offices are located at
<FONT STYLE="white-space:nowrap">177-181</FONT> Avenue Pierre Brossolette, 92120 Montrouge, France, and our telephone number is +33 1 55 42 78 78. Our agent for service of process in the United States is Cogency Global Inc. We maintain a corporate
website at <FONT STYLE="white-space:nowrap">www.dbv-technologies.com.</FONT> Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus supplement and the accompanying prospectus. We have
included our website address in this prospectus supplement and the accompanying prospectus solely as an inactive textual reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ordinary shares
in the form of ADSs have been listed on the Nasdaq Global Select Market under the symbol &#147;DBVT&#148; since October&nbsp;22, 2014. Our ordinary shares have been trading on Euronext Paris under the symbol &#147;DBV&#148; since March&nbsp;28,
2012. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc841346_4"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Global offering </P></TD>
<TD>$125,000,000 of our ordinary shares offered by us, including ordinary shares represented by American depositary shares, or ADSs, in the U.S. offering and the European offering. The total number of ordinary shares in the U.S. offering and
European offering is subject to reallocation between these offerings as permitted under the applicable laws and regulations. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">U.S. offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares in the form of ADSs offered in the United States, Canada and certain countries outside of Europe. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">European offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares offered in Europe (including France). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Ordinary shares to be outstanding after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares (including in the form of ADSs). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional ordinary shares in this offering </P></TD>
<TD>We have agreed to issue, at the option of the underwriters, within 30 days after the date of the underwriting agreement, up to $18,750,000 of our additional ordinary shares in the form of ADSs. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">American Depositary Shares </P></TD>
<TD>Each ADS represents <FONT STYLE="white-space:nowrap">one-half</FONT> of one ordinary share, nominal value &#128;0.10 per share. You will have the rights of an ADS holder as provided in the deposit agreement among us, the depositary and all
holders and beneficial owners of ADSs issued thereunder. To better understand the terms of the ADSs, you should carefully read the section in this prospectus supplement and the accompanying prospectus titled &#147;Description of American Depositary
Shares.&#148; We also encourage you to read the deposit agreement incorporated by reference into the registration statement of which this prospectus supplement forms a part. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Depositary </P></TD>
<TD>Citibank, N.A. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, primarily to prepare for the commercialization of Viaskin Peanut, including marketing efforts related to launch in the second
half of 2020, if approved, as well as to advance the discovery and development of the Company&#146;s product candidates using its Viaskin Platform and for working capital and general corporate purposes. See the section of this prospectus supplement
titled &#147;Use of Proceeds.&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>You should read the &#147;Risk Factors&#148; section of this prospectus supplement for a discussion of factors to consider carefully before deciding to invest in our ordinary shares or ADSs. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Select Market trading symbol </P></TD>
<TD>&#147;DBVT&#148; </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Euronext Paris trading symbol </P></TD>
<TD>&#147;DBV&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of ordinary shares that will be outstanding after the global offering is based on 47,028,510 ordinary shares
outstanding as of December&nbsp;31, 2019 and excludes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,976,271 ordinary shares issuable upon the exercise of share options, free shares (<I>actions gratuites</I>) and
warrants (including employee warrants (BSPCE)) issued pursuant to our share option plans and other delegations of authority from our shareholders at a weighted average exercise price of &#128;30.64 per share (excluding 641,728 ordinary shares
issuable upon the vesting of outstanding free shares that may be issued for free with no exercise price being paid); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,802,226 ordinary shares reserved for future issuance under free share plans, share option plans and other
delegations of authority from our shareholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all information contained in this prospectus supplement
assumes no exercise of the underwriters&#146; option to purchase additional ordinary shares (which may be in the form of ADSs). </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc841346_5"></A>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables summarize our consolidated historical financial data. We derived the summary consolidated statement of income (loss) data for the years
ended December&nbsp;31, 2016, 2017 and 2018 from our audited consolidated financial statements incorporated by reference into this prospectus supplement. The summary consolidated statement of income (loss) data for the years ended December&nbsp;31,
2014 and 2015 are derived from our audited consolidated financial statements and related notes which are not incorporated by reference into this prospectus supplement. We derived the summary consolidated statement of income (loss) data for the nine
months ended September&nbsp;30, 2018 and 2019 and the consolidated statement of financial position data as of September&nbsp;30, 2019 from our unaudited interim condensed consolidated financial statements incorporated by reference into this
prospectus supplement. The unaudited consolidated financial statements were prepared in accordance with IAS 34, <I>Interim Financial Reporting</I>, the standard of IFRS applicable to interim financial statements. Our audited consolidated financial
statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. Our historical results are not necessarily indicative of the results that may be expected in the
future, and our results for the nine months ended September&nbsp;30, 2019 are not necessarily indicative of the results to be expected for the full fiscal year. The following information should be read in conjunction with our audited consolidated
financial statements and related notes, as well as the information under the captions &#147;Item 5. Operating and Financial Review and Prospects&#148; appearing in our <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519094568/0001193125-19-094568-index.htm">Annual
 Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT></A> for the year ended December&nbsp;31, 2018 which is incorporated by reference herein. For more details on how you can obtain our reports and other information filed with the SEC, you
should read the section of this prospectus supplement and the accompanying prospectus titled &#147;Where You Can Find More Information.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Income (Loss) Data (in thousands, except share and per share data): </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Euro</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Euro</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Euro</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Euro</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Euro</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Euro</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Euro</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Operating income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">4,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">6,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">9,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">11,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">14,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10,260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">9,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Cost of goods sold</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(136</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(128</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(78,828</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(105,232</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(107,171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(122,776</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(76,876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(73,673</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80,340</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Sales and marketing</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,282</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,824</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,853</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,785</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,268</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,378</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,859</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,005</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,837</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,399</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,426</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,094</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,803</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Total expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,397</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51,712</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(125,115</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(156,892</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(180,739</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(207,055</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127,754</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(120,745</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(131,672</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Operating (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,636</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(116,031</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(144,983</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(190,401</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(117,495</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(110,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(120,866</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Financial profit (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,709</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(355</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(387</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Net (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,012</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,674</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(114,531</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(147,693</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(166,076</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(190,256</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(115,640</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(111,264</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(121,333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Earnings (loss) per share<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.08</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(5.97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(5.74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.06</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.08</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(5.97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(5.74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.06</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Number of shares used for computing</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,086,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,522,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,454,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,757,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,924,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,924,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,492,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,012,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,012,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,086,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,522,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,454,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,757,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,924,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,924,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,492,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,012,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,012,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman; " ALIGN="left">Translated solely for convenience into dollars at the noon buying rate of the Federal Reserve Bank of New York
of &#128;1.00 = $1.1456 at December&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman; " ALIGN="left">Translated solely for convenience into dollars at the noon buying rate of the Federal Reserve Bank of New York
of &#128;1.00 = $1.0905 at September&nbsp;30, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:7.5pt; font-family:Times New Roman; " ALIGN="left">See Note 22 to our consolidated financial statements for further details on the calculation of basic and
diluted loss per ordinary share. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Financial Position Data (in thousands): </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;September&nbsp;30,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Euro</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>US$<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168,252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Translated solely for convenience into dollars at the noon buying rate of the Federal Reserve Bank of New York
of &#128;1.00 = $1.0905 at September&nbsp;30, 2019. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc841346_6"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>An investment in our securities involves a high degree of risk. Before deciding whether to purchase our securities, you should carefully consider the risk
factors incorporated by reference from Part I, Item 3.D. of our most recent <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519094568/0001193125-19-094568-index.htm">Annual Report on Form
<FONT STYLE="white-space:nowrap">20-F</FONT></A> and the other information contained in this prospectus supplement and the accompanying prospectus, as updated by those subsequent filings with the SEC under the Exchange Act, that are incorporated
herein by reference. These risks could materially affect our business, results of operations or financial condition and cause the value of our securities to decline, in which case you may lose all or part of your investment. For more information,
see &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Information by Reference.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to This Offering
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We Have Broad Discretion In The Use Of The Net Proceeds From This Offering And May Not Use Them Effectively. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion with respect to the use of proceeds of this offering, including for any of the purposes described in the section of
this prospectus supplement titled &#147;Use of Proceeds.&#148; You will be relying on the judgment of our management regarding the application of the proceeds of this global offering. The results and effectiveness of the use of proceeds are
uncertain, and we could spend the proceeds in ways that you do not agree with or that do not improve our results of operations or enhance the value of our ordinary shares or ADSs. Our failure to apply these funds effectively could have a material
adverse effect on our business, delay the development of our product candidates and cause the price of our ordinary shares or ADSs to decline. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce
income or that loses value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If You Purchase Ordinary Shares or ADSs In The Global Offering, You Will Experience Substantial And Immediate Dilution.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you purchase ordinary shares (including in the form of ADSs) in this offering, you will experience substantial and immediate dilution of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share in the net tangible book value as of September&nbsp;30, 2019 after giving effect to this offering because the price that you pay will
be substantially greater than the net tangible book value per ordinary share (including in the form of ADSs) that you acquire. This dilution is due in large part to the fact that certain of our earlier investors paid substantially less than the
public offering price when they purchased their ordinary shares or ADSs. You will experience additional dilution upon exercise of any outstanding options or warrants to purchase ordinary shares under our equity incentive plans, if we issue free
shares to our employees under our equity incentive plans or if we otherwise issue additional ordinary shares or ADSs below the public offering price. For a further description of the dilution that you will experience immediately after this global
offering, see the section of this prospectus supplement titled &#147;Dilution.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You May Experience Future Dilution As A Result Of Future
Equity Offerings. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to raise additional capital, we may in the future offer additional ordinary shares or ADSs or other securities
convertible into or exchangeable for our ordinary shares. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per ordinary share or ADS
paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing shareholders. The price per share at which we sell additional ordinary shares, ADSs or other securities
convertible into or exchangeable for our ordinary shares in future transactions may be higher or lower than the price per ordinary share or ADS in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future Sales Of Ordinary Shares Or ADSs By Existing Shareholders Could Depress The Market Price Of Our
Ordinary Shares and ADSs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2019, 36,157,777 ordinary shares were issued and outstanding. Sales of a substantial number of
shares of our ordinary shares or ADSs in the public market, or the perception that these sales might occur, could depress the market price of our securities and could impair our ability to raise capital through the sale of additional equity
securities. A substantial number of our shares are now generally freely tradable, subject, in the case of sales by our affiliates, to the volume limitations and other provisions of Rule 144 under the Securities Act. If holders of these shares sell,
or indicate an intent to sell, substantial amounts of our securities in the public market, the trading price of our securities could decline significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in connection with the completion of our global offering in March 2018, we entered into a registration rights agreement with entities affiliated
with Baker Bros. Advisors LP, or Baker Brothers, pursuant to which Baker Brothers is entitled to rights with respect to the registration under the Securities Act of ordinary shares and ADSs, including ordinary shares or ADSs issuable upon the
exercise or conversion of any other securities (whether equity, debt or otherwise) owned or subsequently acquired by Baker Brothers. Ordinary shares or ADSs sold under such registration statements can be freely sold in the public market. In the
event such registration rights are exercised and a large number of ordinary shares or ADSs are sold in the public market, such sales could reduce the trading price of our ordinary shares or ADSs. Further, filing of such registration statements could
reduce the trading price of our ordinary shares or ADSs regardless of whether any securities are sold thereunder. See &#147;Description of Share Capital&#151;Registration Rights&#148; for a more detailed description of these registration rights.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have also filed a registration statement with the SEC to register the ordinary shares that may be issued under our equity incentive plans. The
ordinary shares subject to outstanding options under our equity incentive plans, ordinary shares reserved for future issuance under our equity incentive plans and ordinary shares subject to outstanding warrants will become eligible for sale in the
public market in the future, subject to certain legal and contractual limitations. Sales of a large number of the shares issued under these plans in the public market could have an adverse effect on the market price of our securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You May Not Be Able Enforce Civil Liabilities Against Us If Certain Conditions Are Not Met. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are incorporated in France, but a majority of our outstanding securities are owned by U.S. residents. A number of our officers and directors as well as our
subsidiaries are <FONT STYLE="white-space:nowrap">non-residents</FONT> of the United States, and all or a substantial portion of the assets of such persons are located outside the United States. As a result, you may not be able to effect service of
process within the United States upon such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> persons or to enforce judgments outside the United States against them, including judgments obtained in U.S. courts predicated upon the civil liability
provisions of the federal securities laws of the United States. We have been advised by our French counsel that the enforceability in France in original actions, or in actions for enforcement of judgments of U.S. courts, of civil liabilities to the
extent predicated upon the federal securities laws of the United States would be subject to conditions as described under &#147;Enforcement of Civil Liabilities.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, awards of punitive damages in actions brought in the United States or elsewhere may be unenforceable in France. An award for monetary damages
under the U.S. securities laws would be considered punitive if it does not seek to compensate the claimant for loss or damage suffered but is intended to punish the defendant. French law provides that a shareholder, or a group of shareholders, may
initiate a legal action to seek indemnification from the directors of a corporation in the corporation&#146;s interest if it fails to bring such legal action itself. If so, any damages awarded by the court are paid to the corporation and legal fees
relating to such action may be borne by the relevant shareholder or the group of shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The enforceability of any judgment in France will depend
on the particular facts of the case as well as the laws and treaties in effect at the time. The United States and France do not currently have a treaty providing for recognition and enforcement of judgments (other than arbitration awards) in civil
and commercial matters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Dual Listing Of Our Ordinary Shares And The ADSs May Adversely Affect The Liquidity And Value Of
The ADSs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs are traded on the Nasdaq Global Select Market, and our ordinary shares are listed on Euronext Paris. The dual listing of our
ordinary shares and the ADSs may dilute the liquidity of these securities in one or both markets and may adversely affect the maintenance of an active trading market for the ADSs in the United States. The price of the ADSs could also be adversely
affected by trading in our ordinary shares on Euronext Paris, and vice versa. In addition, currency fluctuations as between the euro and U.S. dollar may have an adverse impact on the value of our ADSs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Holders Of ADSs May Suffer Adverse Tax Consequences If We Are Characterized As A Passive Foreign Investment Company. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the U.S. Internal Revenue Code of 1986, as amended, or Code, we will be a passive foreign investment company, or PFIC, for any taxable year in which,
after the application of certain &#147;look-through&#148; rules with respect to subsidiaries, either (i) 75% or more of our gross income consists of &#147;passive income,&#148; or (ii) 50% or more of the average quarterly value of our assets,
including cash, consists of assets that produce, or are held for the production of, &#147;passive income.&#148; Passive income generally includes interest, dividends, rents, certain <FONT STYLE="white-space:nowrap">non-active</FONT> royalties and
capital gains. Whether we will be a PFIC in any year depends on the composition of our income and assets, and the relative fair market value of our assets from time to time, which we expect may vary substantially over time. Based on the composition
of our gross income and gross assets for our 2018 taxable year, the latter determined by reference to the value of the ADSs and shares, we should not be treated as a PFIC for the taxable year ending December&nbsp;31, 2018, and we do not expect to be
classified as a PFIC for the taxable year ending December&nbsp;31, 2019. However, there can be no assurance that we have not been or will not be a PFIC for the current taxable year or any future taxable year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are a PFIC for any taxable year during which a U.S. Holder (as defined below) holds ADSs, a U.S. Holder may be subject to adverse tax consequences if a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election or a qualified electing fund, or QEF, election has not been made with respect to its ADSs. A U.S. Holder may incur significant additional U.S. federal
income taxes on income resulting from certain distributions on, or any gain from the disposition of, such ADSs, as such income generally would be allocated over the U.S. Holder&#146;s holding period for its ADSs. The amount allocated to the current
taxable year (<I>i.e.</I>, the year in which the distribution occurs or the gain is recognized) and any year prior to the first taxable year in which we are a PFIC would be subject to tax as ordinary income earned in the current year, and all other
amounts would be subject to tax at the highest rates of U.S. federal income taxation in effect for such years, with an interest charge then imposed on the resulting taxes in respect of such income. Furthermore, if we are a PFIC for any taxable year
during which the U.S. Holder holds ADSs, dividends paid by us would not be eligible for preferential individual rates of U.S. federal income tax. In addition, U.S. Holders that own an interest in a PFIC are required to comply with certain reporting
requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A U.S. Holder may in certain circumstances mitigate the adverse tax consequences of the PFIC rules by filing an election to treat the PFIC
as a QEF, or, if shares of the PFIC are &#147;marketable stock&#148; for purposes of the PFIC rules, by making a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election with respect to the shares of
the PFIC. See &#147;Material Income Tax Considerations&#151;Certain Material U.S. Federal Income Tax Considerations.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our <FONT STYLE="white-space:nowrap">By-Laws</FONT> And French Corporate Law Contain Provisions That
May Delay Or Discourage A Takeover Attempt. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisions contained in our <FONT STYLE="white-space:nowrap">by-laws</FONT> and the corporate laws of
France, the country in which we are incorporated, could make it more difficult for a third-party to acquire us, even if doing so might be beneficial to our shareholders. In addition, provisions of our <FONT STYLE="white-space:nowrap">by-laws</FONT>
impose various procedural and other requirements, which could make it more difficult for shareholders to effect certain corporate actions. These provisions include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, a <FONT STYLE="white-space:nowrap">non-French</FONT> resident as well as any French entity
controlled by <FONT STYLE="white-space:nowrap">non-French</FONT> residents may have to file a declaration for statistical purposes with the <I>Banque de France</I>, within 20 working days following the date of certain direct foreign investments in
us, including any purchase of our ADSs. In particular, such filings are required in connection with investments exceeding &#128;15,000,000 that lead to the acquisition of at least 10% of our share capital or voting rights or cross such 10%
threshold; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, certain investments in a French company relating to certain strategic industries by individuals
or entities not residents in a Member State of the EU are subject to prior authorization of the Ministry of Economy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the owner of 90% of the share capital and voting rights of a public company listed on a regulated market in a
Member State of the European Union or in a state party to the EEA Agreement, including from the main French Stock Exchange, has the right to force out minority shareholders following a tender offer made to all shareholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a merger (i.e., in a French law context, a share for share exchange following which our company would be
dissolved into the acquiring entity and our shareholders would become shareholders of the acquiring entity) of our company into a company incorporated in the European Union would require the approval of our board of directors as well as a <FONT
STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes held by the shareholders present, represented by proxy or voting by mail at the relevant meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, a cash merger is treated as a share purchase and would require the consent of each
participating shareholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our shareholders have granted and may grant in the future our board of directors broad authorizations to increase
our share capital or to issue additional ordinary shares or other securities (for example, warrants) to our shareholders, the public or qualified investors, including as a possible defense following the launching of a tender offer for our shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our shareholders have preferential subscription rights on a pro rata basis on the issuance by us of any
additional securities for cash or a <FONT STYLE="white-space:nowrap">set-off</FONT> of cash debts, which rights may only be waived by the extraordinary general meeting (by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority vote) of our
shareholders or on an individual basis by each shareholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our board of directors has the right to appoint directors to fill a vacancy created by the resignation or death
of a director, subject to the approval by the shareholders of such appointment at the next shareholders&#146; meeting, which prevents shareholders from having the sole right to fill vacancies on our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our board of directors can only be convened by our chairman or our managing director, if any, or, when no board
meeting has been held for more than two consecutive months, by directors representing at least <FONT STYLE="white-space:nowrap">one-third</FONT> of the total number of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our board of directors meetings can only be regularly held if at least half of the directors attend either
physically or by way of videoconference or teleconference enabling the directors&#146; identification and ensuring their effective participation in the board&#146;s decisions; however, this mode of participation (by way of videoconference or
teleconference) does not apply to the adoption of decisions taken for the closing of the accounts for the fiscal year, including the consolidated financial statements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our shares are nominative or bearer, if the legislation so permits, according to the shareholder&#146;s choice.
Shares issued are registered in individual accounts opened by us or any authorized intermediary, in the name of each shareholder and kept according to the terms and conditions laid down by the legal and regulatory provisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval of at least a majority of the votes held by shareholders present, represented by a proxy, or voting by
mail at the relevant ordinary shareholders&#146; general meeting is required to remove directors with or without cause; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance notice is required for nominations to the board of directors or for proposing matters to be acted upon at
a shareholders&#146; meeting, except that a vote to remove and replace a director can be proposed at any shareholders&#146; meeting without notice; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our <FONT STYLE="white-space:nowrap">by-laws</FONT> can be changed in accordance with applicable laws;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the crossing of certain thresholds has to be disclosed and can impose certain obligations; see the section of our
Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2018 titled &#147;Item 10.B&#151;Memorandum and Articles of Association&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers of shares shall comply with applicable insider trading rules and regulations and in particular with the
Market Abuse Directive and Regulation dated April&nbsp;16, 2014; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursuant to French law, the sections of the <FONT STYLE="white-space:nowrap">by-laws</FONT> relating to the
number of directors and election and removal of a director from office may only be modified by a resolution adopted by at least a two thirds majority vote of our shareholders present, represented by a proxy or voting by mail at the meeting.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc841346_7"></A>MARKET INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ADSs have been listed on the Nasdaq Global Select Market under the symbol &#147;DBVT&#148; since October&nbsp;22, 2014. Prior to that date, there was no
public trading market for our ADSs. Our ordinary shares have been trading on Euronext Paris under the symbol &#147;DBV&#148; since March&nbsp;28, 2012. Prior to that date, there was no public trading market for our ordinary shares. On January 28,
2020, the last reported sale price of the ADSs on the Nasdaq Global Select Market was $11.20 per ADS, and the last reported closing price of the ordinary shares on Euronext Paris was &#128;20.40 per share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc841346_8"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that we will receive net proceeds from this global offering of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) million, based on a public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS in the U.S. offering and &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per
ordinary share in the European offering, after deducting underwriting commissions and estimated offering expenses payable by us. If the underwriters exercise in full their option to purchase additional ordinary shares (which may be in the form of
ADSs), we estimate that we will receive net proceeds from the global offering of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) million, based on a public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS in the U.S. offering and &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share in the European offering, after deducting underwriting commissions and estimated offering
expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, primarily
to prepare for the commercialization of Viaskin Peanut, including marketing efforts related to launch in the second half of 2020, if approved, as well as to advance the discovery and development of the Company&#146;s product candidates using its
Viaskin Platform and for working capital and general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on our current operations, plans and assumptions, we expect the net
proceeds from this offering, combined with our current operating capital, to fund our operations &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, we have not generated any product revenue and we continue to prepare for the potential launch of our Viaskin Peanut product candidate in the United
States in the second half of 2020, if approved. In October 2019, we announced the FDA&#146;s acceptance for review of our Biologics License Application for Viaskin Peanut, with a target action date, provided by the FDA, of August 5, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect operating losses to continue for the foreseeable future. Current cash and cash equivalents are not projected to be sufficient to support our
operating plan for the next 12 months. We believe that our existing cash and cash equivalents will be sufficient to fund our operations through the third quarter of 2020. We expect that we will need to raise additional capital in the future as we
commercialize Viaskin Peanut, if approved, and continue to discover and develop other product candidates using our Viaskin Platform. We may finance our future cash needs through a combination of equity offerings, debt financings and potential
collaborations, and license and development agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This expected use of the net proceeds from this offering represents our intentions based upon our
current plans and business conditions. As of the date of this prospectus supplement, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the amounts that we will
actually spend on the uses set forth above. The amounts and timing of our actual expenditures and the extent of clinical development may vary significantly depending on numerous factors, including the progress of our development efforts, the status
of and results from <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and any ongoing clinical trials or clinical trials we may commence in the future, as well as any collaborations that we may enter into with third parties for our
product candidates and any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments, including
short-term, investment-grade, interest-bearing instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc841346_9"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents and capitalization as of September&nbsp;30, 2019 on: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an actual basis; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an as adjusted basis to reflect: (1)&nbsp;our issuance and sale of
(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares in the European offering at a public offering price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share and
(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ADSs in the U.S. offering at a public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ADS, after deducting underwriting
commissions and estimated offering expenses payable by us; and (2)&nbsp;the application of our net proceeds of this offering as described under the section of this prospectus supplement titled &#147;Use of Proceeds.&#148; </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read this table in conjunction with other sections of this prospectus supplement, the accompanying prospectus and any documents that they
incorporate by reference, including our consolidated financial statements and the related notes. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of September&nbsp;30, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As<BR>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">73,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conditional advances</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share capital:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares, &#128;0.10 nominal value: 36,157,777 shares issued and outstanding, actual;
shares issued and outstanding, as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Premiums related to the share capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">605,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(411,590</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(111,264</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity attributable to our shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">111,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes an exchange rate of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per euro. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of ordinary shares that will be outstanding after the global offering is based on 36,157,777 ordinary shares outstanding as of September&nbsp;30,
2019 and excludes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,133,638 ordinary shares issuable upon the exercise of share options, free shares (<I>actions gratuites</I>) and
warrants (including employee warrants (BSPCE)) issued pursuant to our share option plans and other delegations of authority from our shareholders at a weighted average exercise price of &#128;31.26 per share (excluding 623,545 ordinary shares
issuable upon the vesting of outstanding free shares that may be issued for free with no exercise price being paid); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,922,426 ordinary shares reserved for future issuance under share option plans and other delegations of
authority from our shareholders. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc841346_10"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you invest in the ordinary shares or ADSs in this global offering, your ownership interest will be immediately diluted to the extent of the difference
between the public offering price per ordinary share or ADS paid by purchasers in the global offering and our as adjusted net tangible book value per ordinary share after this offering. Our net tangible book value as of September&nbsp;30, 2019 was
&#128;85.8&nbsp;million ($93.6 million), or &#128;2.37 ($2.59) per ordinary share. Net tangible book value per ordinary share is determined by dividing (1)&nbsp;our total assets less our intangible assets and our total liabilities by (2)&nbsp;the
number of ordinary shares outstanding as of September&nbsp;30, 2019, or 36,157,777 ordinary shares (including ordinary shares represented by ADSs). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After
giving effect to the sale of ordinary shares (which may be in the form of ADSs) in this global offering at a public offering price of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary
share, and after deducting the underwriting commissions and estimated offering expenses payable by our, our as adjusted net tangible book value at September&nbsp;30, 2019 would have been approximately
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share. This
represents an immediate increase in as adjusted net tangible book value of &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share to existing shareholders and immediate dilution of
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share to new investors. The following table illustrates this dilution on a per share basis: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value per share as of September&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to new investors participating in this
global offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option to purchase additional ordinary shares (which may be in the form of ADSs) in full,
the as adjusted net tangible book value per ordinary share after the global offering would be &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , the increase in the as adjusted net tangible book
value to existing shareholders would be &#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, and the dilution to new investors participating in this offering would be
&#128;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tables and calculations
above are based on 36,157,777 ordinary shares outstanding as of September&nbsp;30, 2019 and exclude the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,133,638 ordinary shares issuable upon the exercise of share options, free shares (<I>actions gratuites</I>) and
warrants (including employee warrants (BSPCE)) issued pursuant to our share option plans and other delegations of authority from our shareholders at a weighted average exercise price of &#128;31.26 per share (excluding 623,545 ordinary shares
issuable upon the vesting of outstanding free shares that may be issued for free with no exercise price being paid); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,922,426 ordinary shares reserved for future issuance under share option plans and other delegations of
authority from our shareholders. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc841346_11"></A>DESCRIPTION OF SHARE CAPITAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following description of our share capital summarizes certain provisions of our <FONT STYLE="white-space:nowrap">by-laws.</FONT> Such summaries do not
purport to be complete and are subject to, and are qualified in their entirety by reference to, all of the provisions of our <FONT STYLE="white-space:nowrap">by-laws,</FONT> a copy of which is incorporated by reference into the registration
statement of which this prospectus supplement forms a part. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, our outstanding share capital consisted of a total of 47,028,510 issued ordinary shares, fully paid and with a nominal value
&#128;0.10 per share. We have no preferred shares outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under French law, our <FONT STYLE="white-space:nowrap">by-laws</FONT> set forth only our
issued and outstanding share capital as of the date of the <FONT STYLE="white-space:nowrap">by-laws.</FONT> Our fully diluted share capital represents all issued and outstanding shares, as well as all potential shares which may be issued upon
exercise of outstanding employee warrants, employee share options and <FONT STYLE="white-space:nowrap">non-employee</FONT> warrants, as approved by our shareholders and granted by our board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reconciliation of the Number of Ordinary Shares Outstanding through December&nbsp;31, 2019 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares outstanding at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,990,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares issued in connection with March 2018 Global offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,056,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of ordinary shares issued in connection with the exercise of employee warrants, share
options and <FONT STYLE="white-space:nowrap">non-employee</FONT> warrants and the acquisition of free shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,110,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares outstanding at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,157,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares issued in connection with April 2019 Global offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares issued in connection with October 2019 Global offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,852,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of ordinary shares issued in connection with the exercise of employee warrants, share
options and <FONT STYLE="white-space:nowrap">non-employee</FONT> warrants and the acquisition of free shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares outstanding at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,028,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shareholder Authorizations Regarding Share Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At our 2019 combined shareholders&#146; meeting held on May&nbsp;24, 2019, our board of directors received the following authorizations from shareholders: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorization to <FONT STYLE="white-space:nowrap">buy-back</FONT> up to 5% of our shares (such authorization
being capped to a maximum potential dilution equal to 5% of our share capital at the date of the relevant <FONT STYLE="white-space:nowrap">buy-back)</FONT> for a duration of 18 months (of which 9,000 shares have been bought back as of
December&nbsp;31, 2019); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorization to cancel the shares bought back by the company up to 5% of our shares (such authorization being
capped to a maximum of 5% of our share capital at the date of the relevant cancellation decision) and to decrease our share capital accordingly, for a duration of 24 months (of which no shares have been canceled as of December&nbsp;31, 2019);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delegation of authority to increase our share capital by issuing ordinary shares giving access, if applicable, to
ordinary shares or the allocation of debt securities (of the company or any group company) and/or securities giving access to ordinary shares (of the company or any group company), with preferential subscription rights, for a duration of 26 months
within a maximum aggregate potential dilution of 18,811,404 shares based on the ordinary shares outstanding at December&nbsp;31, 2019 (such delegation of authority being capped to a maximum potential dilution of 40% of our share capital at the date
of the relevant share capital increase) (of which no shares have been issued as of December&nbsp;31, 2019); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delegations of authority to increase our share capital by issuing ordinary shares giving access, if applicable,
to ordinary shares or the allocation of debt securities (of the company or any group company) and/or securities giving access to ordinary shares (of the company or any group company), without preferential subscription rights (except for the rights
offering), through public offerings and/or offerings under Article L. <FONT STYLE="white-space:nowrap">411-2.</FONT> 1&deg; of the French Monetary and Financial Code for the maximum
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
duration permitted under French law (26 months) within a maximum aggregate potential dilution of 14,108,553 or 9,405,702 (depending on the delegations) shares based on the ordinary shares
outstanding at December&nbsp;31, 2019 (each delegation of authority has been capped to a maximum potential dilution equal to a percentage of 30% or 20% of our share capital, respectively (depending on the delegations) at the date of the relevant
share capital increase) (of which no shares have been issued as of December&nbsp;31, 2019), it being specified that any increases of our share capital under these delegations of authority (public offerings and/or offerings under Article L. 411-2.
1&deg; of the French Monetary and Financial Code) together with any increases of our share capital under the delegation of authority mentioned in the following paragraph (authority to increase our share capital to the benefit of persons meeting
certain characteristics) have been granted within a maximum potential dilution of 23,502,555 shares based on the ordinary shares outstanding at the date of the shareholders&#146; meeting (these delegations of authority being capped to a percentage
of 65% of our share capital at the date of the shareholders&#146; meeting) (of which 10,852,733 shares have been issued as of December 31, 2019); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delegation of authority to increase our share capital by issuing ordinary shares giving access, if applicable, to
ordinary shares or the allocation of debt securities (of the company or any group company) and/or securities giving access to ordinary shares (of the company or any group company) without preferential subscription rights, to the benefit of
categories of persons meeting certain characteristics, for a duration of 18 months within a maximum potential dilution of 14,108,553 shares based on the ordinary shares outstanding at December&nbsp;31, 2019 (such delegation of authority being capped
to a maximum potential dilution of 30% of our share capital at the date of the relevant share capital increase) (of which 10,852,733 shares have been issued as of December&nbsp;31, 2019), it being specified that any increases of our share capital
under this delegation of authority (authority to increase our share capital to the benefit of persons meeting certain characteristics) together with any increases of our share capital under the delegation of authority mentioned in the previous
paragraph (authority to increase our share capital through public offerings and/or offerings under Article L. 411-2. 1&deg; of the French Monetary and Financial Code) have been granted within a maximum potential dilution of 23,502,555 shares based
on the ordinary shares outstanding at the date of the shareholders&#146; meeting (these delegations of authority being capped to a percentage of 65% of our share capital at the date of the shareholders&#146; meeting) (of which 10,852,733 shares have
been issued as of December 31, 2019); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delegation of authority to issue equity warrants (<I>bons de souscription d&#146;actions, bons de souscription
et/ou d&#146;acquisition d&#146;actions nouvelles et/ou existantes</I>) or redeemable equity warrants (<I>bons de souscription et/ou d&#146;acquisition d&#146;actions nouvelles et/ou existantes remboursables</I>) without preferential subscription
rights, to the benefit of categories of persons meeting certain characteristics for a maximum duration of 18 months, within a maximum potential dilution of 180,788 shares based on the ordinary shares outstanding at May 24, 2019 (such delegation of
authority being capped to a maximum potential dilution equal to 0.5% of our share capital on the date of the shareholders&#146; meeting) (of which no warrants have been issued as of December&nbsp;31, 2019, for which delegation our shareholders
waived automatically their preferential subscription rights with respect to all such issuances); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delegation of authority to increase our share capital by issuing ordinary shares and/or securities giving access
to our share capital without preferential subscription rights, to the benefit of employees investing in our company saving plan (<I>plan d&#146;&eacute;pargne entreprise</I>), for a duration of 26 months, within a maximum aggregate potential
dilution of 940,570 shares based on the ordinary shares outstanding at December&nbsp;31, 2019 (such delegation of authority being capped to a maximum potential dilution equal to 2% of our share capital at the date of the relevant share capital
increase) (of which no shares have been issued as of December&nbsp;31, 2019, for which such delegation our shareholders automatically waived their preferential subscription rights with respect to all such issuances); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorization to grant free shares (<I>attribution gratuite d&#146;actions</I>) to our employees and/or certain
officers until the next general meeting approving the annual accounts to be held in 2020, within a maximum potential dilution of shares based on the ordinary shares outstanding at May 24, 2019 (such authorization being capped to a 723,155 maximum
potential dilution equal to 2% of our share capital at the date of the shareholders&#146; meeting) (of which 87,350 free shares have been granted but no shares </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
have been issued as of December&nbsp;31, 2019, for which delegation our shareholders waived automatically their preferential subscription rights with respect to all such grants); and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorization to grant share options (<I>options de souscription et/ou d&#146;achat d&#146;actions</I>) to our
employees and/or certain officers for a maximum duration of 18 months, within a maximum potential dilution of 2,711,833 shares based on the ordinary shares outstanding at May 24, 2019 (such delegation of authority being capped to a maximum potential
dilution equal to 7.5% of our share capital at the date of the shareholders&#146; meeting) (of which 726,200 options have been granted but no shares have been issued as of December&nbsp;31, 2019 for which delegation our shareholders waived
automatically their preferential subscription rights with respect to all such grants). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, our board of directors received the
following delegations from the shareholders at our combined shareholders&#146; meeting held on June&nbsp;22, 2018: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delegation of authority to increase our share capital by incorporation of reserves, profits or premium either by
the issuance of new shares attributed to each existing shareholder or by the increase of the nominal value per share for a duration of 26 months within a maximum aggregate potential dilution of 23,514,255 shares based on the ordinary shares
outstanding at December&nbsp;31, 2019 (such delegation of authority being capped to a maximum potential dilution of 50% of our share capital at the date of the relevant share capital increase) (of which no shares have been issued as of
December&nbsp;31, 2019); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delegation of authority to increase our share capital by issuing securities in view of remuneration of
contributions in kind (shares and/or securities giving access to the share capital) to our company for a duration of 26 months within a maximum potential dilution of 3,000,635 shares based on the ordinary shares outstanding at June 22, 2018 (such
delegation of authority being capped to a maximum potential dilution equal to 10% of our share capital at the date of the shareholders&#146; meeting), (of which no shares have been issued as of December&nbsp;31, 2019). </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the completion of
our global offering in March 2018, we entered into a registration rights agreement, or the Registration Rights Agreement, with entities affiliated with Baker Bros. Advisors LP, or Baker Brothers, pursuant to which Baker Brothers is entitled to
rights with respect to the registration under the Securities Act of ordinary shares and ADSs, including ordinary shares or ADSs issuable upon the exercise or conversion of any other securities (whether equity, debt or otherwise) owned or
subsequently acquired by Baker Brothers. These rights include demand registration rights and piggyback registration rights. All fees, costs and expenses of underwritten registrations will be borne by us and all selling expenses, including
underwriting commissions, will be borne by Baker Brothers. Under the terms of the Registration Rights Agreement, we are required, upon the request of Baker Brothers, to file a registration statement covering, and use our reasonable best efforts to
effect the registration of the ordinary shares, including in the form of ADSs, requested to be registered for public resale. In addition, if we register our securities either for our own account or for the account of other security holders under
certain circumstances more than six months following the completion of the March 2018 global offering, Baker Brothers is entitled to include its ordinary shares or ADSs in such registration. Subject to certain exceptions, we and the underwriters may
limit the number of ordinary shares or ADSs included in an underwritten offering conducted pursuant to the terms of the Registration Rights Agreement if the underwriters believe that including such securities would adversely affect the offering. The
registration rights granted under the Registration Rights Agreement will terminate ten years following the completion of this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ADSs are listed on the Nasdaq Global Select Market under the symbol &#147;DBVT&#148; and our ordinary shares are listed on Euronext Paris under
the symbol &#147;DBV.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our ADSs is Citibank, N.A. The transfer agent and registrar for our ordinary shares is Soci&eacute;t&eacute;
G&eacute;n&eacute;rale Securities Services. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc841346_12"></A>DESCRIPTION OF AMERICAN DEPOSITARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citibank, N.A. has agreed to act as the depositary for the American Depositary Shares. Citibank&#146;s depositary offices are located at 388 Greenwich Street,
New York, New York 10013. American Depositary Shares are frequently referred to as ADSs and represent ownership interests in securities that are on deposit with the depositary. ADSs may be represented by certificates that are commonly known as
American Depositary Receipts, or ADRs. The depositary typically appoints a custodian to safekeep the securities on deposit. In this case, the custodian is Citibank International Plc, located at EGSP 186, 1 North Wall Quay, Dublin 1 Ireland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have appointed Citibank as depositary pursuant to a deposit agreement. A copy of the deposit agreement is on file with the SEC under cover of a
Registration Statement on Form <FONT STYLE="white-space:nowrap">F-6.</FONT> You may obtain a copy of the deposit agreement from the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549 and from the SEC&#146;s website at
www.sec.gov. Please refer to Registration Number <FONT STYLE="white-space:nowrap">333-199231</FONT> when retrieving such copy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are providing you with
a summary description of the material terms of the ADSs and of your material rights as an owner of ADSs. Please remember that summaries by their nature lack the precision of the information summarized and that the rights and obligations of an owner
of ADSs will be determined by reference to the terms of the deposit agreement and not by this summary. We urge you to review the deposit agreement in its entirety. The portions of this summary description that are italicized describe matters that
may be relevant to the ownership of ADSs but that may not be contained in the deposit agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each ADS represents the right to receive <FONT
STYLE="white-space:nowrap">one-half</FONT> (1/2) of one ordinary share on deposit with the custodian. An ADS also represents the right to receive any other property received by the depositary or the custodian on behalf of the owner of the ADS but
that has not been distributed to the owners of ADSs because of legal restrictions or practical considerations. The custodian, the depositary and their respective nominees will hold all deposited property for the benefit of the holders and beneficial
owners of ADSs. The deposited property does not constitute the proprietary assets of the depositary, the custodian or their nominees. Beneficial ownership in the deposited property will under the terms of the deposit agreement be vested in the
beneficial owners of the ADSs. The depositary, the custodian and their respective nominees will be the record holders of the deposited property represented by the ADSs for the benefit of the holders and beneficial owners of the corresponding ADSs.
Owners of ADSs will be able to exercise beneficial ownership interests in the deposited property only through the registered holders of the ADSs, by the registered holders of the ADSs (on behalf of the applicable ADS owners) only through the
depositary, and by the depositary (on behalf of the owners of the corresponding ADSs) directly, or indirectly through the custodian or their respective nominees, in each case upon the terms of the deposit agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you become an owner of ADSs, you will become a party to the deposit agreement and therefore will be bound to its terms and to the terms of any ADR that
represents your ADSs. The deposit agreement and the ADR specify our rights and obligations as well as your rights and obligations as owner of ADSs and those of the depositary. As an ADS holder you appoint the depositary to act on your behalf in
certain circumstances. The deposit agreement and the ADRs are governed by New York law. However, our obligations to the holders of ordinary shares will continue to be governed by the laws of France, which may be different from the laws in the United
States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, applicable laws and regulations may require you to satisfy reporting requirements and obtain regulatory approvals in certain
circumstances. You are solely responsible for complying with such reporting requirements and obtaining such approvals. Neither the depositary, the custodian, us or any of their or our respective agents or affiliates shall be required to take any
actions whatsoever on your behalf to satisfy such reporting requirements or obtain such regulatory approvals under applicable laws and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an
owner of ADSs, we will not treat you as one of our shareholders and you will not have direct shareholder rights. The depositary will hold on your behalf the shareholder rights attached to the ordinary shares underlying
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
your ADSs. As an owner of ADSs you will be able to exercise the shareholders rights for the ordinary shares represented by your ADSs through the depositary only to the extent contemplated in the
deposit agreement. To exercise any shareholder rights not contemplated in the deposit agreement you will, as an ADS owner, need to arrange for the cancellation of your ADSs and become a direct shareholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an owner of ADSs, you may hold your ADSs either by means of an ADR registered in your name, through a brokerage or safekeeping account, or through an
account established by the depositary in your name reflecting the registration of uncertificated ADSs directly on the books of the depositary, commonly referred to as the direct registration system, or DRS. The direct registration system reflects
the uncertificated (book-entry) registration of ownership of ADSs by the depositary. Under the direct registration system, ownership of ADSs is evidenced by periodic statements issued by the depositary to the holders of the ADSs. The direct
registration system includes automated transfers between the depositary and The Depository Trust Company, or DTC, the central book-entry clearing and settlement system for equity securities in the United States. If you decide to hold your ADSs
through your brokerage or safekeeping account, you must rely on the procedures of your broker or bank to assert your rights as ADS owner. Banks and brokers typically hold securities such as the ADSs through clearing and settlement systems such as
DTC. The procedures of such clearing and settlement systems may limit your ability to exercise your rights as an owner of ADSs. Please consult with your broker or bank if you have any questions concerning these limitations and procedures. All ADSs
held through DTC will be registered in the name of a nominee of DTC. This summary description assumes you have opted to own the ADSs directly by means of an ADS registered in your name and, as such, we will refer to you as the &#147;holder.&#148;
When we refer to &#147;you,&#148; we assume the reader owns ADSs and will own ADSs at the relevant time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends and Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a holder of ADSs, you generally have the right to receive the distributions we make on the securities deposited with the custodian. Your receipt of these
distributions may be limited, however, by practical considerations and legal limitations. Holders of ADSs will receive such distributions under the terms of the deposit agreement in proportion to the number of ADSs held as of a specified record
date, after deduction the applicable fees, taxes and expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Distributions of Cash </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whenever we make a cash distribution for the securities on deposit with the custodian, we will deposit the funds with the custodian. Upon receipt of
confirmation of the deposit of the requisite funds, the depositary will arrange for the funds to be converted into U.S. dollars and for the distribution of the U.S. dollars to the holders, subject to French laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conversion into U.S. dollars will take place only if practicable and if the U.S. dollars are transferable to the United States. The depositary will apply
the same method for distributing the proceeds of the sale of any property (such as undistributed rights) held by the custodian in respect of securities on deposit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The distribution of cash will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement.
The depositary will hold any cash amounts it is unable to distribute in a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing account for the benefit of the applicable holders and beneficial owners of ADSs until the distribution can be
effected or the funds that the depositary holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Distributions of Shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whenever we make a free
distribution of ordinary shares for the securities on deposit with the custodian, we will deposit the applicable number of ordinary shares with the custodian. Upon receipt of confirmation of such deposit, the depositary will either distribute to
holders new ADSs representing the ordinary shares deposited or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
modify the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio, in which case each ADS you hold will represent rights and interests in the
additional ordinary shares so deposited. Only whole new ADSs will be distributed. Fractional entitlements will be sold and the proceeds of such sale will be distributed as in the case of a cash distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The distribution of new ADSs or the modification of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share
ratio upon a distribution of ordinary shares will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. In order to pay such taxes or governmental charges, the depositary may
sell all or a portion of the new ordinary shares so distributed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No such distribution of new ADSs will be made if it would violate a law (i.e., the U.S.
securities laws) or if it is not operationally practicable. If the depositary does not distribute new ADSs as described above, it may sell the ordinary shares received upon the terms described in the deposit agreement and will distribute the
proceeds of the sale as in the case of a distribution of cash. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Distributions of Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whenever we intend to distribute rights to purchase additional ordinary shares, we will give prior notice to the depositary and we will assist the depositary
in determining whether it is lawful and reasonably practicable to distribute rights to purchase additional ADSs to holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary will establish
procedures to distribute rights to purchase additional ADSs to holders and to enable such holders to exercise such rights if it is lawful and reasonably practicable to make the rights available to holders of ADSs, and if we provide all of the
documentation contemplated in the deposit agreement (such as opinions to address the lawfulness of the transaction). You may have to pay fees, expenses, taxes and other governmental charges to subscribe for the new ADSs upon the exercise of your
rights. The depositary is not obligated to establish procedures to facilitate the distribution and exercise by holders of rights to purchase new ordinary shares other than in the form of ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary will not distribute the rights to you if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we do not timely request that the rights be distributed to you or we request that the rights not be distributed
to you; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we fail to deliver satisfactory documents to the depositary; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is not reasonably practicable to distribute the rights. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary will sell the rights that are not exercised or not distributed if such sale is lawful and reasonably practicable. The proceeds of such sale
will be distributed to holders as in the case of a cash distribution. If the depositary is unable to sell the rights, it will allow the rights to lapse. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Elective Distributions </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whenever we intend to distribute
a dividend payable at the election of shareholders either in cash or in additional shares, we will give prior notice thereof to the depositary and will indicate whether we wish the elective distribution to be made available to you. In such case, we
will assist the depositary in determining whether such distribution is lawful and reasonably practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary will make the election available
to you only if it is reasonably practicable and if we have provided all of the documentation contemplated in the deposit agreement. In such case, the depositary will establish procedures to enable you to elect to receive either cash or additional
ADSs, in each case as described in the deposit agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the election is not made available to you, you will receive either cash or additional ADSs, depending on
what a shareholder in France would receive upon failing to make an election, as more fully described in the deposit agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Distributions
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whenever we intend to distribute property other than cash, ordinary shares or rights to purchase additional ordinary shares, we will notify the
depositary in advance and will indicate whether we wish such distribution to be made to you. If so, we will assist the depositary in determining whether such distribution to holders is lawful and reasonably practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If it is reasonably practicable to distribute such property to you and if we provide all of the documentation contemplated in the deposit agreement, the
depositary will distribute the property to the holders in a manner it deems practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The distribution will be made net of fees, expenses, taxes and
governmental charges payable by holders under the terms of the deposit agreement. In order to pay such taxes and governmental charges, the depositary may sell all or a portion of the property received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary will not distribute the property to you and will sell the property if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we do not request that the property be distributed to you or if we ask that the property not be distributed to
you; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we do not deliver satisfactory documents to the depositary; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary determines that all or a portion of the distribution to you is not reasonably practicable.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proceeds of such a sale will be distributed to holders as in the case of a cash distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Redemption </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whenever we decide to redeem any of the
securities on deposit with the custodian, we will notify the depositary in advance. If it is practicable and if we provide all of the documentation contemplated in the deposit agreement, the depositary will provide notice of the redemption to the
holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The custodian will be instructed to surrender the shares being redeemed against payment of the applicable redemption price. The depositary will
convert the redemption funds received into U.S. dollars upon the terms of the deposit agreement and will establish procedures to enable holders to receive the net proceeds from the redemption upon surrender of their ADSs to the depositary. You may
have to pay fees, expenses, taxes and other governmental charges upon the redemption of your ADSs. If less than all ADSs are being redeemed, the ADSs to be retired will be selected by lot or on a pro rata basis, as the depositary may determine. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes Affecting Ordinary Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ordinary
shares held on deposit for your ADSs may change from time to time. For example, there may be a change in nominal or par value, a <FONT STYLE="white-space:nowrap">split-up,</FONT> cancellation, consolidation or reclassification of such ordinary
shares or a recapitalization, reorganization, merger, consolidation or sale of assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any such change were to occur, your ADSs would, to the extent
permitted by law, represent the right to receive the property received or exchanged in respect of the ordinary shares held on deposit. The depositary may in such circumstances deliver new ADSs to you, amend the deposit agreement, the ADRs and the
applicable Registration Statement(s) on Form <FONT STYLE="white-space:nowrap">F-6,</FONT> call for the exchange of your existing ADSs for new ADSs and take any other actions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that are appropriate to reflect as to the ADSs the change affecting the shares. If the depositary may not lawfully distribute such property to you, the depositary may sell such property and
distribute the net proceeds to you as in the case of a cash distribution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuance of ADSs upon Deposit of Ordinary Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, the ordinary shares being offered pursuant to this prospectus will be deposited by us with the custodian. Upon receipt of
confirmation of such deposit, the depositary will issue ADSs to the underwriters named in this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the closing of this offering,
the depositary may create ADSs on your behalf if you or your broker deposit ordinary shares with the custodian. The depositary will deliver these ADSs to the person you indicate only after you pay any applicable issuance fees and any charges and
taxes payable for the transfer of the ordinary shares to the custodian. Your ability to deposit ordinary shares and receive ADSs may be limited by U.S. and French legal considerations applicable at the time of deposit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The issuance of ADSs may be delayed until the depositary or the custodian receives confirmation that all required approvals have been given and that the
ordinary shares have been duly transferred to the custodian. The depositary will only issue ADSs in whole numbers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When you make a deposit of ordinary
shares, you will be responsible for transferring good and valid title to the depositary. As such, you will be deemed to represent and warrant that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ordinary shares are duly authorized, validly issued, fully paid,
<FONT STYLE="white-space:nowrap">non-assessable</FONT> and legally obtained. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">All preemptive (and similar) rights, if any, with respect to such ordinary shares have been validly waived or
exercised. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You are duly authorized to deposit the ordinary shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ordinary shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge,
mortgage or adverse claim, and are not, and the ADSs issuable upon such deposit will not be, &#147;restricted securities&#148; (as defined in the deposit agreement). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ordinary shares presented for deposit have not been stripped of any rights or entitlements.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of the representations or warranties are incorrect in any way, we and the depositary may, at your cost and expense, take any and
all actions necessary to correct the consequences of the misrepresentations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transfer, Combination and Split Up of ADRs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an ADR holder, you will be entitled to transfer, combine or split up your ADRs and the ADSs evidenced thereby. For transfers of ADRs, you will have to
surrender the ADRs to be transferred to the depositary and also must: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ensure that the surrendered ADR is properly endorsed or otherwise in proper form for transfer;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide such proof of identity and genuineness of signatures as the depositary deems appropriate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide any transfer stamps required by the State of New York or the United States; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay all applicable fees, charges, expenses, taxes and other government charges payable by ADR holders pursuant to
the terms of the deposit agreement, upon the transfer of ADRs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To have your ADRs either combined or split up, you must surrender the
ADRs in question to the depositary with your request to have them combined or split up, and you must pay all applicable fees, charges and expenses payable by ADR holders, pursuant to the terms of the deposit agreement, upon a combination or split up
of ADRs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Withdrawal of Ordinary Shares Upon Cancellation of ADSs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a holder, you will be entitled to present your ADSs to the depositary for cancellation and then receive the corresponding number of underlying ordinary
shares at the custodian&#146;s offices. Your ability to withdraw the ordinary shares may be limited by U.S. and French legal considerations applicable at the time of withdrawal. In order to withdraw the ordinary shares represented by your ADSs, you
will be required to pay to the depositary the fees for cancellation of ADSs and any charges and taxes payable upon the transfer of the ordinary shares being withdrawn. You assume the risk for delivery of all funds and securities upon withdrawal.
Once canceled, the ADSs will not have any rights under the deposit agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you hold ADSs registered in your name, the depositary may ask you to
provide proof of identity and genuineness of any signature and such other documents as the depositary may deem appropriate before it will cancel your ADSs. The withdrawal of the ordinary shares represented by your ADSs may be delayed until the
depositary receives satisfactory evidence of compliance with all applicable laws and regulations. Please keep in mind that the depositary will only accept ADSs for cancellation that represent a whole number of securities on deposit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will have the right to withdraw the securities represented by your ADSs at any time except for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">temporary delays that may arise because (i)&nbsp;the transfer books for the ordinary shares or ADSs are closed,
or (ii)&nbsp;ordinary shares are immobilized on account of a shareholders&#146; meeting or a payment of dividends; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obligations to pay fees, taxes and similar charges; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions imposed because of laws or regulations applicable to ADSs or the withdrawal of securities on
deposit. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The deposit agreement may not be modified to impair your right to withdraw the securities represented by your ADSs except to
comply with mandatory provisions of law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a holder, you generally have the right under the deposit agreement to instruct the depositary to exercise the voting rights for the ordinary shares
represented by your ADSs. The voting rights of holders of ordinary shares are described in the sections of the accompanying prospectus titled &#147;Description of Share Capital&#148; and &#147;Limitations Affecting Shareholders of a French
Company.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At our request, the depositary will distribute to you any notice of shareholders&#146; meeting received from us together with information
explaining how to instruct the depositary to exercise the voting rights of the securities represented by ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the depositary timely receives voting
instructions from a holder of ADSs, it will endeavor to vote the securities (in person or by proxy) represented by the holder&#146;s ADSs in accordance with such voting instructions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the depositary receives voting instructions which fail to specify the manner in which the depositary is to vote the deposited securities, you will be
deemed to have instructed the depositary to vote in favor of all resolutions endorsed by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please note that the ability of the
depositary to carry out voting instructions may be limited by practical and legal limitations and the terms of the securities on deposit. We cannot assure you that you will receive voting materials in time to enable you to return voting instructions
to the depositary in a timely manner. Securities represented by ADSs for which no timely voting instructions have been received by the depositary will not be voted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fees and Charges </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an ADS holder, you will be required to pay the following service fees to the depositary: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Service</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>Fees</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Issuance of ADSs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. $0.05 per ADS issued</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Cancellation of ADSs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. $0.05 per ADS canceled</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Distribution of cash dividends or other cash distributions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. $0.05 per ADS held</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Distribution of ADSs pursuant to stock dividends, free stock distributions or
exercise of rights.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. $0.05 per ADS held</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Distribution of securities other than ADSs or rights to purchase additional
ADSs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. $0.05 per ADS held</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;ADS Services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. $0.05 per ADS held on the applicable record date(s) established by the depositary</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an ADS holder you will also be responsible to pay certain fees and expenses incurred by the depositary and certain taxes
and governmental charges such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fees for the transfer and registration of ordinary shares charged by the registrar and transfer agent for the
ordinary shares in France (i.e., upon deposit and withdrawal of ordinary shares); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred for converting foreign currency into U.S. dollars; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses for cable, telex and fax transmissions and for delivery of securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">taxes and duties upon the transfer of securities (i.e., when ordinary shares are deposited or withdrawn from
deposit); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fees and expenses incurred in connection with the delivery or servicing of ordinary shares on deposit.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depositary fees payable upon the issuance and cancellation of ADSs are typically paid to the depositary by the brokers (on behalf of
their clients) receiving the newly issued ADSs from the depositary and by the brokers (on behalf of their clients) delivering the ADSs to the depositary for cancellation. The brokers in turn charge these fees to their clients. Depositary fees
payable in connection with distributions of cash or securities to ADS holders and the depositary services fee are charged by the depositary to the holders of record of ADSs as of the applicable ADS record date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary fees payable for cash distributions are generally deducted from the cash being distributed. In the case of distributions other than cash (i.e.,
stock dividend, rights), the depositary charges the applicable fee to the ADS record date holders concurrent with the distribution. In the case of ADSs registered in the name of the investor (whether certificated or uncertificated in direct
registration), the depositary sends invoices to the applicable record date ADS holders. In the case of ADSs held in brokerage and custodian accounts (via DTC), the depositary generally collects its fees through the systems provided by DTC (whose
nominee is the registered holder of the ADSs held in DTC) from the brokers and custodians holding ADSs in their DTC accounts. The brokers and custodians who hold their clients&#146; ADSs in DTC accounts in turn charge their clients&#146; accounts
the amount of the fees paid to the depositary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of refusal to pay the depositary fees, the depositary may, under the terms of the deposit
agreement, refuse the requested service until payment is received or may set off the amount of the depositary fees from any distribution to be made to the ADS holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CERTAIN OF THE DEPOSITARY FEES AND CHARGES (SUCH AS THE ADS SERVICES FEE) MAY BECOME PAYABLE SHORTLY AFTER THE CLOSING OF THE ADS OFFERING. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note that the fees and charges you may be required to pay may vary over time and may be changed by us and by the depositary. You will receive prior notice of
such changes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary may reimburse us for certain expenses incurred by us in respect of the ADR program
established pursuant to the deposit agreement, by making available a portion of the depositary fees charged in respect of the ADR program or otherwise, upon such terms and conditions as we and the depositary may agree from time to time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendments and Termination </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may agree with the
depositary to modify the deposit agreement at any time without your consent. We undertake to give holders 30 days&#146; prior notice of any modifications that would materially prejudice any of their substantial rights under the deposit agreement. We
will not consider to be materially prejudicial to your substantial rights any modifications or supplements that are reasonably necessary for the ADSs to be registered under the Securities Act or to be eligible for book-entry settlement, in each case
without imposing or increasing the fees and charges you are required to pay. In addition, we may not be able to provide you with prior notice of any modifications or supplements that are required to accommodate compliance with applicable provisions
of law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will be bound by the modifications to the deposit agreement if you continue to hold your ADSs after the modifications to the deposit
agreement become effective. The deposit agreement cannot be amended to prevent you from withdrawing the ordinary shares represented by your ADSs (except as permitted by law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have the right to direct the depositary to terminate the deposit agreement. Similarly, the depositary may in certain circumstances on its own initiative
terminate the deposit agreement. In either case, the depositary must give notice to the holders at least 30 days before termination. Until termination, your rights under the deposit agreement will be unaffected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After termination, the depositary will continue to collect distributions received (but will not distribute any such property until you request the
cancellation of your ADSs) and may sell the securities held on deposit. After the sale, the depositary will hold the proceeds from such sale and any other funds then held for the holders of ADSs in a
<FONT STYLE="white-space:nowrap">non-interest</FONT> bearing account. At that point, the depositary will have no further obligations to holders other than to account for the funds then held for the holders of ADSs still outstanding (after deduction
of applicable fees, taxes and expenses). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Books of Depositary </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary will maintain ADS holder records at its depositary office. You may inspect such records at such office during regular business hours but solely
for the purpose of communicating with other holders in the interest of business matters relating to the ADSs and the deposit agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary
will maintain in New York facilities to record and process the issuance, cancellation, combination, <FONT STYLE="white-space:nowrap">split-up</FONT> and transfer of ADSs. These facilities may be closed from time to time, to the extent not prohibited
by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitations on Obligations and Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The deposit agreement limits our obligations and the depositary&#146;s obligations to you. Please note the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary are obligated only to take the actions specifically stated in the deposit agreement without
negligence or bad faith. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The depositary disclaims any liability for any failure to carry out voting instructions, for any manner in which
a vote is cast or for the effect of any vote, provided it acts without negligence in good faith and in accordance with the terms of the deposit agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The depositary disclaims any liability for any failure to determine the lawfulness or practicality of any action,
for the content of any document forwarded to you on our behalf or for the accuracy of any translation of such a document, for the investment risks associated with investing in ordinary shares, for the validity or worth of the ordinary shares, for
any tax consequences that result from the ownership of ADSs, for the credit-worthiness of any third party, for allowing any rights to lapse under the terms of the deposit agreement, for the timeliness of any of our notices or for our failure to give
notice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary will not be obligated to perform any act that is inconsistent with the terms of the deposit
agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary disclaim any liability if we or the depositary are prevented or forbidden from, or delayed
in, doing or performing any act or thing required by the terms of the deposit agreement, by reason of any provision, present or future, of any law or regulation, or subject to any civil or criminal penalty or restraint or by reason of any provision,
present or future, of our Articles of Incorporation, or any provision of or governing the securities on deposit, or by reason of any act of God or war or other circumstances beyond our control. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary disclaim any liability by reason of any exercise of, or failure to exercise, any discretion
provided for in the deposit agreement or in our Articles of Incorporation or in any provisions of or governing the securities on deposit. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary further disclaim any liability for any action or inaction in reliance on the advice or
information received from legal counsel, accountants, any person presenting shares for deposit, any holder of ADSs or authorized representatives thereof, or any other person believed by either of us in good faith to be competent to give such advice
or information. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary also disclaim liability for the inability by a holder to benefit from any distribution,
offering, right or other benefit that is made available to holders of ordinary shares but is not, under the terms of the deposit agreement, made available to you. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary may rely without any liability upon any written notice, request or other document believed
to be genuine and to have been signed or presented by the proper parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary also disclaim liability for any consequential or punitive damages for any breach of the
terms of the deposit agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No disclaimer of any Securities Act liability is intended by any provision of the deposit agreement.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Pre-Release</FONT> Transactions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions of the deposit agreement, the depositary may issue to broker/dealers ADSs before receiving a deposit of ordinary shares or
release ordinary shares to broker/dealers before receiving ADSs for cancellation. These transactions are commonly referred to as <FONT STYLE="white-space:nowrap">&#147;pre-release</FONT> transactions,&#148; and are entered into between the
depositary and the applicable broker/dealer. The deposit agreement limits the aggregate size of <FONT STYLE="white-space:nowrap">pre-release</FONT> transactions (not to exceed 30% of the ordinary shares on deposit in the aggregate) and imposes a
number of conditions on such transactions (i.e., the need to receive collateral, the type of collateral required, the representations required from brokers, etc.). The depositary may retain the compensation received from the <FONT
STYLE="white-space:nowrap">pre-release</FONT> transactions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will be responsible for the taxes and other governmental charges payable on the ADSs and the securities represented by the ADSs. We, the depositary and the
custodian may deduct from any distribution the taxes and governmental charges payable by holders and may sell any and all property on deposit to pay the taxes and governmental charges payable by holders. You will be liable for any deficiency if the
sale proceeds do not cover the taxes that are due. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary may refuse to issue ADSs, to deliver, transfer, split and combine ADRs or to release
securities on deposit until all taxes and charges are paid by the applicable holder. The depositary and the custodian may take reasonable administrative actions to obtain tax refunds and reduced tax withholding for any distributions on your behalf.
However, you may be required to provide to the depositary and to the custodian proof of taxpayer status and residence and such other information as the depositary and the custodian may require to fulfill legal obligations. You are required to
indemnify us, the depositary and the custodian for any claims with respect to taxes based on any tax benefit obtained for you. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency
Conversion </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary will arrange for the conversion of all foreign currency received into U.S. dollars if such conversion is practical, and
it will distribute the U.S. dollars in accordance with the terms of the deposit agreement. You may have to pay fees and expenses incurred in converting foreign currency, such as fees and expenses incurred in complying with currency exchange controls
and other governmental requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the conversion of foreign currency is not practical or lawful, or if any required approvals are denied or not
obtainable at a reasonable cost or within a reasonable period, the depositary may take the following actions in its discretion: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">convert the foreign currency to the extent practical and lawful and distribute the U.S. dollars to the holders
for whom the conversion and distribution is lawful and practical; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distribute the foreign currency to holders for whom the distribution is lawful and practical; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hold the foreign currency (without liability for interest) for the applicable holders. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc841346_13"></A>MATERIAL INCOME TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Material U.S. Federal Income Tax Considerations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of certain material U.S. federal income tax considerations relating to the acquisition, ownership and disposition of ADSs by a U.S.
Holder (as defined below). This summary addresses only the U.S. federal income tax considerations for U.S. Holders that are initial purchasers of the ADSs pursuant to the offering and that will hold such ADSs as capital assets. This summary does not
address all U.S. federal income tax matters that may be relevant to a particular U.S. Holder. This summary does not address tax considerations applicable to a holder of ADSs that may be subject to special tax rules including, without limitation, the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, financial institutions or insurance companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers, dealers or traders in securities, currencies, commodities, or notional principal contracts;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> entities or organizations, including an &#147;individual
retirement account&#148; or &#147;Roth IRA&#148; as defined in Section&nbsp;408 or 408A of the Code (as defined below), respectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts, regulated investment companies or grantor trusts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that hold the ADSs as part of a &#147;hedging,&#148; &#147;integrated&#148; or &#147;conversion&#148;
transaction or as a position in a &#147;straddle&#148; for U.S. federal income tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships (including entities or arrangements treated as partnerships for U.S. federal income tax purposes) or
other pass-through entities, or persons that will hold the ADSs through such an entity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">S corporations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain former citizens or long term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that are subject to Section&nbsp;451(b) of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that received ADSs as compensation for the performance of services; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that acquire ADSs as a result of holding or owning our preferred shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">holders that own directly, indirectly, or through attribution 10% or more of our ADSs and shares; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">holders that have a &#147;functional currency&#148; other than the U.S. dollar. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, this summary does not address the U.S. federal estate, gift, or alternative minimum tax considerations, or any U.S. state, local, or <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> tax considerations of the acquisition, ownership and disposition of the ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This description is based on the
U.S. Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), existing, proposed and temporary U.S. Treasury Regulations promulgated thereunder and administrative and judicial interpretations thereof, in each case as in effect and available
on the date hereof. All the foregoing is subject to change, which change could apply retroactively, and to differing interpretations, all of which could affect the tax considerations described below. There can be no assurances that the U.S. Internal
Revenue Service (the &#147;IRS&#148;) will not take a position concerning the tax consequences of the acquisition, ownership and disposition of the ADSs or that such a position would not be sustained. Holders should consult their own tax advisers
concerning the U.S. federal, state, local and <FONT STYLE="white-space:nowrap">non-</FONT> U.S. tax consequences of acquiring, owning, and disposing of the ADSs in their particular circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this summary, a &#147;U.S. Holder&#148; is a beneficial owner of ADSs that is (or is treated as), for U.S. federal income tax purposes:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation, or other entity that is treated as a corporation for U.S. federal income tax purposes, created or
organized in or under the laws of the United States, any state thereof, or the District of Columbia; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust, if a court within the United States is able to exercise primary supervision over its administration and
one or more U.S. persons have the authority to control all of the substantial decisions of such trust or has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a United States person. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a partnership (or any other entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds ADSs, the U.S. federal income tax
consequences relating to an investment in the ADSs will depend in part upon the status of the partner and the activities of the partnership. Such a partner or partnership should consult its tax advisor regarding the U.S. federal income tax
considerations of acquiring, owning and disposing of the ADSs in its particular circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As indicated below, this discussion is subject to U.S.
federal income tax rules applicable to a &#147;passive foreign investment company,&#148; or a PFIC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Persons considering an investment in the ADSs
should consult their own tax advisors as to the particular tax consequences applicable to them relating to the acquisition, ownership and disposition of the ADSs, including the applicability of U.S. federal, state and local tax laws and <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> tax laws. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The discussion below assumes that the representations contained in the deposit agreement are
true and that the obligations in the deposit agreement and any related agreement will be complied with in accordance with their terms. Generally, a holder of an ADS should be treated for U.S. federal income tax purposes as the beneficial owner of
the ordinary shares represented by the ADS. Accordingly, no gain or loss will be recognized upon an exchange of ADSs for ordinary shares. The U.S. Treasury has expressed concerns that intermediaries in the chain of ownership between the holder of an
ADS and the issuer of the security underlying the ADS may be taking actions that are inconsistent with the beneficial ownership by the holder of the underlying security. Accordingly, the creditability of foreign taxes, if any, as described below,
could be affected by actions taken by intermediaries in the chain of ownership between the holders of ADSs and our company if as a result of such actions the holders of ADSs are not properly treated as beneficial owners of the underlying ordinary
shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Distributions. </I></B>Subject to the discussion under &#147;<I>Passive Foreign Investment Company Considerations,</I>&#148; below, the
gross amount of any distribution (before reduction for any amounts withheld in respect of French withholding tax) actually or constructively received by a U.S. Holder with respect to ADSs will be taxable to the U.S. Holder as a dividend to the
extent of the U.S. Holder&#146;s pro rata share of our current and accumulated earnings and profits as determined under U.S. federal income tax principles. Distributions in excess of earnings and profits will be
<FONT STYLE="white-space:nowrap">non-taxable</FONT> to the U.S. Holder to the extent of, and will be applied against and reduce, the U.S. Holder&#146;s adjusted tax basis in the ADSs. Distributions in excess of earnings and profits and such adjusted
tax basis will generally be taxable to the U.S. Holder as either long-term or short-term capital gain depending upon whether the U.S. Holder has held the ADSs for more than one year as of the time such distribution is received. However, since we do
not calculate our earnings and profits under U.S. federal income tax principles, it is expected that any distribution will be reported as a dividend, even if that distribution would otherwise be treated as a
<FONT STYLE="white-space:nowrap">non-taxable</FONT> return of capital or as capital gain under the rules described above. <FONT STYLE="white-space:nowrap">Non-corporate</FONT> U.S. Holders may qualify for the preferential rates of taxation with
respect to dividends on ADSs applicable to long-term capital gains (i.e., gains from the sale of capital assets held for more than one year) applicable to qualified dividend income (as discussed below) if we are a &#147;qualified foreign
corporation&#148; and certain other requirements (discussed below) are met. A <FONT STYLE="white-space:nowrap">non-</FONT> United States corporation (other than a corporation that is classified as a PFIC for the taxable year in which the dividend is
paid or the preceding taxable year) generally will be considered to be a qualified foreign corporation (a)&nbsp;if it is eligible for the benefits of a comprehensive tax treaty with the United States which the Secretary of Treasury of the United
States determines is satisfactory for purposes of these rules and which includes an exchange of information provision, or (b)&nbsp;with respect to any dividend it pays on ADSs which are readily tradable on an established securities market in the
United States. The ADSs are listed on the Nasdaq </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Global Select Market, which is an established securities market in the United States, and we expect the ADSs to be readily tradable on the Nasdaq Global Select Market. However, there can be no
assurance that the ADSs will be considered readily tradable on an established securities market in the United States in the current taxable year or later years. The company, which is incorporated under the laws of France, believes that it qualifies
as a resident of France for purposes of, and is eligible for the benefits of, the Convention between the Government of the United States of America and the Government of the French Republic for the Avoidance of Double Taxation and the Prevention of
Fiscal Evasion with Respect to Taxes on Income and Capital, signed on August&nbsp;31, 1994, as amended and currently in force, or the U.S.-France Tax Treaty, although there can be no assurance in this regard. Further, the IRS has determined that the
U.S.-France Tax Treaty is satisfactory for purposes of the qualified dividend rules and that it includes an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">exchange-of-information</FONT></FONT> program. Therefore, subject to the
discussion under &#147;<I>Passive Foreign Investment Company Considerations</I>,&#148; below, such dividends will generally be &#147;qualified dividend income&#148; in the hands of <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders,
provided that a holding period requirement (more than 60 days of ownership, without protection from the risk of loss, during the <FONT STYLE="white-space:nowrap">121-day</FONT> period beginning 60 days before the
<FONT STYLE="white-space:nowrap">ex-dividend</FONT> date) and certain other requirements are met. The dividends will not be eligible for the dividends-received deduction generally allowed to corporate U.S. Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A U.S. Holder generally may claim the amount of any French withholding tax as either a deduction from gross income or a credit against U.S. federal income tax
liability. However, the foreign tax credit is subject to numerous complex limitations that must be determined and applied on an individual basis. Generally, the credit cannot exceed the proportionate share of a U.S. Holder&#146;s U.S. federal income
tax liability that such U.S. Holder&#146;s taxable income bears to such U.S. Holder&#146;s worldwide taxable income. In applying this limitation, a U.S. Holder&#146;s various items of income and deduction must be classified, under complex rules, as
either &#147;foreign source&#148; or &#147;U.S. source.&#148; In addition, this limitation is calculated separately with respect to specific categories of income. The amount of a distribution with respect to the ADSs that is treated as a
&#147;dividend&#148; may be lower for U.S. federal income tax purposes than it is for French income tax purposes, potentially resulting in a reduced foreign tax credit for the U.S. Holder. Each U.S. Holder should consult its own tax advisors
regarding the foreign tax credit rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, the amount of a distribution paid to a U.S. Holder in a foreign currency will be the dollar value of
the foreign currency calculated by reference to the spot exchange rate on the day the U.S. Holder receives the distribution, regardless of whether the foreign currency is converted into U.S. dollars at that time. Any foreign currency gain or loss a
U.S. Holder realizes on a subsequent conversion of foreign currency into U.S. dollars will be U.S. source ordinary income or loss. If dividends received in a foreign currency are converted into U.S. dollars on the day they are received, a U.S.
Holder should not be required to recognize foreign currency gain or loss in respect of the dividend. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sale, Exchange or Other Taxable Disposition of
the ADSs. </I></B>A U.S. Holder will generally recognize gain or loss for U.S. federal income tax purposes upon the sale, exchange or other taxable disposition of ADSs in an amount equal to the difference between the U.S. dollar value of the amount
realized from such sale or exchange and the U.S. Holder&#146;s tax basis for those ADSs. Subject to the discussion under &#147;<I>Passive Foreign Investment Company Considerations</I>&#148; below, this gain or loss will generally be a capital gain
or loss. The adjusted tax basis in the ADSs generally will be equal to the cost of such ADSs. Capital gain from the sale, exchange or other taxable disposition of ADSs of a <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder is
generally eligible for a preferential rate of taxation applicable to capital gains, if the <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder&#146;s holding period determined at the time of such sale, exchange or other taxable
disposition for such ADSs exceeds one year (i.e., such gain is long-term capital gain). The deductibility of capital losses for U.S. federal income tax purposes is subject to limitations under the Code. Any such gain or loss that a U.S. Holder
recognizes generally will be treated as U.S. source income or loss for foreign tax credit limitation purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a cash basis taxpayer, units of foreign currency paid or received are translated into U.S. dollars at
the spot rate on the settlement date of the purchase or sale. In that case, no foreign currency exchange gain or loss will result from currency fluctuations between the trade date and the settlement date of such a purchase or sale. An accrual basis
taxpayer, however, may elect the same treatment required of cash basis taxpayers with respect to purchases and sales of the ADSs that are traded on an established securities market, provided the election is applied consistently from year to year.
Such election may not be changed without the consent of the IRS. For an accrual basis taxpayer who does not make such election, units of foreign currency paid or received are translated into U.S. dollars at the spot rate on the trade date of the
purchase or sale. Such an accrual basis taxpayer may recognize exchange gain or loss based on currency fluctuations between the trade date and the settlement date. Any foreign currency gain or loss a U.S. Holder realizes will be U.S. source ordinary
income or loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Medicare Tax. </I></B>Certain U.S. Holders that are individuals, estates or trusts are subject to a 3.8% tax on all or a portion of
their &#147;net investment income,&#148; which may include all or a portion of their dividend income and net gains from the disposition of ADSs. Each U.S. Holder that is an individual, estate or trust is urged to consult its tax advisors regarding
the applicability of the Medicare tax to its income and gains in respect of its investment in the ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Passive Foreign Investment Company
Considerations. </I></B>If we are classified as a passive foreign investment company (&#147;PFIC&#148;) in any taxable year, a U.S. Holder would be subject to special rules generally intended to reduce or eliminate any benefits from the deferral of
U.S. federal income tax that a U.S. Holder could derive from investing in a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> company that does not distribute all of its earnings on a current basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A corporation organized outside the United States generally will be classified as a PFIC for U.S. federal income tax purposes in any taxable year in which,
after applying certain look-through rules with respect to the income and assets of its subsidiaries, either: (i)&nbsp;at least 75% of its gross income is &#147;passive income&#148; or (ii)&nbsp;at least 50% of the average quarterly value of its
total gross assets (which, if we are publicly traded for the entire year being tested, would be measured by the fair market value of our assets, and for which purpose the total value of our assets may be determined in part by the market value of the
ADSs and our ordinary shares, which are subject to change) is attributable to assets that produce &#147;passive income&#148; or are held for the production of &#147;passive income.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Passive income for this purpose generally includes dividends, interest, royalties, rents, gains from commodities and securities transactions, the excess of
gains over losses from the disposition of assets which produce passive income, and includes amounts derived by reason of the temporary investment of funds raised in offerings of the ADSs. If a <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
corporation owns directly or indirectly at least 25% by value of the stock of another corporation, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation is treated for purposes of the PFIC tests as owning its proportionate share of the
assets of the other corporation and as receiving directly its proportionate share of the other corporation&#146;s income. If we are classified as a PFIC in any year with respect to which a U.S. Holder owns the ADSs, we will continue to be treated as
a PFIC with respect to such U.S. Holder in all succeeding years during which the U.S. Holder owns the ADSs, regardless of whether we continue to meet the tests described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market value of our assets may be determined in large part by reference to the market price of the ADSs and our ordinary shares, which is likely to
fluctuate after the offering. In addition, the composition of our income and assets will be affected by how, and how quickly, we use the cash proceeds from this global offering in our business. Whether we are a PFIC for any taxable year will depend
on our assets and income (including whether we receive certain <FONT STYLE="white-space:nowrap">non-refundable</FONT> grants or subsidies and whether such amounts, and the amounts of any reimbursements of research tax credits we receive, will
constitute gross income for purposes of the PFIC income test) in each year, and because this is a factual determination made annually after the end of each taxable year, there can be no assurance that we will not be considered a PFIC in any taxable
year. Nevertheless, based on the composition of our assets and income for our 2018 taxable year, we believe we were not likely a PFIC for our 2018 taxable year and do not expect to be a PFIC for our 2019 taxable year. However, there can be no
assurance that we have not been or will not be a PFIC for the current taxable year or any future taxable year. Our U.S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
counsel expresses no opinion with respect to our PFIC status for our taxable year ending December&nbsp;31, 2018, and also expresses no opinion with regard to our expectations regarding our PFIC
status in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are a PFIC, and you are a U.S. Holder, then unless you make one of the elections described below, a special tax regime will
apply to both (a)&nbsp;any &#147;excess distribution&#148; by us to you (generally, your ratable portion of distributions in any year which are greater than 125% of the average annual distribution received by you in the shorter of the three
preceding years or your holding period for the ADSs) and (b)&nbsp;any gain realized on the sale or other disposition of the ADSs. Under this regime, any excess distribution and realized gain will be treated as ordinary income and will be subject to
tax as if (a)&nbsp;the excess distribution or gain had been realized ratably over your holding period, (b)&nbsp;the amount deemed realized in each year had been subject to tax in each year of that holding period at the highest marginal rate for such
year (other than income allocated to the current period or any taxable period before we became a PFIC, which would be subject to tax at the U.S. Holder&#146;s regular ordinary income rate for the current year and would not be subject to the interest
charge discussed below), and (c)&nbsp;the interest charge generally applicable to underpayments of tax had been imposed on the taxes deemed to have been payable in those years. In addition, dividend distributions made to you will not qualify for the
lower rates of taxation applicable to long-term capital gains discussed above under &#147;Distributions.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain elections exist that may alleviate
some of the adverse consequences of PFIC status and would result in an alternative treatment (such as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> treatment) of the ADSs. If a U.S. Holder makes the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-</FONT></FONT> market election, the U.S. Holder generally will recognize as ordinary income any excess of the fair market value of the ADSs at the end of each taxable year over
their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the ADSs over their fair market value at the end of the taxable year (but only to the extent of the net amount of income previously
included as a result of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election). If a U.S. Holder makes the election, the U.S. Holder&#146;s tax basis in the ADSs will be adjusted to reflect these
income or loss amounts. Any gain recognized on the sale or other disposition of ADSs in a year when we are a PFIC will be treated as ordinary income and any loss will be treated as an ordinary loss (but only to the extent of the net amount of income
previously included as a result of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election). The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT>
election is available only if we are a PFIC and the ADSs are &#147;regularly traded&#148; on a &#147;qualified exchange.&#148; The ADSs will be treated as &#147;regularly traded&#148; in any calendar year in which more than a de minimis quantity of
the ADSs are traded on a qualified exchange on at least 15 days during each calendar quarter (subject to the rule that trades that have as one of their principal purposes the meeting of the trading requirement are disregarded). The Nasdaq Global
Select Market is a qualified exchange for this purpose and, consequently, if the ADSs are regularly traded, the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election will be available to a U.S.
Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not currently intend to provide the information necessary for U.S. Holders to make qualified electing fund elections if we are treated as a
PFIC for any taxable year. U.S. Holders should consult their tax advisors to determine whether any of these elections would be available and if so, what the consequences of the alternative treatments would be in their particular circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are determined to be a PFIC, the general tax treatment for U.S. Holders described in this section would apply to indirect distributions and gains deemed
to be realized by U.S. Holders in respect of any of our subsidiaries that also may be determined to be PFICs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a U.S. Holder owns ADSs during any
taxable year in which we are a PFIC, the U.S. Holder generally will be required to file an IRS Form 8621 (Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund) with respect to the company, generally
with the U.S. Holder&#146;s federal income tax return for that year. If our company were a PFIC for a given taxable year, then you should consult your tax advisor concerning your annual filing requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The U.S. federal income tax rules relating to PFICs are complex. Prospective U.S. investors are urged to consult their own tax advisers with respect to the
acquisition, ownership and disposition of the ADSs, the consequences to them of an investment in a PFIC, any elections available with respect to the ADSs and the </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>
IRS information reporting obligations with respect to the acquisition, ownership and disposition of the ADSs. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Backup Withholding and Information Reporting. </I></B>U.S. Holders generally will be subject to information reporting requirements with respect to
dividends on ADSs and on the proceeds from the sale, exchange or disposition of ADSs that are paid within the United States or through U.S.-related financial intermediaries, unless the U.S. Holder is an &#147;exempt recipient.&#148; In addition,
U.S. Holders may be subject to backup withholding on such payments, unless the U.S. Holder provides a taxpayer identification number and a duly executed IRS Form <FONT STYLE="white-space:nowrap">W-9</FONT> or otherwise establishes an exemption.
Backup withholding is not an additional tax, and the amount of any backup withholding will be allowed as a credit against a U.S. Holder&#146;s U.S. federal income tax liability and may entitle such holder to a refund, provided that the required
information is timely furnished to the IRS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Asset Reporting. </I></B>Certain U.S. Holders who are individuals are required to report
information relating to an interest in the ADSs, subject to certain exceptions (including an exception for shares held in accounts maintained by U.S. financial institutions) by filing IRS Form 8938 (Statement of Specified Foreign Financial Assets)
with their federal income tax return. U.S. Holders are urged to consult their tax advisors regarding their information reporting obligations, if any, with respect to their ownership and disposition of the ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE DISCUSSION ABOVE IS A GENERAL SUMMARY. IT DOES NOT COVER ALL TAX MATTERS THAT MAY BE OF IMPORTANCE TO A PROSPECTIVE INVESTOR. EACH PROSPECTIVE INVESTOR
IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO IT OF AN INVESTMENT IN ADSS IN LIGHT OF THE INVESTOR&#146;S OWN CIRCUMSTANCES. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>French Tax Consequences </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following describes the
material French tax consequences to U.S. Holders (as defined below) of purchasing, owning and disposing of our ADSs and, unless otherwise noted, this discussion is the opinion of McDermott Will&nbsp;&amp; Emery AARPI, our French tax counsel, insofar
as it relates to matters of French tax law and legal conclusions with respect to those matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion does not purport to be a complete
analysis or listing of all potential tax effects of the acquisition, ownership or disposition of our ADSs to any particular investor, and does not discuss tax considerations that arise from rules of general application or that are generally assumed
to be known by investors. All of the following is subject to change. Such changes could apply retroactively and could affect the consequences described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">French tax rules applicable to French assets that are held by or in foreign trusts provide inter alia for the inclusion of trust assets in the settlor&#146;s
net assets for purpose of assessing the French real estate wealth tax, the French gift and estate tax, the specific tax on value of the French assets, within the scope of the French real estate wealth tax, held in or by foreign trusts not already
subject to the French real estate wealth tax, and for a number of French tax reporting and disclosure obligations. The following discussion does not address the French tax consequences applicable to ADSs held in trusts. If ADSs are held in trust,
the grantor, trustee and beneficiary are urged to consult their own tax adviser regarding the specific tax consequences of acquiring, owning and disposing of securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The description of the French income tax and wealth tax consequences set forth below is based on the Convention Between the Government of the United States of
America and the Government of the French Republic for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income and Capital of August&nbsp;31, 1994, or the Treaty, which came into force on December&nbsp;30, 1995 (as amended by any subsequent protocols, including
the protocol of January&nbsp;13, 2009), and the tax guidelines issued by the French tax authorities in force as of the date of this prospectus (the &#147;Treaty&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this discussion, a &#147;U.S. Holder&#148; is a beneficial owner of ADSs that is (or is
treated as), for U.S. federal income tax purposes: (1)&nbsp;an individual who is a citizen or resident of the United States; (2)&nbsp;a corporation, or other entity that is treated as a corporation for U.S. federal income tax purposes, created or
organized in or under the laws of the United States, any state thereof, or the District of Columbia; (3)&nbsp;an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or (4)&nbsp;a trust, if a court within
the United States is able to exercise primary supervision over its administration and one or more U.S. persons have the authority to control all of the substantial decisions of such trust or has a valid election in effect under applicable U.S.
Treasury Regulations to be treated as a United States person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a partnership (or any other entity treated as partnership for U.S. federal income tax
purposes) holds ADSs, the tax treatment of the partnership and a partner in such partnership generally will depend on the status of the partner and the activities of the partnership. Such partner or partnership is urged to consult its own tax
adviser regarding the specific tax consequences of acquiring, owning and disposing of securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion applies only to investors that hold
ADSs as capital assets that have the U.S. dollar as their functional currency, that are entitled to Treaty benefits under the &#147;Limitation on Benefits&#148; provision contained in the Treaty, and whose ownership of the ADSs is not effectively
connected to a permanent establishment or a fixed base in France. Certain U.S. Holders (including, but not limited to, U.S. expatriates, partnerships or other entities classified as partnerships for U.S. federal income tax purposes, banks, insurance
companies, regulated investment companies, <FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations, financial institutions, persons subject to the alternative minimum tax, persons who acquired the securities pursuant to the exercise of
employee share options or otherwise as compensation, persons that own (directly, indirectly or by attribution) 5% or more of our voting stock or 5% or more of our outstanding share capital, dealers in securities or currencies, persons that elect to
mark their securities to market for U.S. federal income tax purposes and persons holding securities as a position in a synthetic security, straddle or conversion transaction) may be subject to special rules not discussed below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Holders are urged to consult their own tax advisers regarding the tax consequences of the purchase, ownership and disposition of securities in light of
their particular circumstances, especially with regard to the &#145;&#145;Limitations on Benefits&#146;&#146; provision. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Estate and Gift Taxes and
Transfer Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, a transfer of securities by gift or by reason of death of a U.S. Holder that would otherwise be subject to French gift or
inheritance tax, respectively, will not be subject to such French tax by reason of the Convention between the Government of the United States of America and the Government of the French Republic for the Avoidance of Double Taxation and the
Prevention of Fiscal Evasion with Respect to Taxes on Estates, Inheritances and Gifts, dated November&nbsp;24, 1978 (as amended by the protocol of December&nbsp;8, 2004), unless the donor or the transferor is domiciled in France at the time of
making the gift or at the time of his or her death, or the securities were used in, or held for use in, the conduct of a business through a permanent establishment or a fixed base in France. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Article 235 ter ZD of the<I> Code g&eacute;n&eacute;ral des imp&ocirc;ts</I> (French Tax Code, or FTC), purchases of shares or ADSs of a French
company listed on a regulated market of the European Union or an exchange formally acknowledged by the French Financial Market Authority (AMF) are subject to a 0.3% French tax on financial transactions provided that the issuer&#146;s market
capitalization exceeds 1&nbsp;billion euros as of December&nbsp;1 of the year preceding the taxation year. A list of French relevant companies whose market capitalization exceeds 1&nbsp;billion euros as of December&nbsp;1 of the year preceding the
taxation year is published annually by the French State. Although we were included in the list published for calendar years 2016 and 2017, we were not included in the list published for calendar years 2018, 2019 and 2020, but this may change in the
future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Article 726 II d) of the FTC, transfers of securities that are subject to the French tax on financial transactions are exempt from
any transfer tax in France. Conversely, in the case where Article 235 ter ZD of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
FTC is not applicable, transfers of shares issued by a French listed company will be subject to uncapped registration duties at the rate of 0.1% if the transfer is evidenced by a written
statement (&#147;<I>acte</I>&#148;) executed either in France or outside France. Although there is no case law or official guidelines published by the French tax authorities on this point, transfers of ADSs should remain outside of the scope of the
aforementioned 0.1% registration duties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Wealth Tax </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The French real estate wealth tax (<I>imp&ocirc;t sur la fortune immobili&egrave;re</I>), introduced by French Finance Bill dated December 30<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> 2017, applies only to individuals who own, directly or indirectly, through one or more legal entities, real estate property in France (subject to certain exemptions) ) and whose net taxable assets
amount to at least &#128;1,300,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">French real estate wealth tax in France may only apply to U.S. Holders, with respect to shares, rights, or interest
in a company, to the extent that such company holds real estate assets that are not allocated to its operational activity, for the fraction of the value of the shares, rights or interest in the company representing such real estate assets, In any
case, pursuant to Article 965 2&deg; of the FTC, shares of an operating entity holding French real estate assets in which the taxpayer holds, directly and indirectly, less than 10% of the share capital or voting rights are exempt from real estate
wealth tax. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Taxation of Dividends </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends paid by
a French corporation to <FONT STYLE="white-space:nowrap">non-residents</FONT> of France are generally subject to French withholding tax at a rate of 12.8% when the recipient is an individual and at the standard corporate income tax rate set forth in
Article <FONT STYLE="white-space:nowrap">219-I</FONT> of the FTC i.e., 28% in 2020) otherwise. Dividends paid by a French corporation in a <FONT STYLE="white-space:nowrap">non-cooperative</FONT> State or territory, within the meaning of Article <FONT
STYLE="white-space:nowrap">238-0</FONT> A of the FTC (other than the <FONT STYLE="white-space:nowrap">non-cooperative</FONT> States or territories mentioned in Article <FONT STYLE="white-space:nowrap">238-0</FONT> A 2 bis 2&deg; of the FTC), will
generally be subject to French withholding tax at a rate of 75%. However, eligible U.S. Holders, other than individuals subject to the French withholding tax at a rate of 12.8%, entitled to Treaty benefits under the &#147;Limitation on
Benefits&#148; provision contained in the Treaty who are U.S. residents, as defined pursuant to the provisions of the Treaty, may be subject to the withholding tax at a reduced rate (as described below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Treaty, the rate of French withholding tax on dividends paid to an eligible U.S. Holder which is a U.S. resident as defined pursuant to the
provisions of the Treaty and which ownership of the ordinary shares or ADSs is not effectively connected with a permanent establishment or fixed base that such U.S. Holder has in France may be capped at 15%, or 5% if such U.S. Holder is a
corporation and owns directly or indirectly at least 10% of the share capital of the issuer; such U.S. Holder may claim a refund from the French tax authorities of the amount withheld in excess of the Treaty rates of 15% or 5%, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For U.S. Holders that are not individuals but are U.S. residents, as defined pursuant to the provisions of the Treaty, the requirements for eligibility for
Treaty benefits, including the reduced 5% or 15% withholding tax rates, contained in the &#147;Limitation on Benefits&#148; provision of the Treaty, are complex. U.S. Holders are advised to consult their own tax advisers regarding their eligibility
for Treaty benefits in light of their own particular circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends paid to an eligible U.S. Holder may immediately be subject to the reduced
rates provided that such U.S. Holder establishes before the date of payment that it is a U.S. resident under the Treaty by completing and providing the depositary with a treaty form (Form 5000). Dividends paid to a U.S. Holder, other than
individuals subject to the French withholding tax at the rate of 12.8%, that has not filed the Form 5000 before the dividend payment date will be subject to French withholding tax at the rate of 28%, or 75% if paid in a <FONT
STYLE="white-space:nowrap">non-cooperative</FONT> State or territory (within the meaning of Article <FONT STYLE="white-space:nowrap">238-0</FONT> A of the FTC, other than the <FONT STYLE="white-space:nowrap">non-cooperative</FONT> States or
territories mentioned in Article <FONT STYLE="white-space:nowrap">238-0</FONT> A 2 bis 2&deg; of the FTC), and then reduced at a later date to 5% or 15%, provided that such holder duly completes and provides the depositary with the treaty forms Form
5000 and Form 5001 before December&nbsp;31 of the second calendar year following the year during which the dividend is paid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Certain qualifying pension funds and certain other <FONT STYLE="white-space:nowrap">tax-exempt</FONT> entities are subject to the same general filing requirements as other U.S. Holders except
that they may have to supply additional documentation evidencing their entitlement to these benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form 5000 and Form 5001, together with
instructions, will be provided by the depositary to all U.S. Holders registered with the depositary. The depositary will arrange for the filing with the French Tax authorities of all such forms properly completed and executed by U.S. Holders of
ordinary shares or ADSs and returned to the depositary in sufficient time so that they may be filed with the French tax authorities before the distribution in order to obtain immediately a reduced withholding tax rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The withholding tax refund, if any, ordinarily occurs within 12 months from filing the applicable French Treasury Form, but not before January&nbsp;15 of the
year following the calendar year in which the related dividend was paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the withholding tax rate applicable under French domestic law to U.S.
Holders who are individuals does not exceed the cap provided in the Treaty (i.e. 15%), the 12.8% rate shall apply to dividends paid to those U.S. Holders, without any reduction provided under the Treaty. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax on Sale or Other Disposition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, under the
Treaty, a U.S. Holder who is a U.S. resident for purposes of the Treaty will not be subject to French tax on any capital gain from the redemption, sale or exchange of ordinary shares or ADSs unless the ordinary shares or the ADSs form part of the
business property of a permanent establishment or fixed base that the U.S. Holder has in France. Special rules apply to U.S. Holders who are residents of more than one country. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc841346_14"></A>UNDERWRITERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The global offering consists of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an offering of a total of ordinary shares in the form of ADSs in the United States, Canada and countries outside
Europe; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a concurrent offering of a total of ordinary shares in Europe (including France) exclusively addressed to
&#147;qualified investors&#148; (as this term is defined under EU Regulation n&deg;2017/1129). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms and subject to the
conditions in an underwriting agreement dated the date of this prospectus supplement, the U.S. underwriters named below, for whom Goldman Sachs International, Citigroup Global Markets Inc. and Citigroup Global Markets Limited are acting as managers,
have severally agreed to purchase, and we have agreed to sell to them, severally, the number of ADSs and/or ordinary shares indicated below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>ADSs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Ordinary<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs International</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Limited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters are offering the ADSs and ordinary shares subject to their acceptance of the ADSs and ordinary shares from us
and subject to prior sale. The underwriting agreement provides that the obligations of the several underwriters to pay for and accept delivery of the ADSs and ordinary shares offered by this prospectus supplement are subject to the approval of
certain legal matters by their counsel and to certain other conditions. The underwriters are obligated to take and pay for all of the ADSs and ordinary shares offered by this prospectus supplement if any such securities are taken. However, the
underwriters are not required to take or pay for the ADSs and ordinary shares covered by the underwriters&#146; option to purchase additional shares described below. The offering price and the total underwriting commissions per ADS or per ordinary
share for the U.S. offering and the European offering are identical, subject to the ratio of ADSs/ordinary shares and currency conversion. The underwriters may provide their services in this global offering through or in conjunction with one or more
of their respective affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters initially propose to offer part of the ADSs and ordinary shares directly to the public at the offering
price listed on the cover page of this prospectus supplement and part to certain dealers. After the initial offering of the ADSs and ordinary shares, the offering price and other selling terms may from time to time be varied by the representative.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have agreed to issue at the option of the underwriters up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional ordinary shares in the form of ADSs at the public offering price listed on the cover page of this prospectus supplement, less underwriting
commissions. The option granted may be exercised at any time in whole or in part by the underwriters within 30 days from the date of the underwriting agreement. To the extent the option is exercised, each underwriter will become obligated, subject
to certain conditions, to purchase about the same percentage of the additional ordinary shares in the form of ADSs as the number listed next to the underwriter&#146;s name in the preceding table bears to the total number of ADSs or ordinary shares,
as applicable, listed next to the names of all underwriters in the preceding table. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The address of Goldman Sachs International is Plumtree Court, 25 Shoe
Lane, London EC4A 4AU, the address of Citigroup Global Markets Inc. is 388 Greenwich Street, New York, New York 10013 and the address of Citigroup Global Markets Limited is Citigroup Centre, Canada Square, Canary Wharf E14 5LB&#151;United Kingdom.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows the per share and total public offering price, underwriting commissions, and
proceeds before expenses to us. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional ordinary shares in the form of ADSs. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Paid by DBV Technologies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per Ordinary Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per ADS<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes an exchange rate of $ per Euro. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The estimated offering expenses payable by us, exclusive of the underwriting commissions, are approximately $1.0 million. We have agreed to reimburse the
underwriters for expense relating to clearance of this offering with the Financial Industry Regulatory Authority up to $30,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs are listed on
the Nasdaq Global Select Market under the trading symbol &#147;DBVT,&#148; and the ordinary shares are listed on Euronext Paris under the symbol &#147;DBV.&#148; The public offering price for the ordinary shares and ADSs was determined by
negotiations between us and the representatives and based, in part, on the trading price of our ordinary shares on Euronext Paris and our ADSs on the Nasdaq Global Select Market, and prevailing market conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, all of our directors and officers have agreed that, without the prior written consent of Goldman Sachs International and Citigroup Global Markets Inc. on
behalf of the underwriters, we and they will not, subject to specified exemptions offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of or announce the intention to otherwise dispose of, or enter into any swap, hedge or
similar agreement or arrangement that transfers, in whole or in part, the economic risk of ownership of, directly or indirectly, or make any demand or request or exercise any right with respect to the registration of, or file with the Securities and
Exchange Commission a registration statement under the Securities Act of 1933, as amended, relating to, any ordinary shares or securities convertible into or exchangeable or exercisable for any ordinary shares (including ADSs). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The restrictions described in the immediately preceding paragraph to do not apply to the following, subject to specified exceptions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ordinary shares or ADSs acquired in the global offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ordinary shares or ADSs acquired in open market transactions on or after the date of this prospectus
supplement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ordinary shares or ADSs disposed of as bona fide gifts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers to any trust for the shareholder&#146;s direct or indirect benefit or to its immediate family, or to
any beneficiary; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by will or intestate succession upon death; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by operation of law pursuant to a qualified domestic order or in connection with a divorce settlement; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the shareholder is a corporation, partnership, limited liability company, trust or other business entity
(A)&nbsp;to another corporation, partnership, limited liability company, trust or other business entity that is the shareholder&#146;s affiliate or (B)&nbsp;as part of a distribution without consideration by us to our stockholders, partners, members
or other equity holders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs International and Citigroup Global Markets Inc., in their sole discretion, may release the
ordinary shares or ADSs and other securities subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above in whole or in part at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to facilitate the offering of the ADSs and ordinary shares, the underwriters may engage in
transactions that stabilize, maintain or otherwise affect the price of the ADSs and ordinary shares. Stabilization transactions will need to comply with European Union laws and notably the Market Abuse Regulations. These activities may have the
effect of stabilizing or maintaining the market price of the ADSs and ordinary shares at the level above the one that might otherwise prevail in the open market. Specifically, the underwriters may sell more shares than they are obligated to purchase
under the underwriting agreement, creating a short position. A short sale is covered if the short position is no greater than the number of shares available for purchase by the underwriters under the option. The underwriters can close out a covered
short sale by exercising the option or purchasing shares in the open market. In determining the source of shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of shares compared to the
price available under the option. The underwriters may also sell shares in excess of the option, creating a naked short position. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short
position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the ADSs and ordinary shares in the open market after pricing that could adversely affect investors who purchase in this
offering. As an additional means of facilitating this offering, the underwriters may bid for, and purchase, ADSs and ordinary shares in the open market to stabilize the price of the ADSs and ordinary shares. These activities may raise or maintain
the market price of the ADSs and ordinary shares above independent market levels or prevent or retard a decline in the market price of the ADSs and ordinary shares. The underwriters are not required to engage in these activities and may end any of
these activities at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and the underwriters have agreed to indemnify each other against certain liabilities, including liabilities under the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A prospectus supplement in electronic format may be made available on websites maintained by one or more underwriters, or selling group
members, if any, participating in this offering. The representatives may agree to allocate a number of ADSs and ordinary shares to underwriters for sale to their online brokerage account holders. Internet distributions will be allocated by the
representatives to underwriters that may make Internet distributions on the same basis as other allocations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters and their respective
affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging.
financing and brokerage activities. Certain of the underwriters and their respective affiliates have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they
received or will receive customary fees and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their various business activities, the underwriters and
their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of
their customers and may at any time hold long and short positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and their respective affiliates may also
make investment recommendations or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such securities and
instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Extended Settlement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that
delivery of the ordinary shares and ADSs will be made to investors on or about the third business day following the date of the final prospectus supplement (this settlement cycle being referred to as &#147;T+3&#148;). Under Rule 15c6-1 of the
Securities Exchange Act of 1934, as amended, trades in the secondary market are required to settle in two business days, unless the parties to any such trade expressly agree otherwise. Accordingly, if you wish to trade the securities before their
delivery, you will be required, because the securities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
initially will settle in T+3, to specify an alternate settlement cycle at the time of any such trade to prevent a failed settlement. If you wish to trade the securities before their delivery, you
should consult your advisors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Economic Area </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In relation to each Member
State of the European Economic Area (each, a &#147;Member State&#148;), no offer of shares may be made to the public in that Member State other than: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to any legal entity which is a &#147;qualified investor&#148; as defined in the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus
Regulation), subject to obtaining the prior consent of the underwriters for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, provided that no such offer
of shares shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any shares
or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the underwriters and us that it is a &#147;qualified investor&#148; as defined in the Prospectus Regulation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of any shares being offered to a financial intermediary as that term is used in Article 5 of the Prospectus Regulation, each such financial
intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a nondiscretionary basis on behalf of, nor have they been acquired with a view to their offer or resale
to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in a Member State to qualified investors as so defined or in circumstances in which the prior consent of the underwriters has
been obtained to each such proposed offer or resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer of shares to the public&#148; in
relation to any shares in any Member State means the communication in any form and by means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase shares, and the expression
&#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129 (as amended). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to the product governance requirements contained within:
(a)&nbsp;EU Directive 2014/65/EU on markets in financial instruments, as amended (&#147;MiFID II&#148;); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c)&nbsp;local implementing measures (together
the &#147;MiFID II Product Governance Requirements&#148;), and disclaiming all and any liability, which any &#147;manufacturer&#148; (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the
target market assessment in respect of the ordinary shares offered in the global offering has led to the conclusion that the ordinary shares are: (i)&nbsp;compatible with an end target market of retail investors and investors who meet the criteria
of eligible counterparties and professional clients, each as defined in MiFID II; and (ii)&nbsp;eligible for distribution through all distribution channels as are permitted by MiFID II (the &#147;Target Market Assessment&#148;). The Target Market
Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the European offering tranche of the global offering. Furthermore, it is noted that, notwithstanding the Target Market
Assessment, the joint lead book-running managers and the <FONT STYLE="white-space:nowrap">co-managers</FONT> will only procure investors who meet the criteria of professional clients and eligible counterparties with respect to the ordinary shares.
The Target Market Assessment is conducted solely for the purposes of the manufacturer&#146;s product approval process and neither constitutes an assessment for any particular client of suitability or appropriateness for the purposes of MiFID II nor
a recommendation to invest in, or purchase, or take any other action whatsoever with respect to the ordinary shares. Notwithstanding the Target Market Assessment, the attention of distributors is drawn to the fact that: the price of the ordinary
shares sold in the European offering could decline and investors could lose all or part of their investment; the ordinary shares sold in the European </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
offering offer no guaranteed income and no capital protection; and that an investment in such shares is compatible only with investors who do not need a guaranteed income or capital protection,
who are capable (either alone or in conjunction with an appropriate financial or other adviser) of evaluating the merits and risks of such an investment and have sufficient resources to be able to bear any losses that may result therefrom. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>France </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs and the ordinary shares have not
been offered or sold and will not be offered or sold, directly or indirectly, to the public in France and no offering or this prospectus or any marketing materials relating to the ADSs and the ordinary shares must be made available or distributed in
any way that would constitute, directly or indirectly, an offer to the public in France. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs and the ordinary shares may only be offered or sold in
Europe (including France) pursuant to article L. <FONT STYLE="white-space:nowrap">411-2</FONT> of the French <I>Code mon&eacute;taire et financier </I>to qualified investors (<I>investisseurs qualifi&eacute;s</I>) acting for their own account, as
defined in Prospectus Regulation 2017/1129 dated June 14, 2017 (&#147;Prospectus Regulation&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prospective investors are informed that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither this prospectus nor any other offering materials relating to the ADSs described in this prospectus has
been submitted for clearance to the French financial market authority (<I>Autorit&eacute; des march&eacute;s financiers</I>); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">neither this prospectus, nor any offering material relating to the ADSs and the ordinary shares has been or will
be released, issued, distributed or caused to be released, issued or distributed to investors other than qualified investors (as defined under Article 2(e) of the Prospectus Regulation) in France or used in connection with any offer for subscription
or sale of the ADSs and the ordinary shares to the public in France within the meaning of the Prospectus Regulation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">individuals or entities referred to as &#147;qualified investors&#148; under Article 2 point (e)&nbsp;of the
Prospectus Regulation may participate in the global offering for their own account, as provided under articles <FONT STYLE="white-space:nowrap">D.411-1</FONT> and <FONT STYLE="white-space:nowrap">D.411-2</FONT> of the French Monetary and Financial
Code (<I>Code mon&eacute;taire et financier</I>) ; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the direct and indirect distribution or sale to the public of the ordinary shares, including in the form of ADSs,
acquired by them may only be made in compliance with Prospectus Regulation and articles <FONT STYLE="white-space:nowrap">L.&nbsp;411-1</FONT> to L. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">411-2-1,</FONT></FONT> L. <FONT
STYLE="white-space:nowrap">412-1</FONT> and L. <FONT STYLE="white-space:nowrap">621-8</FONT> to L. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">621-8-2</FONT></FONT> of the French <I>Code mon&eacute;taire et financier</I>.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United Kingdom </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each
underwriter has represented and agreed that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it has only communicated or caused to be communicated and will only communicate or cause to be communicated an
invitation or inducement to engage in investment activity (within the meaning of Section&nbsp;21 of the Financial Services and Markets Act 2000 (&#147;FSMA&#148;) received by it in connection with the issue or sale of the shares of our ADSs in
circumstances in which Section&nbsp;21(1) of the FSMA does not apply to us; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it
in relation to the shares of our ADSs in, from or otherwise involving the United Kingdom. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities may not be offered or sold in Hong Kong by means of any document other than (i)&nbsp;in circumstances which do not constitute an offer to the
public within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong), or (ii)&nbsp;to &#147;professional investors&#148; within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made
thereunder, or (iii)&nbsp;in other circumstances which do not result in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
document being a &#147;prospectus&#148; within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong) and no advertisement, invitation or document relating to the securities may be
issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if
permitted to do so under the laws of Hong Kong) other than with respect to the securities which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; within the meaning of the
Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Japan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No registration pursuant to Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as amended) (the
&#147;FIEL&#148;) has been made or will be made with respect to the solicitation of the application for the acquisition of the ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, the
securities have not been, directly or indirectly, offered or sold and will not be, directly or indirectly, offered or sold in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan,
including any corporation or other entity organized under the laws of Japan) or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or <FONT STYLE="white-space:nowrap">re-sale,</FONT> directly or indirectly, in Japan or to, or for the
benefit of, any resident of Japan except pursuant to an exemption from the registration requirements, and otherwise in compliance with, the FIEL and the other applicable laws and regulations of Japan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>For Qualified Institutional Investors (&#147;QII&#148;) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph 2, Article 4 of the FIEL) in relation to the
securities constitutes either a &#147;QII only private placement&#148; or a &#147;QII only secondary distribution&#148; (each as described in Paragraph 1, Article <FONT STYLE="white-space:nowrap">23-13</FONT> of the FIEL). Disclosure regarding any
such solicitation, as is otherwise prescribed in Paragraph 1, Article 4 of the FIEL, has not been made in relation to the ADSs. The ADSs may only be transferred to QIIs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>For <FONT STYLE="white-space:nowrap">Non-QII</FONT> Investors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph 2, Article 4 of the FIEL) in relation to the
securities constitutes either a &#147;small number private placement&#148; or a &#147;small number private secondary distribution&#148; (each as is described in Paragraph 4, Article <FONT STYLE="white-space:nowrap">23-13</FONT> of the FIEL).
Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article 4 of the FIEL, has not been made in relation to the securities. The securities may only be transferred en bloc without subdivision to a single investor.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Singapore </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus has not been
registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the securities may not be
circulated or distributed, nor may the securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor
under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (the &#147;SFA&#148;), (ii) to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the
conditions specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to compliance with conditions set forth in the SFA.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where the securities are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business
of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each
beneficiary of the trust is an individual who is an accredited investor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares, debentures and units of shares and debentures of that corporation or the beneficiaries&#146; rights and
interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the securities pursuant to an offer made under Section&nbsp;275 of the SFA except: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to an institutional investor (for corporations, under Section&nbsp;274 of the SFA) or to a relevant person
defined in Section&nbsp;275(2) of the SFA, or to any person pursuant to an offer that is made on terms that such shares, debentures and units of shares and debentures of that corporation or such rights and interest in that trust are acquired at a
consideration of not less than $0.2&nbsp;million (or its equivalent in a foreign currency) for each transaction, whether such amount is to be paid for in cash or by exchange of securities or other assets, and further for corporations, in accordance
with the conditions specified in Section&nbsp;275 of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where no consideration is or will be given for the transfer; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where the transfer is by operation of law. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Canada </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities may be sold only to
purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> <I>Prospectus Exemptions</I> or subsection 73.3(1) of the <I>Securities
Act</I> (Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>. Any resale of the securities must be made
in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or
damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the
purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National Instrument <FONT
STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (&#147;NI <FONT STYLE="white-space:nowrap">33-105&#148;),</FONT> the underwriters are not required to comply with the disclosure requirements of NI
<FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Switzerland
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or the SIX, or on any other stock
exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for
listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the
securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither this document nor any other offering
or marketing material relating to the offering, the company or the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of securities will not be
supervised by, the Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection
afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc841346_15"></A>MATERIAL CHANGES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as described above or otherwise described in our <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519094568/0001193125-19-094568-index.htm">Annual
 Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT></A> for the fiscal year ended December&nbsp;31, 2018 and in our Form <FONT STYLE="white-space:nowrap">6-Ks</FONT> incorporated by reference into this prospectus supplement, no reportable
material changes have occurred since December&nbsp;31, 2018. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc841346_16"></A>ENFORCEMENT OF CIVIL LIABILITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a corporation organized under the laws of France. The majority of our directors are citizens and residents of countries other than the United States,
and the majority of our assets are located outside of the United States. Accordingly, it may be difficult for investors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to obtain jurisdiction over us or our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> resident officers and
directors in U.S. courts in actions predicated on the civil liability provisions of the U.S. federal securities laws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to enforce judgments obtained in such actions against us or our <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
resident officers and directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to bring an original action in a French court to enforce liabilities based upon the U.S. federal securities laws
against us or our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> resident officers or directors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to enforce against us or our directors in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> courts, including
French courts, judgments of U.S. courts predicated upon the civil liability provisions of the U.S. federal securities laws. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nevertheless, a final judgment for the payment of money rendered by any federal or state court in the United States based on civil liability, whether or not
predicated solely upon the U.S. federal securities laws, would be recognized and enforced in France provided that a French judge considers that this judgment meets the French legal requirements concerning the recognition and the enforcement of
foreign judgments and is capable of being immediately enforced in the United States. A French court is therefore likely to grant the enforcement of a foreign judgment without a review of the merits of the underlying claim thereby adjudicated through
an action for exequatur, only if (1)&nbsp;such U.S. judgment was rendered by a court having jurisdiction over the matter because the dispute is clearly connected to the jurisdiction of such court (i.e., there was no international forum shopping);
(2) the choice of U.S. court was not fraudulent and the French courts did not have exclusive jurisdiction over the matter; (3)&nbsp;that judgment resulted from legal proceedings compatible with French standards of due process; (4)&nbsp;that judgment
does not contravene international public order and public policy of France; (5)&nbsp;the jurisdiction of the United States federal or state court is consistent with French conflict of jurisdiction rules and (6)&nbsp;there are no proceedings pending
before French courts at the time enforcement of the U.S. judgment is sought and having the same or similar subject matter as the U.S. judgment and no such proceedings are filed before French courts after the enforcement proceedings have been
initiated. The French court would also require that the U.S. judgment is not tainted with fraud and is not incompatible with a judgment rendered by a French court in the same matter, or with an earlier judgment rendered by a foreign court in the
same matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, French law guarantees full compensation for the harm suffered but is limited to the actual damages, so that the victim does not
suffer or benefit from the situation. Such system excludes damages such as, but not limited to, punitive and exemplary damages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, the
enforcement, by U.S. investors, of any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities law against us or members of our board of directors, officers or certain experts named
herein who are residents of France or countries other than the United States would be subject to the above conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finally, there may be doubt as to
whether a French court would impose civil liability on us, the members of our board of directors, our officers or certain experts named herein in an original action predicated solely upon the U.S. federal securities laws brought in a court of
competent jurisdiction in France against us or such members, officers or experts, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc841346_17"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cooley LLP, Boston, Massachusetts, will be representing us in connection with this offering. McDermott Will&nbsp;&amp; Emery AARPI will pass upon the validity
of the ordinary shares, including ordinary shares represented by ADSs, to be offered and other legal matters relating to French law, including matters of French income tax law, in connection with this offering. Goodwin Procter LLP, New York, New
York, and Gide Loyrette Nouel A.A.R.P.I are representing the underwriters in connection with this offering. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc841346_18"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements as of December&nbsp;31, 2017 and 2018, and for each of the three years in the period ended December&nbsp;31, 2018,
appearing in our Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2018, and the effectiveness of internal control over financial reporting as of December&nbsp;31, 2018, have been audited by
Deloitte&nbsp;&amp; Associ&eacute;s, an independent registered public accounting firm, as stated in their reports thereon, included therein, and are incorporated by reference herein (which reports: (1)&nbsp;express an unqualified opinion on the
consolidated financial statements and includes an explanatory paragraph referring to going concern and (2)&nbsp;express an unqualified opinion on the effectiveness of internal control over financial reporting). Such consolidated financial statements
have been so incorporated in reliance upon the reports of such firm given upon their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offices of
Deloitte&nbsp;&amp; Associ&eacute;s are located at 6, place de la Pyramide, 92908 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Paris-la-D&eacute;fense</FONT></FONT> Cedex, Puteaux, France. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc841346_19"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">F-3</FONT> under the Securities Act with respect to the
securities described in this prospectus supplement and the accompanying prospectus. This prospectus supplement and the accompanying prospectus do not contain all of the information included in that registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC maintains an Internet website at www.sec.gov that contains reports, proxy and information statements and other information regarding issuers, such as
us, that file electronically with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the information reporting requirements of the Exchange Act applicable to foreign private
issuers and under those requirements we file reports with the SEC. Those reports may be inspected without charge at the locations described above. As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the
furnishing and content of proxy statements, and our officers, directors and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions contained in Section&nbsp;16 of the Exchange Act. In addition, we are not
be required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as United States companies whose securities are registered under the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc841346_20"></A><A NAME="suptoc841346_20"></A><A NAME="suptoc841346_20"></A><A NAME="suptoc841346_20">
</A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; into this prospectus supplement and
the accompanying prospectus the information we have filed with the SEC. This means that we can disclose important information by referring you to another document filed separately with the SEC. The information incorporated by reference is considered
to be a part of this prospectus supplement, and information that we file later with the SEC will also be deemed to be incorporated by reference into this prospectus supplement and to be a part hereof from the date of filing of such documents and
will automatically update and supersede previously filed information, including information contained in this document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We incorporate by reference into
this prospectus supplement the following documents that we have filed with the SEC: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519094568/d676474d20f.htm">Annual Report on Form
 <FONT STYLE="white-space:nowrap">20-F</FONT></A> for the fiscal year ended December&nbsp;31, 2018, filed with the SEC on April&nbsp;1, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">6-K</FONT> furnished to the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519001156/d672661d6k.htm">January&nbsp;3,
 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519037995/d671794d6k.htm">February&nbsp;13, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519048310/d713123d6k.htm">February&nbsp;
22, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519064105/d702858d6k.htm">March&nbsp;5, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519097939/d698055d6k.htm">April&nbsp;
4, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519100905/d581756d6k.htm">April&nbsp;9, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519144274/d687176d6k.htm">May&nbsp;
10, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519145975/d701620d6k.htm">May&nbsp;14, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519157095/d714491d6k.htm">May&nbsp;
24, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519163521/d749236d6k.htm">June&nbsp;3, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519181889/d600200d6k.htm">June&nbsp;
26, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519209920/d784121d6k.htm">August&nbsp;1, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519215368/d780374d6k.htm">August&nbsp;
7, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519257384/d747502d6k.htm">September&nbsp;27, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519262728/d820310d6k.htm">October&nbsp;
4, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519265129/d801543d6k.htm">October&nbsp;9, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312520000728/d862323d6k.htm">January&nbsp;
3, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312520004087/d824406d6k.htm">January&nbsp;9, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312520006362/d862560d6k.htm">January&nbsp;13, 2020</A> and
<A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312520018377/d874485d6k.htm">January&nbsp;29, 2020</A>; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our ordinary shares contained in our <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312514375129/d798615d8a12b.htm">Registration
 Statement on Form <FONT STYLE="white-space:nowrap">8-A</FONT></A>, filed with the SEC on October&nbsp;17, 2014. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also
incorporating by reference all subsequent annual reports on Form <FONT STYLE="white-space:nowrap">20-F</FONT> that we file with the SEC and those of our current reports on Form <FONT STYLE="white-space:nowrap">6-K</FONT> that we furnish to the SEC
that we specifically identify in such form as being incorporated by reference into this prospectus supplement after the date hereof and prior to the completion of an offering of securities under this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will furnish without charge to each person, including any beneficial owner, to whom a prospectus supplement and the accompanying prospectus is delivered,
on written or oral request, a copy of any or all of the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, including exhibits to these documents. You should direct any requests for documents, either in
writing to Corporate Secretary, c/o DBV Technologies S.A., <FONT STYLE="white-space:nowrap">177-181</FONT> Avenue Pierre Brossolette, 92120 Montrouge, France or by telephone at +33 1 55 42 78 78. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You also may access these filings on our website at <FONT STYLE="white-space:nowrap">www.dbv-technologies.com.</FONT> We do not incorporate the information on
our website into this prospectus supplement or the accompanying prospectus and you should not consider any information on, or that can be accessed through, our website as part of this prospectus supplement or the accompanying prospectus (other than
those filings with the SEC that we specifically incorporate by reference into this prospectus supplement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any statement contained in a document
incorporated or deemed to be incorporated by reference in this prospectus supplement will be deemed modified, superseded or replaced for purposes of this prospectus or any prospectus supplement to the extent that a statement contained in any other
subsequently filed document that also is or is deemed to be incorporated by reference in this prospectus or any prospectus supplement modifies, supersedes or replaces such statement. Any statement that is modified or superseded will not constitute a
part of this prospectus or prospectus supplement, except as modified or superseded. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suptoc841346_21"></A>EXPENSES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the expenses, other than any underwriting commissions or agency fees and other items constituting underwriters&#146; or
agents&#146; compensation, expected to be incurred by us in connection with a possible offering of securities registered under the registration statement of which this prospectus supplement is a part. All amounts are estimated. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">550,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>990,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g841346g31k50.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>DBV TECHNOLOGIES S.A. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$300,000,000 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Ordinary
Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Ordinary Shares in the Form of American Depositary Shares </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer from time to time the securities described in this prospectus, either individually or in any combination, in one or more offerings at prices and
on terms that will be determined at the time of the offering. The aggregate initial offering price of the securities that we may offer and sell under this prospectus will not exceed $300,000,000. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer and sell these securities on a continuous or delayed basis to or through one or more underwriters, dealers and agents, or directly to purchasers.
For additional information on the methods of sale, you should refer to the section titled &#147;Plan of Distribution&#148; in this prospectus. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than
any securities sold in connection with a rights offering, we will only sell securities pursuant to this prospectus for which preferential subscription rights shall have been waived by our shareholders in accordance with French law. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ordinary shares may be sold in the form of American Depositary Shares, or ADSs. Each ADS represents <FONT STYLE="white-space:nowrap">one-half</FONT> of one
ordinary share. Our ordinary shares in the form of ADSs are listed on the Nasdaq Global Select Market under the symbol &#147;DBVT.&#148; On September&nbsp;5, 2019, the last reported sale price of the ADSs on Nasdaq was $9.94 per ADS. Our ordinary
shares are traded on Euronext Paris under the symbol &#147;DBV.&#148; On September&nbsp;5, 2019, the last reported sale price of the ordinary shares on Euronext Paris was &#128;17.85 per share. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus describes the general terms of the securities we may offer and the general manner in which we may offer these securities. We will provide the
specific terms of any offering of securities in one or more supplements to this prospectus. Such prospectus supplements may also add, update or change information contained in this prospectus. You should carefully read this prospectus and the
applicable prospectus supplement, together with the documents we incorporate by reference, before you invest. This prospectus may not be used to consummate a sale of securities unless accompanies by the applicable prospectus supplement. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at <FONT STYLE="white-space:nowrap">177-181</FONT> Avenue Pierre Brossolette&#151;92120 Montrouge France and our
telephone number is +33 1 55 42 78 78. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>INVESTING IN OUR SECURITIES INVOLVES A HIGH DEGREE OF RISK. YOU SHOULD REVIEW CAREFULLY THE RISKS AND UNCERTAINTIES REFERENCED UNDER THE HEADING &#147;<A HREF="#toc841346_4">RISK
 FACTORS</A>&#148; ON PAGE 7 OF THIS PROSPECTUS AS WELL AS THOSE CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT AND ANY RELATED FREE WRITING PROSPECTUS, AND IN THE OTHER DOCUMENTS THAT ARE INCORPORATED BY REFERENCE INTO THIS PROSPECTUS OR THE APPLICABLE
 PROSPECTUS SUPPLEMENT. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the United States Securities and Exchange Commission nor any state securities commission has approved or
disapproved of these securities or passed upon the adequacy or the accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is October 1, 2019. </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_3">ABOUT DBV TECHNOLOGIES S.A.</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_6">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_7">DESCRIPTION OF SHARE CAPITAL</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_8">DESCRIPTION OF AMERICAN DEPOSITARY SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_9">LIMITATIONS AFFECTING SHAREHOLDERS OF A FRENCH COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_10">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_11">ENFORCEMENT OF CIVIL LIABILITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_12">TAXATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_13">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_14">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_15">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841346_16">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841346_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission, or the SEC, as a &#147;shelf&#148;
registration process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under this shelf registration, we may offer our ordinary shares, ordinary shares in the form of ADSs or any combination thereof
from time to time in one or more offerings, for an aggregate offering price of up to $300,000,000. This prospectus only provides you with a general description of the securities we may offer. Each time we sell securities described herein, we will
provide prospective investors with a supplement to this prospectus that will contain specific information about the terms of that offering, including the specific amounts, prices and terms of the securities offered. The prospectus supplement may
also add to, update or change information contained in this prospectus. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement
and any related free writing prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus. Accordingly,
to the extent inconsistent, information in this prospectus is superseded by the information in any prospectus supplement. You should carefully read this prospectus, any applicable prospectus supplement and any related free writing prospectus,
together with the information incorporated herein by reference as described under the heading &#147;Incorporation of Certain Information by Reference,&#148; before investing in any of the securities offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated or the context otherwise requires, references in this prospectus to &#147;DBV,&#148; &#147;the company,&#148; &#147;our
company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to DBV Technologies S.A. and our consolidated subsidiary. All references in this prospectus to &#147;$,&#148; &#147;US$,&#148; &#147;U.S.$,&#148; &#147;U.S. dollars,&#148;
&#147;dollars&#148; and &#147;USD&#148; mean U.S. dollars and all references to &#147;&#128;&#148; and &#147;euros,&#148; mean euros, unless otherwise noted. Throughout this prospectus, references to ADSs mean ADSs or ordinary shares represented by
ADSs, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is
made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by
reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading &#147;Where You Can Find More Information.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither we, nor any agent, underwriter or dealer has authorized any person to give any information or to make any representation other than those contained or
incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus prepared by or on behalf of us or to which we have referred you. This prospectus, any applicable supplement to this prospectus
or any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus, any applicable supplement to this
prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should not assume that the information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus is
accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this
prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered, or securities are sold, on a later date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For investors outside the United States: We have not done anything that would permit the offering or
possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about,
and observe any restrictions relating to, the offering of the securities described herein and the distribution of this prospectus outside the United States. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TRADEMARKS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We own various trademark registrations and applications, and unregistered trademarks and servicemarks, including &#147;Viaskin<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>,&#148; &#147;EPIT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>,&#148; &#147;DBV Technologies<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>,&#148; &#147;Abyldis<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&#148; and our corporate logo. All other trademarks or trade names referred to in this prospectus and any prospectus supplement are the property of their respective owners. Trade names, trademarks
and service marks of other companies appearing in this prospectus or any prospectus supplement are the property of their respective holders. Solely for convenience, the trademarks and trade names in this prospectus or any prospectus supplement may
be referred to without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but such references should not be construed as any indicator that their respective owners
will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend to use or display other companies&#146; trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other
companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841346_2"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus, any prospectus supplement and the information incorporated by reference in this prospectus and any prospectus supplement contain
forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Exchange Act of 1934, as amended, or the Exchange Act, that involve a number of risks and
uncertainties. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently
subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All statements other than present and historical facts and conditions contained in this prospectus, any prospectus supplement and the information incorporated
by reference in this prospectus and any prospectus supplement including statements regarding our future results of operations and financial positions, business strategy, plans and our objectives for future operations, are forward-looking statements.
The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;can,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;is designed to,&#148; &#147;may,&#148; &#147;might,&#148; &#147;plan,&#148;
&#147;potential,&#148; &#147;predict,&#148; &#147;objective,&#148; &#147;should,&#148; or the negative of these and similar expressions identify forward-looking statements. Forward-looking statements include, but are not limited to, statements
about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory filings and approvals, including with respect to our submission of a
Biologics License Application to the U.S. Food and Drug Administration for Viaskin Peanut in August 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to continue as a going concern; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress and results of our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies
and clinical trials, and our research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance product candidates into, and successfully complete, clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance our Viaskin manufacturing capabilities, manufacture clinical and commercial supplies of
our product candidates and comply with regulatory requirements related to the manufacturing of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop sales and marketing capabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commercialization of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our business model, strategic plans for our business, product candidates and technology;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our
product candidates and technology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimates of our expenses, future revenues, capital requirements and our needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential benefits of strategic collaboration agreements and our ability to enter into strategic
arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain and establish collaborations or obtain additional grant funding; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of our product candidates, if approved by regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments relating to our competitors and our industry, including competing therapies; and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risks and uncertainties, including those listed under the caption &#147;Risk Factors&#148; in this
prospectus, any prospectus supplement and the information incorporated by reference in this prospectus and any prospectus supplement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of these factors, we cannot assure you that the forward-looking statements in this prospectus, any prospectus supplement and the information
incorporated by reference in this prospectus and any prospectus supplement will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in
these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to
publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should
read this prospectus, any prospectus supplement and the information incorporated by reference in this prospectus and any prospectus supplement completely and with the understanding that our actual future results may be materially different from what
we expect. We qualify all of our forward-looking statements by these cautionary statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus, any prospectus supplement and the
information incorporated by reference in this prospectus and any prospectus supplement may contain market data and industry forecasts that were obtained from industry publications. These data involve a number of assumptions and limitations, and you
are cautioned not to give undue weight to such estimates. While we believe the market position, market opportunity and market size information included in this prospectus, any prospectus supplement and the information incorporated by reference in
this prospectus and any prospectus supplement is generally reliable, such information is inherently imprecise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841346_3"></A>ABOUT DBV TECHNOLOGIES S.A. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called
Viaskin. Our therapeutic approach is based on epicutaneous immunotherapy, or EPIT, our proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. We have generated significant data
demonstrating that Viaskin&#146;s mechanism of action is novel and differentiated as it targets specific antigen-presenting immune cells in the skin, called Langerhans cells, which capture the antigen and migrate to the lymph node in order to
activate the immune system without allowing passage of the antigen into the bloodstream, minimizing systemic exposure in the body. We are advancing this unique technology to address areas of unmet medical need, including in patients suffering from
food allergies, for whom safety is paramount as the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our legal and commercial name is DBV Technologies S.A. We were incorporated as a <I>soci&eacute;t&eacute; par actions simplifi&eacute;e (S.A.S.)</I> under the
laws of the French Republic on March&nbsp;29, 2002 for a period of 99 years and subsequently converted on March&nbsp;13, 2003 into a <I>soci&eacute;t&eacute; anonyme</I>. We are registered at the Nanterre Commerce and Companies Register under the
number 441 772 522. Our principal executive offices are located at <FONT STYLE="white-space:nowrap">177-181</FONT> Avenue Pierre Brossolette&#151;92120 Montrouge France and our telephone number is +33 1 55 42 78 78. Our agent for service of process
in the United States is Cogency Global Inc. We maintain a corporate website at <FONT STYLE="white-space:nowrap">www.dbv-technologies.com.</FONT> Information contained on, or that can be accessed through, our website does not constitute a part of
this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ordinary shares in the form of ADSs
have been listed on the Nasdaq Global Select Market under the symbol &#147;DBVT&#148; since October&nbsp;22, 2014. Our ordinary shares have been trading on Euronext Paris under the symbol &#147;DBV&#148; since March&nbsp;28, 2012. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841346_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An investment in our securities involves a high degree of risk. Before deciding whether to purchase our securities, you should carefully consider the risk
factors incorporated by reference from Part I, Item 3.D. of our most recent <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519094568/d676474d20f.htm">Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT></A> and the
other information contained in this prospectus or any applicable prospectus supplement, as updated by those subsequent filings with the SEC under the Exchange Act, that are incorporated herein by reference. These risks could materially affect our
business, results of operations or financial condition and cause the value of our securities to decline, in which case you may lose all or part of your investment. For more information, see &#147;Where You Can Find More Information&#148; and
&#147;Incorporation of Certain Information by Reference.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841346_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise set forth in a prospectus supplement, we currently intend to use the net proceeds of any offering of securities for working capital and other
general corporate purposes. Accordingly, we will have significant discretion in the use of any net proceeds. We may provide additional information on the use of the net proceeds from the sale of the offered securities in an applicable prospectus
supplement relating to the offered securities. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841346_6"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to include information about our capitalization and indebtedness in prospectus supplements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841346_7"></A>DESCRIPTION OF SHARE CAPITAL </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following description of our share capital summarizes certain provisions of our <FONT STYLE="white-space:nowrap">by-laws.</FONT> Such summaries do not
purport to be complete and are subject to, and are qualified in their entirety by reference to, all of the provisions of our <FONT STYLE="white-space:nowrap">by-laws,</FONT> a copy of which has been filed with the SEC. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, our outstanding
share capital consisted of a total of 30,157,777 issued ordinary shares, fully paid and with a nominal value &#128;0.10 per share. As of August&nbsp;31, 2019, our outstanding share capital consisted of a total of 36,157,777 issued ordinary shares,
fully paid and with a nominal value &#128;0.10 per share. We have no preferred shares outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under French law, our
<FONT STYLE="white-space:nowrap">by-laws</FONT> set forth only our issued and outstanding share capital as of the date of the <FONT STYLE="white-space:nowrap">by-laws.</FONT> Our fully diluted share capital represents all issued and outstanding
shares, as well as all potential shares which may be issued upon exercise of outstanding employee warrants, employee share options and <FONT STYLE="white-space:nowrap">non-employee</FONT> warrants, as approved by our shareholders and granted by our
board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reconciliation of the Number of Ordinary Shares Outstanding through August&nbsp;31, 2019 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares outstanding at December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,990,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares issued in connection with March 2018 Global offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,056,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of ordinary shares issued in connection with the exercise of employee warrants, share
options and <FONT STYLE="white-space:nowrap">non-employee</FONT> warrants and the acquisition of free shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,110,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares outstanding at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,157,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of shares issued in connection with April 2019 Global offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of ordinary shares issued in connection with the exercise of employee warrants, share
options and <FONT STYLE="white-space:nowrap">non-employee</FONT> warrants and the acquisition of free shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares outstanding at August&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,157,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shareholder Authorizations Regarding Share Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At our 2019 combined shareholders&#146; meeting held on May&nbsp;24, 2019, our board of directors received the following authorizations from shareholders: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorization to <FONT STYLE="white-space:nowrap">buy-back</FONT> up to 5% of our shares (such authorization
being capped to a maximum potential dilution equal to 5% of our share capital at the date of the relevant <FONT STYLE="white-space:nowrap">buy-back)</FONT> for a duration of 18 months (of which 30,281 shares have been bought back as of
August&nbsp;31, 2019); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorization to cancel the shares bought back by the company up to 5% of our shares (such authorization being
capped to a maximum of 5% of our share capital at the date of the relevant cancellation decision) and to decrease our share capital accordingly, for a duration of 24 months (of which no shares have been canceled as of August&nbsp;31, 2019);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delegation of authority to increase our share capital by issuing ordinary shares giving access, if applicable, to
ordinary shares or the allocation of debt securities (of the company or any group company) and/or securities giving access to ordinary shares (of the company or any group company), with preferential subscription rights, for a duration of 26 months
within a maximum aggregate potential dilution of 14,463,110 shares based on the ordinary shares outstanding at August&nbsp;31, 2019 (such delegation of authority being capped to a maximum potential dilution of 40% of our share capital at the date of
the relevant share capital increase) (of which no shares have been issued as of August&nbsp;31, 2019); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delegations of authority to increase our share capital by issuing ordinary shares giving access, if applicable,
to ordinary shares or the allocation of debt securities (of the company or any group company) and/or securities giving access to ordinary shares (of the company or any group company), without preferential subscription rights (except for the rights
offering), through public offerings and/or private placements for the maximum duration permitted under French law (26 months) within a maximum aggregate potential dilution of 10,847,333 or 7,231,555 (depending on the delegations) shares based on the
ordinary shares outstanding at August&nbsp;31, 2019 (each delegation of authority has been capped to a maximum potential dilution equal to a percentage of 30% or 20% of our share capital, respectively (depending on the delegations) at the date of
the relevant share capital increase) (of which no shares have been issued as of August&nbsp;31, 2019); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delegation of authority to increase our share capital by issuing ordinary shares giving access, if applicable, to
ordinary shares or the allocation of debt securities (of the company or any group company) and/or securities giving access to ordinary shares (of the company or any group company) without preferential subscription rights, to the benefit of
categories of persons meeting certain characteristics, for a duration of 18 months within a maximum potential dilution of 10,847,333 shares based on the ordinary shares outstanding at August&nbsp;31, 2019 (such delegation of authority being capped
to a maximum potential dilution of 30% of our share capital at the date of the relevant share capital increase) (of which no shares have been issued as of August&nbsp;31, 2019); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delegation of authority to issue equity warrants (<I>bons de souscription d&#146;actions, bons de souscription
et/ou d&#146;acquisition d&#146;actions nouvelles et/ou existantes</I>) or redeemable equity warrants (<I>bons de souscription et/ou d&#146;acquisition d&#146;actions nouvelles et/ou existantes remboursables</I>) without preferential subscription
rights, to the benefit of categories of persons meeting certain characteristics for a maximum duration of 18 months, within a maximum potential dilution of 180,788 shares based on the ordinary shares outstanding at August&nbsp;31, 2019 (such
delegation of authority being capped to a maximum potential dilution equal to 0.5% of our share capital on the date of the shareholders&#146; meeting) (of which no warrants have been issued as of August&nbsp;31, 2019, for which delegation our
shareholders waived automatically their preferential subscription rights with respect to all such issuances); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delegation of authority to increase our share capital by issuing ordinary shares and/or securities giving access
to our share capital without preferential subscription rights, to the benefit of employees investing in our company saving plan (<I>plan d&#146;&eacute;pargne entreprise</I>), for a duration of 26 months, within a maximum aggregate potential
dilution of 723,155 shares based on the ordinary shares outstanding at August&nbsp;31, 2019 (such delegation of authority being capped to a maximum potential dilution equal to 2% of our share capital at the date of the relevant share capital
increase) (of which no shares have been issued as of August&nbsp;31, 2019, for which such delegation our shareholders automatically waived their preferential subscription rights with respect to all such issuances); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorization to grant free shares (<I>attribution gratuite d&#146;actions</I>) to our employees and/or certain
officers until the next general meeting approving the annual accounts to be held in 2020, within a maximum potential dilution of 723,155 shares based on the ordinary shares outstanding at August&nbsp;31, 2019 (such authorization being capped to a
maximum potential dilution equal to 2% of our share capital at the date of the shareholders&#146; meeting) (of which 23,750 free shares have been granted but no shares have been issued as of August&nbsp;31, 2019, for which delegation our
shareholders waived automatically their preferential subscription rights with respect to all such grants); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorization to grant share options (<I>options de souscription et/ou d&#146;achat d&#146;actions</I>) to our
employees and/or certain officers for a maximum duration of 18 months, within a maximum potential dilution of 2,711,833 shares based on the ordinary shares outstanding at August&nbsp;31, 2019 (such delegation of authority being capped to a maximum
potential dilution equal to 7.5% of our share capital at the date of the shareholders&#146; meeting) (of which 635,600 share options have been granted but no shares have been issued as of August&nbsp;31, 2019 for which delegation our shareholders
waived automatically their preferential subscription rights with respect to all such grants). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Provisions of Our <FONT STYLE="white-space:nowrap">By-laws</FONT> and French Law Affecting Our
Ordinary Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The description below reflects the terms of our <FONT STYLE="white-space:nowrap">by-laws,</FONT> and summarizes the material rights
of holders of our ordinary shares under French law. Please note that this is only a summary and is not intended to be exhaustive. For further information, please refer to the full version of our <FONT STYLE="white-space:nowrap">by-laws.</FONT>
</I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Corporate Purpose (Article 4 of the <FONT STYLE="white-space:nowrap">By-laws)</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our corporate purpose in France and abroad includes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the development of any innovative medical product, and in particular any drug, diagnostic, or care product;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the study, research, development, industrial manufacture, and marketing of such products; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the use and the development of all patents or any licenses relating to these products, and generally, all
commercial transactions, moveable or immoveable, financial or otherwise, directly or indirectly related, in whole or in part, to the company&#146;s objective or any other similar or related objective, which may facilitate operation and business
development. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Directors&#146; Designation</I></B>. Directors are designated at a shareholders&#146; ordinary general meeting, by a simple majority vote of the
shareholders present and voting at the meeting in person or by proxy, for a period of two years that expires at the end of the shareholders&#146; general meeting convened to approve the financial statements for the past fiscal year and held in the
year during which the respective director&#146;s term expires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Vacancies on the Board of Directors</I></B>. Under French law, vacancies on the
board of directors resulting from death or a resignation, provided that at least three directors remain in office, may be filled by a majority of the remaining directors pending ratification by the shareholders by the next shareholders&#146;
meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Quorum and Voting (Article 11 of the <FONT STYLE="white-space:nowrap">By-laws).</FONT> </I></B>The board of directors can only deliberate
if at least half of the directors attend the meeting in the manners provided for in our <FONT STYLE="white-space:nowrap">by-laws.</FONT> French law and the rules of procedure of the board allow directors to attend meetings of the board of directors
in person or, to the extent permitted by applicable law, by videoconference or other telecommunications arrangements. Decisions of the board of directors are taken by the majority of the voting rights held by the directors present or represented.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Directors&#146; Voting Powers on Proposal, Arrangement or Contract in which any Director Is Materially Interested. </I></B>Under French law, any
agreement entered into (directly or through an intermediary) between us and any director that is not entered into (1)&nbsp;in the ordinary course of our business and (2)&nbsp;upon standard market terms is subject to the prior authorization of the
board of directors (it being specified that the interested director cannot vote on such decision). The same provision applies to agreements between us and another company if one of our directors is the owner or a general partner, manager, director,
general manager or member of the executive or supervisory board of the other company, as well as to agreements in which one of our directors has an indirect interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Directors&#146; Compensation. </I></B>The aggregate amount of attendance fees (<I>jetons de pr&eacute;sence</I>) of the board of directors is determined
at the shareholders&#146; annual ordinary general meeting, on the basis of a submission of the board of directors of proposed compensation for the board of directors, following the recommendation of the compensation committee (<I>comit&eacute; des
r&eacute;mun&eacute;rations</I>) which is comprised of four directors, of which at least two are independent, to the board. The board of directors then divides this aggregate amount among some or all of its members by a simple majority vote, on the
basis of a proposal of the compensation committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the board of directors may grant exceptional compensation (<I>r&eacute;mun&eacute;rations
exceptionnelles</I>) to individual directors on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis for special and temporary assignments. The board of directors may
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
also authorize the reimbursement of reasonable travel and accommodation expenses, as well as other expenses incurred by directors in the corporate interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board of Directors&#146; Borrowing Powers. </I></B>There are currently no limits imposed on the amounts of loans or borrowings that the board of
directors may approve. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Directors&#146; Age Limits (Article 10 of the <FONT STYLE="white-space:nowrap">By-laws).</FONT> </I></B>The number of
directors who are more than 80 years old may not exceed <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors in office. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Directors&#146; Share Ownership Requirements. </I></B>None. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rights, Preferences and Restrictions Attaching to Ordinary Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends (Article 37 of the <FONT STYLE="white-space:nowrap">By-laws).</FONT> </I></B>We may only distribute dividends out of our &#147;distributable
profits,&#148; plus any amounts held in our reserves that the shareholders decide to make available for distribution, other than those reserves that are specifically required by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Distributable Profits&#148;</I></B> consist of our unconsolidated net profit in each fiscal year, as increased or reduced by any profit or loss
carried forward from prior years, less any contributions to the reserve accounts pursuant to French law (see below). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Reserve.
</I></B>Pursuant to French law, we must allocate 5% of our unconsolidated net profit for each year to our legal reserve fund before dividends may be paid with respect to that year. Funds must be allocated until the amount in the legal reserve is
equal to 10% of the aggregate par value of the issued and outstanding share capital. This restriction on the payment of dividends also applies to our French subsidiary on an unconsolidated basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Approval of Dividends. </I></B>Pursuant to French law, our board of directors may propose a dividend for approval by the shareholders at the annual
ordinary general meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon recommendation of our board of directors, our shareholders may decide to allocate all or part of any distributable profits
to special or general reserves, to carry them forward to the next fiscal year as retained earnings or to allocate them to the shareholders as dividends. However, dividends may not be distributed when our net assets are or would become as a result of
such distribution lower than the amount of the share capital plus the amount of the legal reserves which, under French law, may not be distributed to shareholders (the amount of our share capital which may not be distributed was equal to &#128;3.6
million on August&nbsp;31, 2019). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors may distribute interim dividends after the end of the fiscal year but before the approval of the
financial statements for the relevant fiscal year when the interim balance sheet, established during such year and certified by an auditor, reflects that we have earned distributable profits since the close of the last financial year, after
recognizing the necessary depreciation and provisions and after deducting prior losses, if any, and the sums to be allocated to reserves, as required by law or the <FONT STYLE="white-space:nowrap">by-laws,</FONT> and including any retained earnings.
The amount of such interim dividends may not exceed the amount of the profit so defined. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Distribution of Dividends. </I></B>Dividends are
distributed to shareholders<I> pro rata</I> according to their respective holdings of shares. In the case of interim dividends, distributions are made to shareholders on the date set by our board of directors during the meeting in which the
distribution of interim dividends is approved. The actual dividend payment date is decided by the shareholders at an ordinary general shareholders&#146; meeting or by our board of directors in the absence of such a decision by the shareholders.
Shareholders that own shares on the actual payment date are entitled to the dividend. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends may be paid in cash or, if the shareholders&#146; meeting
so decides, in kind, provided that all shareholders receive a whole number of assets of the same nature paid in lieu of cash. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Timing of Payment. </I></B>Pursuant to French law, dividends must be paid within a maximum of nine
months after the close of the relevant fiscal year, unless extended by court order. Dividends not claimed within five years after the payment date shall be deemed to expire and revert to the French state. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights (Article 33 of the <FONT STYLE="white-space:nowrap">By-laws).</FONT> </I></B>Each share shall entitle its holder to vote and be
represented in the shareholders&#146; meetings in accordance with the provisions of French law and of our <FONT STYLE="white-space:nowrap">by-laws.</FONT> Ownership of one share implies, ipso jure, adherence to our
<FONT STYLE="white-space:nowrap">by-laws</FONT> and the decisions of the shareholders&#146; meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, each shareholder is entitled to one vote
per share at any general shareholders&#146; meeting. Pursuant to Law no. <FONT STYLE="white-space:nowrap">2014-384</FONT> of March&nbsp;29, 2014, as of April 2016, double voting rights are granted to the shares being registered, unless the <FONT
STYLE="white-space:nowrap">by-laws</FONT> are modified in order to provide otherwise. Our <FONT STYLE="white-space:nowrap">by-laws</FONT> (Article 23 of the <FONT STYLE="white-space:nowrap">by-laws)</FONT> were amended by the general meeting dated
June&nbsp;23, 2015 in order to expressly prohibit the use of double voting rights following the modification of the provisions of Article L. <FONT STYLE="white-space:nowrap">225-123</FONT> of the French Commercial Code by Law no. <FONT
STYLE="white-space:nowrap">2014-384</FONT> of March&nbsp;29, 2014. As a consequence, each shareholder is entitled to one vote per share at any general shareholders&#146; meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under French law, treasury shares or shares held by entities controlled by us are not entitled to voting rights and do not count for quorum purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rights to Share in Our Profit. </I></B>Each ordinary share entitles its holder to a portion of the corporate profits and assets proportional to the
amount of share capital represented thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rights to Share in the Surplus in the Event of Liquidation (Article 38 of the <FONT
STYLE="white-space:nowrap">By-laws).</FONT> </I></B>If we are liquidated, any assets remaining after payment of the debts, liquidation expenses and all of the remaining obligations will first be used to repay in full the par value of our shares. Any
surplus will be distributed pro rata among shareholders in proportion to the number of shares respectively held by them, taking into account, where applicable, of the rights attached to shares of different classes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Repurchase and Redemption of Shares. </I></B>Under French law, we may acquire our own shares for the following purposes only: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to decrease our share capital, provided that such a decision is not driven by losses and that a purchase offer is
made to all shareholders on a pro rata basis, with the approval of the shareholders at an extraordinary general meeting; in this case, the shares repurchased must be cancelled within one month from the expiry of the purchase offer;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide shares for distribution to employees or managers under a profit-sharing, free share or share option
plan; in this case the shares repurchased must be distributed within 12 months from their repurchase failing which they must be cancelled; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under a <FONT STYLE="white-space:nowrap">buy-back</FONT> program to be authorized by the shareholders in
accordance with the provisions of Article L. 225&#151;209 of the French Commercial Code and in accordance with Regulation (EU) No 596/2014 of the European Parliament and of the Council of April&nbsp;16, 2014 on market abuse, Commission Delegated
Regulation (EU) 2016/1052 of March&nbsp;8, 2016, and the general regulations of, and market practices accepted by the <I>Autorit&eacute; des march&eacute;s financiers</I>, or the AMF. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No such repurchase of shares may result in us holding, directly or through a person acting on our behalf, more than 10% of our issued share capital. Shares
repurchased by us continue to be deemed &#147;issued&#148; under French law but are not entitled to dividends or voting rights so long as we hold them directly or indirectly, and we may not exercise the preemptive rights attached to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sinking Fund Provisions. </I></B>Our <FONT STYLE="white-space:nowrap">by-laws</FONT> do not provide for any sinking fund provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liability to Further Capital Calls. </I></B>Shareholders are liable for corporate liabilities only up to the par value of the shares they hold; they are
not liable to further capital calls. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Requirements for Holdings Exceeding Certain Percentages. </I></B>None except as described under the
section of this prospectus titled &#147;&#151;Form, Holding and Transfer of Shares&#151;Ownership of Shares by <FONT STYLE="white-space:nowrap">Non-French</FONT> Persons.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Actions Necessary to Modify Shareholders&#146; Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders&#146; rights may be modified as allowed by French law. Only the extraordinary shareholders&#146; meeting is authorized to amend any and all
provisions of our <FONT STYLE="white-space:nowrap">by-laws.</FONT> It may not, however, increase shareholder commitments without the prior approval of each shareholder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Special Voting Rights of Warrant Holders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under
French law, the holders of warrants of the same class (i.e., warrants that were issued at the same time and with the same rights), including founders&#146; warrants, are entitled to vote as a separate class at a general meeting of that class of
warrant holders under certain circumstances, principally in connection with any proposed modification of the terms and conditions of the class of warrants or any proposed issuance of preferred shares or any modification of the rights of any
outstanding class or series of preferred shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rules for Admission to and Calling Annual Shareholders&#146; Meetings and Extraordinary
Shareholders&#146; Meetings </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Access to, Participation in and Voting Rights at Shareholders&#146; Meetings (Articles 20 &amp; 21 of the <FONT
STYLE="white-space:nowrap">By-laws).</FONT> </I></B>Shareholders&#146; meetings are composed of all shareholders. Each shareholder has the right to attend the meetings and participate in the discussions (1)&nbsp;personally, or (2)&nbsp;by granting
proxy to any individual or legal entity of his choosing; or (3)&nbsp;by sending a proxy to the company without indication of the mandate, or (4)&nbsp;by voting by correspondence, or (5)&nbsp;by videoconference or another means of telecommunication
in accordance with applicable laws that allow identification. The board of directors organizes, in accordance with legal and regulatory requirements, the participation and vote of these shareholders at the meeting, assuring, in particular, the
effectiveness of the means of identification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Participation in shareholders&#146; general meetings, in any form whatsoever, is subject to registration or
registration of shares under the conditions and time limits provided for applicable laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The final date for returning voting ballots by correspondence
is set by the board of directors and disclosed in the notice of meeting published in the French Journal of Mandatory Statutory Notices (<I>Bulletin des Annonces L&eacute;gales Obligatoires (BALO)</I>). This date cannot be earlier than three days
prior to the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shareholder having voted by correspondence will no longer be able to participate directly in the meeting or to be represented.
In the case of returning the proxy form and the voting by correspondence form, the proxy form is taken into account, subject to the votes cast in the voting by correspondence form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any shareholder may be represented at meetings by any individual or legal entity of his choosing, by means of a proxy form which is addressed to him by us
(1)&nbsp;at his request, addressed to us by any means. This request must be received at the registered office at least five days before the date of the meeting; or (2)&nbsp;at our initiative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proxy is only valid for a single meeting or for successive meetings convened with the same agenda. It can also be granted for two meetings, one ordinary,
the other extraordinary, held on the same day or within a period of fifteen days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any shareholder may vote by correspondence by means of a voting form,
which is sent by us (1)&nbsp;upon request, addressed in writing (this request must be received at the registered office at least six days before the date of the meeting); or (2)&nbsp;at our initiative; or (3)&nbsp;in appendix to a proxy voting form
under the conditions provided for by current laws and requirements. In any case this voting form is available on our website at least 21 days before the date of the meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The voting by correspondence form addressed by a shareholder is only valid for a single meeting or for
successive meetings convened with the same agenda. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To better understand the voting rights of the ADSs, you should carefully read the section in this
prospectus titled &#147;Description of American Depositary Shares&#151;Voting Rights.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Notice of Annual Shareholders&#146; Meetings.
</I></B>Shareholders&#146; meetings are convened by our board of directors, or, failing that, by the statutory auditors, or by a court appointed agent or liquidator in certain circumstances. Meetings are held at our registered offices or at any
other location indicated in the convening notice. A convening notice is published in the French Journal of Mandatory Statutory Notices (<I>Bulletin des Annonces L&eacute;gales Obligatoires (BALO)</I>) at least 35 days prior to a meeting, as well as
on our website at least 21 days prior to the meeting. In addition to the particulars relative to the company, it indicates, notably, the meeting&#146;s agenda and the draft resolutions that will be presented. The requests for recording of issues or
draft resolutions on the agenda must be addressed to the company under the conditions provided for in the current legislation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to special legal
provisions, the meeting notice is sent out at least fifteen days prior to the date of the meeting, by means of a notice inserted both in a legal announcement bulletin of the registered office department and in the French Journal of Mandatory
Statutory Notices (<I>Bulletin des Annonces L&eacute;gales Obligatoires (BALO)</I>). Further, the holders of registered shares for at least a month at the time of the latest of the insertions of the notice of meeting shall be summoned individually,
by regular letter (or by registered letter if they request it and include an advance of expenses) sent to their last known address. This notice may also be transmitted by electronic means of telecommunication, in lieu of any such mailing, to any
shareholder requesting it beforehand by registered letter with acknowledgment of receipt in accordance with legal and regulatory requirements, specifying his <FONT STYLE="white-space:nowrap">e-mail</FONT> address. The latter may at any time
expressly request by registered letter to the company with acknowledgment of receipt that the aforementioned means of telecommunication should be replaced in the future by a mailing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The convening notice must also indicate the conditions under which the shareholders may vote by correspondence and the places and conditions in which they can
obtain voting forms by mail. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The convening notice may be addressed, where appropriate, with a proxy form and a voting by correspondence form, under the
conditions specified in our <FONT STYLE="white-space:nowrap">by-laws,</FONT> or with a voting by correspondence form alone, under the conditions specified in our <FONT STYLE="white-space:nowrap">by-laws.</FONT> When the shareholders&#146; meeting
cannot deliberate due to the lack of the required quorum, the second meeting must be called at least ten days in advance in the same manner as used for the first notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Agenda and Conduct of Annual Shareholders&#146; Meetings. </I></B>The agenda of the shareholders&#146; meeting shall appear in the notice to convene the
meeting and is set by the author of the notice. The shareholders&#146; meeting may only deliberate on the items on the agenda except for the removal of directors and the appointment of their successors which may be put to vote by any shareholder
during any shareholders&#146; meeting. One or more shareholders representing a percentage of share capital required by French law (currently at 5%), and acting in accordance with legal requirements and within applicable time limits, may request the
inclusion of items or proposed resolutions on the agenda. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders&#146; meetings shall be chaired by the Chairman of the board of directors or, in
his or her absence, the meeting itself shall elect a Chairman. Vote counting shall be performed by the two members of the meeting who are present and accept such duties, who represent, either on their own behalf or as proxies, the greatest number of
votes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ordinary Shareholders&#146; Meeting. </I></B>Ordinary shareholders&#146; meetings are those meetings called to make any and all decisions
that do not amend our <FONT STYLE="white-space:nowrap">by-laws.</FONT> An ordinary meeting shall be convened at least once a year within six months of the end of each fiscal year in order to approve the annual and consolidated accounts for the
relevant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fiscal year or, in case of postponement, within the period established by court order. Upon first notice, the meeting may validly deliberate only if the shareholders present or represented by
proxy or voting by mail represent at least <FONT STYLE="white-space:nowrap">one-fifth</FONT> of the shares entitled to vote. Upon second notice, no quorum is required. Decisions are made by a majority of the votes held by the shareholders present,
or represented by proxy, or voting by mail. Abstentions will have the same effect of a &#147;no&#148; vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Extraordinary Shareholders&#146;
Meeting. </I></B>Only an extraordinary shareholders&#146; meeting is authorized to amend our <FONT STYLE="white-space:nowrap">by-laws.</FONT> It may not, however, increase shareholder commitments without the approval of each shareholder. Subject to
the legal provisions governing share capital increases from reserves, profits or share premiums, the resolutions of the extraordinary meeting shall be valid only if the shareholders present, represented by proxy or voting by mail represent at least <FONT
STYLE="white-space:nowrap">one-fifth</FONT> of all shares entitled to vote upon first notice, it being specified that, upon second notice, no quorum is required as long as the original agenda is not modified. If the latter quorum is not reached, the
second meeting may be postponed to a date no later than two months after the date for which it was initially called. Decisions are made by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes held by the shareholders present,
represented by proxy, or voting by mail. Abstentions will have the same effect of a &#147;no&#148; vote. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions Having the Effect of Delaying,
Deferring or Preventing a Change in Control of the Company </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisions contained in our <FONT STYLE="white-space:nowrap">by-laws</FONT> and the
corporate laws of France, the country in which we are incorporated, could make it more difficult for a third-party to acquire us, even if doing so might be beneficial to our shareholders. These provisions include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a merger (i.e., in a French law context, a stock for stock exchange following which our company would be
dissolved into the acquiring entity and our shareholders would become shareholders of the acquiring entity) of our company into a company incorporated in the European Union would require the approval of our board of directors as well as a <FONT
STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes held by the shareholders present, represented by proxy or voting by mail at the relevant meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a merger of our company into a company incorporated outside of the European Union would require 100% of our
shareholders to approve it; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, a cash merger is treated as a share purchase and would require the consent of each
participating shareholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our shareholders have granted and may grant in the future our board of directors broad authorizations to increase
our share capital or to issue additional ordinary shares or other securities (for example, warrants) to our shareholders, the public or qualified investors, including as a possible defense following the launching of a tender offer for our shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our shareholders have preferential subscription rights on a pro rata basis on the issuance by us of any
additional securities for cash or a <FONT STYLE="white-space:nowrap">set-off</FONT> of cash debts, which rights may only be waived by the extraordinary general meeting (by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority vote) of our
shareholders or on an individual basis by each shareholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our board of directors has the right to appoint directors to fill a vacancy created by the resignation or death
of a director, subject to the approval by the shareholders of such appointment at the next shareholders&#146; meeting, which prevents shareholders from having the sole right to fill vacancies on our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our board of directors can only be convened by its chairman or, when no board meeting has been held for more than
two consecutive months, by directors representing at least one fourth of the total number of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our board of directors meetings can only be regularly held if at least half of the directors attend either
physically or by way of videoconference or teleconference enabling the directors&#146; identification and ensuring their effective participation in the board&#146;s decisions; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the shares are nominative or bearer, if the legislation so permits, according to the shareholder&#146;s choice.
Shares issued are registered in individual accounts opened by the company or any authorized intermediary, in the name of each shareholder and kept according to the terms and conditions laid down by the legal and regulatory provisions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">under French law, a <FONT STYLE="white-space:nowrap">non-resident</FONT> of France may have to file an
administrative notice with French authorities in connection with a direct or indirect investment in us, as defined by administrative rulings; see the section of this prospectus titled &#147;Limitations Affecting Shareholders of a French
Company&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval of at least a majority of the votes held by shareholders present, represented by a proxy, or voting by
mail at the relevant ordinary shareholders&#146; general meeting is required to remove directors with or without cause; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance notice is required for nominations to the board of directors or for proposing matters to be acted upon at
a shareholders&#146; meeting, except that a vote to remove and replace a director can be proposed at any shareholders&#146; meeting without notice; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">by-laws</FONT> can be changed in accordance with applicable laws;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the crossing of certain thresholds has to be disclosed and can impose certain obligations; see the section of
this prospectus below titled &#147;Declaration of Crossing of Ownership Thresholds&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transfers of shares shall comply with applicable insider trading rules; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursuant to French law, the sections of the <FONT STYLE="white-space:nowrap">by-laws</FONT> relating to the
number of directors and election and removal of a director from office may only be modified by a resolution adopted by at least a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority vote of our shareholders present, represented by a proxy or
voting by mail at the meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Declaration of Crossing of Ownership Thresholds </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Set forth below is a summary of certain provisions of our <FONT STYLE="white-space:nowrap">by-laws</FONT> and of the French Commercial Code applicable to
us. This summary is not intended to be a complete description of applicable rules under French law. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any individual or legal entity referred to in
Articles <FONT STYLE="white-space:nowrap">L.233-7,</FONT> <FONT STYLE="white-space:nowrap">L.233-9</FONT> and <FONT STYLE="white-space:nowrap">L.223-10</FONT> of the French Commercial Code coming to directly or indirectly own, alone or in concert, a
number of shares representing a fraction of the company&#146;s capital or voting rights greater or equal to 2.5% or a multiple of this percentage must inform the company of the total number of shares and voting rights and of securities giving access
to the capital or voting rights that it owns immediately or over time, by registered letter with request for acknowledgment of receipt addressed to the registered office within a period of four trading days from the crossing of the said holding
thresholds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This obligation also applies under the same conditions when crossing each of the above-mentioned thresholds in a downward direction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In case of failure to declare, shares or voting rights exceeding the fraction that should have been declared are deprived of voting rights at general meetings
of shareholders for any meeting that would be held until the expiry of a period of two years from the date of regularization of the notification in accordance with Article L. <FONT STYLE="white-space:nowrap">233-14</FONT> of the Commercial Code, if
the failure to declare has been determined and one or several shareholders holding at least 2.5% of the capital make the request recorded in the minutes of the general meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These requirements are without prejudice to the threshold crossing declarations provided for under French law which impose a declaration to us and to the AMF
upon crossing of the following thresholds no later than the 4th training day following the crossing: 5%, 10%, 15%, 20%, 25%, 30%, 33.33%, 50%, 66.66%, 90% and 95%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, any shareholder crossing, alone or acting in concert, the 10%, 15%, 20% or 25% threshold shall file
a declaration pursuant to which it shall expose its intention over the following 6 months, including notably whether it intends to continue acquiring shares of the company, it intends to acquire control over the company, its intended strategy for
the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, and subject to certain exemptions, any shareholder crossing, alone or acting in concert, the 30% threshold shall file a mandatory
public tender offer. Also, any shareholder holding directly or indirectly a number between 30% and 50% of the capital or voting rights and who, in less than twelve consecutive months, increases his/her/its holding of capital or voting rights by at
least 1% company&#146;s capital or voting rights, shall file a mandatory public tender offer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in Share Capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Increases in Share Capital. </I></B>Pursuant to French law, our share capital may be increased only with shareholders&#146; approval at an extraordinary
general shareholders&#146; meeting following the recommendation of our board of directors. The shareholders may delegate to our board of directors either the authority (<I>d&eacute;l&eacute;gation de comp&eacute;tence</I>) or the power
(<I>d&eacute;l&eacute;gation de pouvoir</I>) to carry out any increase in share capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Increases in our share capital may be effected by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issuing additional shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increasing the par value of existing shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">creating a new class of equity securities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exercising the rights attached to securities giving access to the share capital. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Increases in share capital by issuing additional securities may be effected through one or a combination of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in consideration for cash; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in consideration for assets contributed in kind; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through an exchange offer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by conversion of previously issued debt instruments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by capitalization of profits, reserves or share premium; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to certain conditions, by way of offset against debt incurred by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Decisions to increase the share capital through the capitalization of reserves, profits and/or share premium require shareholders&#146; approval at an
extraordinary general shareholders&#146; meeting, acting under the quorum and majority requirements applicable to ordinary shareholders&#146; meetings. Increases effected by an increase in the par value of shares require unanimous approval of the
shareholders, unless effected by capitalization of reserves, profits or share premium. All other capital increases require shareholders&#146; approval at an extraordinary general shareholders&#146; meeting acting under the regular quorum and
majority requirements for such meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reduction in Share Capital. </I></B>Pursuant to French law, any reduction in our share capital requires
shareholders&#146; approval at an extraordinary general shareholders&#146; meeting following the recommendation of our board of directors. The share capital may be reduced either by decreasing the par value of the outstanding shares or by reducing
the number of outstanding shares. The number of outstanding shares may be reduced by the repurchase and cancellation of shares. Holders of each class of shares must be treated equally unless each affected shareholder agrees otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferential Subscription Right</I></B>. According to French law, if we issue additional securities
for cash, current shareholders will have preferential subscription rights to these securities on a pro rata basis. Preferential subscription rights entitle the individual or entity that holds them to subscribe pro rata based on the number of shares
held by them to the issuance of any securities increasing, or that may result in an increase of, our share capital by means of a cash payment or a <FONT STYLE="white-space:nowrap">set-off</FONT> of cash debts. The preferential subscription rights
are transferable during the subscription period relating to a particular offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preferential subscription rights with respect to any particular
offering may be waived at an extraordinary general meeting by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> vote of our shareholders or individually by each shareholder. Our board of directors and our independent auditors are required by
French law to present reports to the shareholders&#146; meeting that specifically address any proposal to waive the preferential subscription rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
the future, to the extent permitted under French law, we may seek shareholder approval to waive preferential subscription rights at an extraordinary general shareholders&#146; meeting in order to authorize the board of directors to issue additional
shares and/or other securities convertible or exchangeable into shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Form, Holding and Transfer of Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Form of Shares. </I></B>The shares are nominative or bearer, if the legislation so permits, according to the shareholder&#146;s choice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, in accordance with applicable laws, we may request at any time from the central depository responsible for holding our shares, the information
referred to in Article L. <FONT STYLE="white-space:nowrap">228-2</FONT> of the French Commercial Code. Thus, we are, in particular and at any time, entitled to request the name and year of birth or, in the case of a legal entity, the name and the
year of incorporation, nationality and address of holders of securities conferring immediate or long-term voting rights at its general meetings of shareholders and the amount of securities owned by each of them and, where applicable, the
restrictions that the securities could be affected by. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Holding of Shares. </I></B>In accordance with French law concerning the
&#147;dematerialization&#148; of securities, the ownership rights of shareholders are represented by book entries instead of share certificates. Shares issued are registered in individual accounts opened by us or any authorized intermediary, in the
name of each shareholder and kept according to the terms and conditions laid down by the legal and regulatory provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ownership of Shares by <FONT
STYLE="white-space:nowrap">Non-French</FONT> Persons. </I></B>Neither French law nor our <FONT STYLE="white-space:nowrap">by-laws</FONT> limit the right of <FONT STYLE="white-space:nowrap">non-residents</FONT> of France or <FONT
STYLE="white-space:nowrap">non-French</FONT> persons to own or, where applicable, to vote our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Assignment and Transfer of Shares.
</I></B>Shares are freely negotiable, subject to applicable legal and regulatory provisions. French law notably provides for standstill obligations and prohibition of insider trading. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ADSs are listed on the Nasdaq Global Select
Market under the symbol &#147;DBVT&#148; and our ordinary shares are listed on Euronext Paris under the symbol &#147;DBV.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and
Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our ADSs is Citibank, N.A. The transfer agent and registrar for our ordinary shares is
Soci&eacute;t&eacute; G&eacute;n&eacute;rale Securities Services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Differences in Corporate Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The laws applicable to French soci&eacute;t&eacute;s anonymes differ from laws applicable to U.S. corporations and their shareholders. Set forth below is a
summary of certain differences between the provisions of the French </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
Commercial Code applicable to us and the Delaware General Corporation Law relating to shareholders&#146; rights and protections. This summary is not intended to be a complete discussion of the
respective rights and it is qualified in its entirety by reference to Delaware law and French law. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Number of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, a <I>soci&eacute;t&eacute; anonyme </I>must have at least three and may have up to 18 directors. The number of directors is fixed by or in the manner provided in the
<FONT STYLE="white-space:nowrap">by-laws.</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, a corporation must have at least one director and the number of directors shall be fixed by or in the manner provided in the <FONT STYLE="white-space:nowrap">by-laws.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Director Qualifications</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, a corporation may prescribe qualifications for directors under its <FONT STYLE="white-space:nowrap">by-laws.</FONT> In addition, under French law, members of a board of directors of a corporation may be legal
entities, and such legal entities may designate an individual to represent them and to act on their behalf at meetings of the board of directors.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, a corporation may prescribe qualifications for directors under its certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws.</FONT> Under Delaware law, only individuals may be members of a
corporation&#146;s board of directors.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Removal of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, directors may be removed from office, with or without cause, at any shareholders&#146; meeting without notice or justification, by a simple majority vote of the shareholders present and voting at the meeting in
person or by proxy.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, unless otherwise provided in the certificate of incorporation, directors may be removed from office, with or without cause, by a majority stockholder vote, though in the case of a corporation whose board is
classified, stockholders may effect such removal only for cause.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Vacancies on the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, vacancies on the board of directors resulting from death or a resignation, provided that at least three directors remain in office, may be filled by a majority of the remaining directors pending ratification by the
shareholders by the next shareholders&#146; meeting.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, vacancies on a corporation&#146;s board of directors, including those caused by an increase in the number of directors, may be filled by a majority of the remaining directors.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Annual General Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, the annual general meeting of shareholders shall be held at such place, on such date and at such time as decided each year by the board of directors and notified to the shareholders in the convening notice of the
annual meeting, within six months after the close of the relevant fiscal year unless such period is extended by court order.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, the annual meeting of stockholders shall be held at such place, on such date and at such time as may be designated from time to time by the board of directors or as provided in the certificate of incorporation or
by the <FONT STYLE="white-space:nowrap">by-laws.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">General Meeting</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, general meetings of the shareholders may be called by the board of directors or, failing that,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, special meetings of the stockholders may be called by the board of directors or by such</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">by the statutory auditors, or by a court appointed agent or liquidator in certain circumstances, or by the majority shareholder in capital or voting rights following a public tender offer or exchange offer or the transfer of a
controlling block on the date&nbsp;decided by the board of directors or the relevant person.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">person or persons as may be authorized by the certificate of incorporation or by the <FONT STYLE="white-space:nowrap">by-laws.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2">Notice of General Meetings</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A convening notice is published in the French Journal of Mandatory Statutory Notices (<I>Bulletin des Annonces L&eacute;gales
Obligatoires (BALO)</I>) at least 35 days prior to a meeting and made available on the website of the company at least <FONT STYLE="white-space:nowrap">twenty-one</FONT> day prior to the meeting. Subject to special legal provisions, the meeting
notice is sent out at least fifteen days prior to the date of the meeting, by means of a notice inserted both in a legal announcement bulletin of the registered office department and in the BALO. Further, the holders of registered shares for at
least a month at the time of the latest of the insertions of the notice of meeting shall be summoned individually, by regular letter (or by registered letter if they request it and include an advance of expenses) sent to their last known address.
This notice may also be transmitted by electronic means of telecommunication, in lieu of any such mailing, to any shareholder requesting it beforehand by registered letter with acknowledgment of receipt in accordance with legal and regulatory
requirements, specifying his <FONT STYLE="white-space:nowrap">e-mail</FONT> address.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The convening notice must also indicate the conditions under which the shareholders may vote by correspondence and the places and conditions in which they can
obtain voting forms by mail.</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Under Delaware law, unless otherwise provided in the certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws,</FONT> written notice of any meeting of the stockholders must be given to each stockholder
entitled to vote at the meeting not less than 10 nor more than 60 days before the date of the meeting and shall specify the place, date, hour, and purpose or purposes of the meeting.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Proxy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Each shareholder has the right to attend the meetings and participate in the discussions (i)&nbsp;personally, or (ii)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, at any meeting of stockholders, a stockholder may designate another person to act for</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">by granting proxy to any individual or legal entity of his choosing; or&nbsp;(iii) by sending a proxy to the company without indication of the mandate, or (iv) by voting by correspondence, or (v) by videoconference or another means
of telecommunication in accordance with applicable laws that allow identification. The proxy is only valid for a single meeting or for successive meetings convened with the same agenda. It can also be granted for two meetings, one ordinary, the
other extraordinary, held on the same day or within a period of fifteen days.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shareholder Action by Written Consent</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, shareholders&#146; action by written consent is not permitted in a <I>soci&eacute;t&eacute; anonyme. </I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, a corporation&#146;s certificate of incorporation (1) may permit stockholders to act by written consent if such action is signed by all stockholders, (2) may permit stockholders to act by written consent signed
by stockholders having the minimum number of votes that would be necessary to take such action at a meeting or (3) may prohibit actions by written consent.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2">Preemptive Rights</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2">Under French law, in case of issuance of additional shares or other securities for cash or <FONT STYLE="white-space:nowrap">set-off</FONT> against cash debts, the existing shareholders have preferential subscription
rights to these securities on a pro rata basis unless such rights are waived by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes held by the shareholders present at the extraordinary meeting deciding or authorizing the
capital increase, voting in person or represented by proxy or voting by mail. In case such rights are not waived by the extraordinary general meeting, each stockholder may individually either exercise, assign or not exercise its preferential
rights.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, unless otherwise provided in a corporation&#146;s certificate of incorporation, a stockholder does not, by operation of law, possess preemptive rights to subscribe to additional issuances of the
corporation&#146;s stock.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sources of Dividends</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, dividends may only be paid by a French <I>soci&eacute;t&eacute; anonyme</I> out of &#147;<I>distributable profits</I>,&#148; plus any distributable</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, dividends may be paid by a Delaware corporation either out of (1)&nbsp;surplus or (2)&nbsp;in case there is no surplus, out of its net</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">reserves and &#147;<I>distributable premium</I>&#148; that the shareholders decide to make available for distribution, other than those
reserves that are specifically required by law. &#147;<I>Distributable profits</I>&#148; consist of the unconsolidated net profits of the relevant corporation for each fiscal year, as increased or reduced by any profit or loss carried forward from
prior years.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<I>Distributable premium</I>&#148; refers to the contribution
paid by the stockholders in addition to the par value of their shares for their subscription that the stockholders decide to make available for distribution.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Except in case of a share capital reduction, no distribution can be made to the stockholders when the net equity is, or would become, lower than the amount of
the share capital plus the reserves which cannot be distributed in accordance with the law or <FONT STYLE="white-space:nowrap">by-laws.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year, except when the capital is diminished by depreciation in the value of its property, or by losses, or otherwise, to an amount less than
the aggregate amount of capital represented by issued and outstanding stock having a preference on the distribution of assets.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="3">Repurchase of Shares</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under French law, a corporation may acquire its own shares for the following purposes only:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;to decrease its share
capital, provided that such decision is not driven by losses and that a purchase offer is made to all shareholders on a pro rata basis, with the approval of the shareholders at the extraordinary general meeting deciding the capital reduction;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;with&nbsp;a view to
distributing within one year of their repurchase the relevant shares to employees or managers under a profit-sharing, free share or share option plan; or</P></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under Delaware law, a corporation may generally redeem or repurchase shares of its stock unless the capital of the corporation is
impaired or such redemption or repurchase would impair the capital of the corporation.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;with a view to distributing within one year of their repurchase the relevant
shares to employees or managers under a profit-sharing, free share or share option plan; or</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;under a <FONT STYLE="white-space:nowrap">buy-back</FONT> program to be
authorized by the shareholders in accordance with the provisions of Article L. 225&#151;209 of the French Commercial Code, in accordance with Regulation (EU) No 596/2014 of the European Parliament and of the Council of April&nbsp;16, 2014 on market
abuse, Commission Delegated Regulation (EU) 2016/1052 of March&nbsp;8, 2016, and in accordance with the general regulations of the AMF.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">No such repurchase of shares may result in the company holding, directly or through a person acting on its behalf, more than 10% of its issued share capital.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Liability of Directors and Officers</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, the <FONT STYLE="white-space:nowrap">by-laws</FONT> may not include any provisions limiting the liability of directors.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, a corporation&#146;s certificate of incorporation may include a provision eliminating or limiting the personal liability of a director to the corporation and its stockholders for damages arising from a breach of
fiduciary duty as a director. However, no provision can limit the liability of a director for:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;any breach of the director&#146;s duty of loyalty to the corporation or its
stockholders;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;acts or omissions not in good faith or that involve intentional misconduct or
a knowing violation of law;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;intentional or negligent payment of unlawful dividends or stock purchases or
redemptions; or</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;any transaction from which the director derives an improper personal
benefit.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Voting Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">French law provides that, unless otherwise provided in the <FONT STYLE="white-space:nowrap">by-laws,</FONT> each shareholder is entitled to one vote for each share of capital stock held by such shareholder. Further to the
introduction of Law <FONT STYLE="white-space:nowrap">No.&nbsp;2014-384</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware law provides that, unless otherwise provided in the certificate of incorporation, each stockholder is entitled to one vote for each share of capital stock held by such
stockholder.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">dated March&nbsp;29, 2014 (Loi Florange), shares registered under a shareholder&#146;s name for more than two years shall automatically be granted double voting rights from 2016, unless the
<FONT STYLE="white-space:nowrap">by-laws</FONT> expressly reject this measure.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="2">Shareholder Vote on Certain Transactions</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, under French law, completion of a merger, dissolution, sale, lease or exchange of all or substantially all of a
corporation&#146;s assets requires:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the approval of the board of directors; and</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;approval by a <FONT
STYLE="white-space:nowrap">two-thirds</FONT> majority of the votes held by the shareholders present, represented by proxy or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;voting by mail at the relevant meeting or, in the case of a merger with a <FONT
STYLE="white-space:nowrap">non-EU</FONT> company, approval of all shareholders of the corporation.</P></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, under Delaware law, unless the certificate of incorporation provides for the vote of a larger portion of the stock,
completion of a merger, consolidation, sale, lease or exchange of all or substantially all of a corporation&#146;s assets or dissolution requires:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the approval of the board of directors; and</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;approval by the vote of the
holders of a majority of the outstanding stock or, if the certificate of incorporation provides for more or less than one vote per share, a majority of the votes of the outstanding stock of a corporation entitled to vote on the matter.</P></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dissent or Dissenters Appraisal Rights</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">French law does not provide for any such right but provides that a merger is subject to shareholders&#146; approval by a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority vote as stated above.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, a holder of shares of any class or series has the right, in specified circumstances, to dissent from a merger or consolidation by demanding payment in cash for the stockholder&#146;s shares equal to the fair
value of those shares, as determined by the Delaware Chancery Court in an action timely brought by the corporation or a dissenting stockholder. Delaware law grants these appraisal rights only in the case of mergers or consolidations and not in the
case of a sale or transfer of assets or a purchase of assets for stock. Further, no appraisal rights are available for shares of any class or series that is listed on a national securities exchange or held of record by more than 2,000 stockholders,
unless the agreement of merger or consolidation requires the holders to</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">accept for their shares anything other than:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;shares of stock of the surviving corporation;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;shares of stock of another corporation that are either listed on a national
securities exchange or held of record by more than 2,000 stockholders;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;cash in lieu of fractional shares of the stock described in the two preceding
bullet points; or</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;any combination of the above.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">In addition, appraisal rights are not available to holders of shares of the surviving corporation in specified mergers that do not require the vote of the stockholders of the surviving corporation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Standard of Conduct for Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">French law does not contain specific provisions setting forth the standard of conduct of a director. However, directors have a duty to act without self-interest, on a well-informed basis and they cannot make any decision against a
corporation&#146;s corporate interest (<I>int&eacute;r&ecirc;t social</I>).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Delaware law does not contain specific provisions setting forth the standard of conduct of a director. The scope of the fiduciary duties of directors is generally determined by the courts of the State of Delaware. In general,
directors have a duty to act without self-interest, on a well- informed basis and in a manner they reasonably believe to be in the best interest of the stockholders.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shareholder Suits</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">French law provides that a shareholder, or a group of shareholders, may initiate a legal action to seek indemnification from the directors of
a corporation in the corporation&#146;s interest if it fails to bring such legal action itself. If so, any damages awarded by the court are paid to the corporation and any legal fees relating to such action are borne by the relevant shareholder or
the group of shareholders.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The plaintiff must remain a shareholder through the
duration of the legal action.</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">There is no other case where shareholders may initiate
a derivative action to enforce a right of a corporation.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Delaware law, a stockholder may initiate a derivative action to enforce a right of a corporation if the corporation fails to enforce
the right itself. The complaint must:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff
complains or that the plaintiff&#146;s shares thereafter devolved on the plaintiff by operation of law; and</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;allege with particularity the efforts made by the plaintiff to obtain the action the plaintiff
desires from the directors and the reasons for the plaintiff&#146;s failure to obtain the action; or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;state the reasons for not making the
effort.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="35%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>France</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Delaware</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">A shareholder may alternatively or cumulatively bring individual legal
action against the directors, provided he has suffered distinct damages from those suffered by the corporation. In this case, any damages awarded by the court are paid to the relevant shareholder.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Additionally, the plaintiff must remain a stockholder through the duration of the derivative suit.
The action will not be dismissed or compromised without the approval of the Delaware Court of Chancery.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amendment of Certificate of Incorporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Unlike companies incorporated under Delaware law, which organizational documents are comprised of a certificate of incorporation and <FONT STYLE="white-space:nowrap">by-laws,</FONT> companies incorporated under French law only have <FONT
STYLE="white-space:nowrap">by-laws</FONT> (<I>statuts</I>) as organizational documents. As indicated below, only the extraordinary shareholders&#146; meeting is authorized to adopt or amend the <FONT STYLE="white-space:nowrap">by-laws</FONT> under
French law.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Delaware law, generally a corporation may amend its certificate of incorporation if:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;its board of directors has
adopted a resolution setting forth the amendment proposed and declared its advisability; and</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;the amendment is adopted by the affirmative votes of a majority (or greater percentage as may be
specified by the corporation) of the outstanding shares entitled to vote on the amendment and a majority (or greater percentage as may be specified by the corporation) of the outstanding shares of each class or series of stock, if any, entitled to
vote on the amendment as a class or series.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Amendment of <FONT STYLE="white-space:nowrap">By-laws</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under French law, only the extraordinary shareholders&#146; meeting is authorized to adopt or amend the <FONT STYLE="white-space:nowrap">by-laws.</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Delaware law, the stockholders entitled to vote have the power to adopt, amend or repeal <FONT STYLE="white-space:nowrap">by-laws.</FONT> A corporation may also confer, in its certificate of incorporation, that power upon the
board of directors.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841346_8"></A>DESCRIPTION OF AMERICAN DEPOSITARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citibank, N.A. acts as the depositary for our ADSs. Citibank&#146;s depositary offices are located at 388 Greenwich Street, New York, New York 10013. ADSs
represent ownership interests in securities that are on deposit with the depositary. ADSs may be represented by certificates that are commonly known as American Depositary Receipts, or ADRs. The depositary typically appoints a custodian to safekeep
the securities on deposit. In this case, the custodian is Citibank International Plc, located at EGSP 186, 1 North Wall Quay, Dublin 1 Ireland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
appointed Citibank as depositary pursuant to a deposit agreement. A copy of the deposit agreement is on file with the SEC under cover of a Registration Statement on Form <FONT STYLE="white-space:nowrap">F-6.</FONT> You may obtain a copy of the
deposit agreement from the SEC&#146;s website at www.sec.gov. Please refer to Registration Number <FONT STYLE="white-space:nowrap">333-199231</FONT> when retrieving such copy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are providing you with a summary description of the material terms of the ADSs and of your material rights as an owner of ADSs. Please remember that
summaries by their nature lack the precision of the information summarized and that the rights and obligations of an owner of ADSs will be determined by reference to the terms of the deposit agreement and not by this summary. We urge you to review
the deposit agreement in its entirety. Each ADS represents the right to receive <FONT STYLE="white-space:nowrap">one-half</FONT> of one ordinary share on deposit with the custodian. An ADS also represents the right to receive any other property
received by the depositary or the custodian on behalf of the owner of the ADS but that has not been distributed to the owners of ADSs because of legal restrictions or practical considerations. The custodian, the depositary and their respective
nominees will hold all deposited property for the benefit of the holders and beneficial owners of ADSs. The deposited property does not constitute the proprietary assets of the depositary, the custodian or their nominees. Beneficial ownership in the
deposited property will under the terms of the deposit agreement be vested in the beneficial owners of the ADSs. The depositary, the custodian and their respective nominees will be the record holders of the deposited property represented by the ADSs
for the benefit of the holders and beneficial owners of the corresponding ADSs. Owners of ADSs will be able to exercise beneficial ownership interests in the deposited property only through the registered holders of the ADSs, by the registered
holders of the ADSs (on behalf of the applicable ADS owners) only through the depositary, and by the depositary (on behalf of the owners of the corresponding ADSs) directly, or indirectly through the custodian or their respective nominees, in each
case upon the terms of the deposit agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you become an owner of ADSs, you will become a party to the deposit agreement and therefore will be
bound to its terms and to the terms of any ADR that represents your ADSs. The deposit agreement and the ADR specify our rights and obligations as well as your rights and obligations as owner of ADSs and those of the depositary. As an ADS holder you
appoint the depositary to act on your behalf in certain circumstances. The deposit agreement and the ADRs are governed by New York law. However, our obligations to the holders of ordinary shares will continue to be governed by the laws of France,
which may be different from the laws in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, applicable laws and regulations may require you to satisfy reporting requirements
and obtain regulatory approvals in certain circumstances. You are solely responsible for complying with such reporting requirements and obtaining such approvals. Neither the depositary, the custodian, us or any of their or our respective agents or
affiliates shall be required to take any actions whatsoever on your behalf to satisfy such reporting requirements or obtain such regulatory approvals under applicable laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an owner of ADSs, we will not treat you as one of our shareholders and you will not have direct shareholder rights. The depositary will hold on your behalf
the shareholder rights attached to the ordinary shares underlying your ADSs. As an owner of ADSs you will be able to exercise the shareholders rights for the ordinary shares represented by your ADSs through the depositary only to the extent
contemplated in the deposit agreement. To exercise any shareholder rights not contemplated in the deposit agreement you will, as an ADS owner, need to arrange for the cancellation of your ADSs and become a direct shareholder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an owner of ADSs, you may hold your ADSs either by means of an ADR registered in your name, through a
brokerage or safekeeping account, or through an account established by the depositary in your name reflecting the registration of uncertificated ADSs directly on the books of the depositary, commonly referred to as the direct registration system, or
DRS. The direct registration system reflects the uncertificated (book-entry) registration of ownership of ADSs by the depositary. Under the direct registration system, ownership of ADSs is evidenced by periodic statements issued by the depositary to
the holders of the ADSs. The direct registration system includes automated transfers between the depositary and The Depository Trust Company, or DTC, the central book-entry clearing and settlement system for equity securities in the United States.
If you decide to hold your ADSs through your brokerage or safekeeping account, you must rely on the procedures of your broker or bank to assert your rights as ADS owner. Banks and brokers typically hold securities such as the ADSs through clearing
and settlement systems such as DTC. The procedures of such clearing and settlement systems may limit your ability to exercise your rights as an owner of ADSs. Please consult with your broker or bank if you have any questions concerning these
limitations and procedures. All ADSs held through DTC will be registered in the name of a nominee of DTC. This summary description assumes you have opted to own the ADSs directly by means of an ADS registered in your name and, as such, we will refer
to you as the &#147;holder.&#148; When we refer to &#147;you,&#148; we assume the reader owns ADSs and will own ADSs at the relevant time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends and Distributions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a holder of ADSs,
you generally have the right to receive the distributions we make on the securities deposited with the custodian. Your receipt of these distributions may be limited, however, by practical considerations and legal limitations. Holders of ADSs will
receive such distributions under the terms of the deposit agreement in proportion to the number of ADSs held as of a specified record date, after deduction the applicable fees, taxes and expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Distributions of Cash </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whenever we make a cash
distribution for the securities on deposit with the custodian, we will deposit the funds with the custodian. Upon receipt of confirmation of the deposit of the requisite funds, the depositary will arrange for the funds to be converted into U.S.
dollars and for the distribution of the U.S. dollars to the holders, subject to French laws and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conversion into U.S. dollars will take
place only if practicable and if the U.S. dollars are transferable to the United States. The depositary will apply the same method for distributing the proceeds of the sale of any property (such as undistributed rights) held by the custodian in
respect of securities on deposit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The distribution of cash will be made net of the fees, expenses, taxes and governmental charges payable by holders
under the terms of the deposit agreement. The depositary will hold any cash amounts it is unable to distribute in a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing account for the benefit of the applicable holders and beneficial owners
of ADSs until the distribution can be effected or the funds that the depositary holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Distributions of Ordinary Shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whenever we make a free
distribution of ordinary shares for the securities on deposit with the custodian, we will deposit the applicable number of ordinary shares with the custodian. Upon receipt of confirmation of such deposit, the depositary will either distribute to
holders new ADSs representing the ordinary shares deposited or modify the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio, in which case each ADS you hold will represent rights and
interests in the additional ordinary shares so deposited. Only whole new ADSs will be distributed. Fractional entitlements will be sold and the proceeds of such sale will be distributed as in the case of a cash distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The distribution of new ADSs or the modification of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share
ratio upon a distribution of ordinary shares will be made net of the fees, expenses, taxes and governmental charges payable by holders under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the terms of the deposit agreement. In order to pay such taxes or governmental charges, the depositary may sell all or a portion of the new ordinary shares so distributed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No such distribution of new ADSs will be made if it would violate a law (<I>i.e.</I>, the U.S. securities laws) or if it is not operationally practicable. If
the depositary does not distribute new ADSs as described above, it may sell the ordinary shares received upon the terms described in the deposit agreement and will distribute the proceeds of the sale as in the case of a distribution of cash. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Distributions of Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whenever we intend to distribute
rights to purchase additional ordinary shares, we will give prior notice to the depositary and we will assist the depositary in determining whether it is lawful and reasonably practicable to distribute rights to purchase additional ADSs to holders.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary will establish procedures to distribute rights to purchase additional ADSs to holders and to enable such holders to exercise such rights
if it is lawful and reasonably practicable to make the rights available to holders of ADSs, and if we provide all of the documentation contemplated in the deposit agreement (such as opinions to address the lawfulness of the transaction). You may
have to pay fees, expenses, taxes and other governmental charges to subscribe for the new ADSs upon the exercise of your rights. The depositary is not obligated to establish procedures to facilitate the distribution and exercise by holders of rights
to purchase new ordinary shares other than in the form of ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary will<I> not </I>distribute the rights to you if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we do not timely request that the rights be distributed to you or we request that the rights not be distributed
to you; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we fail to deliver satisfactory documents to the depositary; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is not reasonably practicable to distribute the rights. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary will sell the rights that are not exercised or not distributed if such sale is lawful and reasonably practicable. The proceeds of such sale
will be distributed to holders as in the case of a cash distribution. If the depositary is unable to sell the rights, it will allow the rights to lapse. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Elective Distributions </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whenever we intend to distribute
a dividend payable at the election of shareholders either in cash or in additional ordinary shares, we will give prior notice thereof to the depositary and will indicate whether we wish the elective distribution to be made available to you. In such
case, we will assist the depositary in determining whether such distribution is lawful and reasonably practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary will make the election
available to you only if it is reasonably practicable and if we have provided all of the documentation contemplated in the deposit agreement. In such case, the depositary will establish procedures to enable you to elect to receive either cash or
additional ADSs, in each case as described in the deposit agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the election is not made available to you, you will receive either cash or
additional ADSs, depending on what a shareholder in France would receive upon failing to make an election, as more fully described in the deposit agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Distributions </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whenever we intend to distribute
property other than cash, ordinary shares or rights to purchase additional ordinary shares, we will notify the depositary in advance and will indicate whether we wish such distribution to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be made to you. If so, we will assist the depositary in determining whether such distribution to holders is lawful and reasonably practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If it is reasonably practicable to distribute such property to you and if we provide all of the documentation contemplated in the deposit agreement, the
depositary will distribute the property to the holders in a manner it deems practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The distribution will be made net of fees, expenses, taxes and
governmental charges payable by holders under the terms of the deposit agreement. In order to pay such taxes and governmental charges, the depositary may sell all or a portion of the property received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary will<I> not </I>distribute the property to you and will sell the property if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we do not request that the property be distributed to you or if we ask that the property not be distributed to
you; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we do not deliver satisfactory documents to the depositary; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary determines that all or a portion of the distribution to you is not reasonably practicable.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proceeds of such a sale will be distributed to holders as in the case of a cash distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Redemption </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whenever we decide to redeem any of the
securities on deposit with the custodian, we will notify the depositary in advance. If it is practicable and if we provide all of the documentation contemplated in the deposit agreement, the depositary will provide notice of the redemption to the
holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The custodian will be instructed to surrender the ordinary shares being redeemed against payment of the applicable redemption price. The
depositary will convert the redemption funds received into U.S. dollars upon the terms of the deposit agreement and will establish procedures to enable holders to receive the net proceeds from the redemption upon surrender of their ADSs to the
depositary. You may have to pay fees, expenses, taxes and other governmental charges upon the redemption of your ADSs. If less than all ADSs are being redeemed, the ADSs to be retired will be selected by lot or on a <I>pro rata</I> basis, as the
depositary may determine. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes Affecting Ordinary Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ordinary shares held on deposit for your ADSs may change from time to time. For example, there may be a change in nominal or par value, a <FONT
STYLE="white-space:nowrap">split-up,</FONT> cancellation, consolidation or reclassification of such ordinary shares or a recapitalization, reorganization, merger, consolidation or sale of assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any such change were to occur, your ADSs would, to the extent permitted by law, represent the right to receive the property received or exchanged in
respect of the ordinary shares held on deposit. The depositary may in such circumstances deliver new ADSs to you, amend the deposit agreement, the ADRs and the applicable Registration Statement(s) on Form <FONT STYLE="white-space:nowrap">F-6,</FONT>
call for the exchange of your existing ADSs for new ADSs and take any other actions that are appropriate to reflect as to the ADSs the change affecting the ordinary shares. If the depositary may not lawfully distribute such property to you, the
depositary may sell such property and distribute the net proceeds to you as in the case of a cash distribution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuance of ADSs upon Deposit of
Ordinary Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon completion of an offering, the ordinary shares being offered pursuant to this prospectus will be deposited by us with the
custodian. Upon receipt of confirmation of such deposit, the depositary will issue ADSs to the underwriters, dealer or other purchaser. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary may create ADSs on your behalf if you or your broker deposit ordinary shares with the
custodian. The depositary will deliver these ADSs to the person you indicate only after you pay any applicable issuance fees and any charges and taxes payable for the transfer of the ordinary shares to the custodian. Your ability to deposit ordinary
shares and receive ADSs may be limited by U.S. and French legal considerations applicable at the time of deposit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The issuance of ADSs may be delayed
until the depositary or the custodian receives confirmation that all required approvals have been given and that the ordinary shares have been duly transferred to the custodian. The depositary will only issue ADSs in whole numbers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When you make a deposit of ordinary shares, you will be responsible for transferring good and valid title to the depositary. As such, you will be deemed to
represent and warrant that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ordinary shares are duly authorized, validly issued, fully paid,
<FONT STYLE="white-space:nowrap">non-assessable</FONT> and legally obtained. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">All preemptive (and similar) rights, if any, with respect to such ordinary shares have been validly waived or
exercised. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">You are duly authorized to deposit the ordinary shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ordinary shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge,
mortgage or adverse claim, and are not, and the ADSs issuable upon such deposit will not be, &#147;restricted securities&#148; (as defined in the deposit agreement). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The ordinary shares presented for deposit have not been stripped of any rights or entitlements.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of the representations or warranties are incorrect in any way, we and the depositary may, at your cost and expense, take any and
all actions necessary to correct the consequences of the misrepresentations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transfer, Combination and Split Up of ADRs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an ADR holder, you will be entitled to transfer, combine or split up your ADRs and the ADSs evidenced thereby. For transfers of ADRs, you will have to
surrender the ADRs to be transferred to the depositary and also must: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ensure that the surrendered ADR is properly endorsed or otherwise in proper form for transfer;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide such proof of identity and genuineness of signatures as the depositary deems appropriate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide any transfer stamps required by the State of New York or the United States; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay all applicable fees, charges, expenses, taxes and other government charges payable by ADR holders pursuant to
the terms of the deposit agreement, upon the transfer of ADRs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To have your ADRs either combined or split up, you must surrender the
ADRs in question to the depositary with your request to have them combined or split up, and you must pay all applicable fees, charges and expenses payable by ADR holders, pursuant to the terms of the deposit agreement, upon a combination or split up
of ADRs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Withdrawal of Ordinary Shares Upon Cancellation of ADSs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a holder, you will be entitled to present your ADSs to the depositary for cancellation and then receive the corresponding number of underlying ordinary
shares at the custodian&#146;s offices. Your ability to withdraw the ordinary shares may be limited by U.S. and French legal considerations applicable at the time of withdrawal. In order to withdraw the ordinary shares represented by your ADSs, you
will be required to pay to the depositary the fees for cancellation of ADSs and any charges and taxes payable upon the transfer of the ordinary shares being withdrawn. You assume the risk for delivery of all funds and securities upon withdrawal.
Once canceled, the ADSs will not have any rights under the deposit agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you hold ADSs registered in your name, the depositary may ask you to provide proof of identity and
genuineness of any signature and such other documents as the depositary may deem appropriate before it will cancel your ADSs. The withdrawal of the ordinary shares represented by your ADSs may be delayed until the depositary receives satisfactory
evidence of compliance with all applicable laws and regulations. Please keep in mind that the depositary will only accept ADSs for cancellation that represent a whole number of securities on deposit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will have the right to withdraw the securities represented by your ADSs at any time except for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">temporary delays that may arise because (i)&nbsp;the transfer books for the ordinary shares or ADSs are closed,
or (ii)&nbsp;ordinary shares are immobilized on account of a shareholders&#146; meeting or a payment of dividends; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obligations to pay fees, taxes and similar charges; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions imposed because of laws or regulations applicable to ADSs or the withdrawal of securities on
deposit. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The deposit agreement may not be modified to impair your right to withdraw the securities represented by your ADSs except to
comply with mandatory provisions of law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a holder, you generally have the right under the deposit agreement to instruct the depositary to exercise the voting rights for the ordinary shares
represented by your ADSs. The voting rights of holders of ordinary shares are described in the sections of this prospectus titled &#147;Description of Share Capital&#148; and &#147;Limitations Affecting Shareholders of a French Company.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At our request, the depositary will distribute to you any notice of shareholders&#146; meeting received from us together with information explaining how to
instruct the depositary to exercise the voting rights of the securities represented by ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the depositary timely receives voting instructions from a
holder of ADSs, it will endeavor to vote the securities (in person or by proxy) represented by the holder&#146;s ADSs in accordance with such voting instructions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please note that the ability of the depositary to carry out voting instructions may be limited by practical and legal limitations and the terms of the
securities on deposit. We cannot assure you that you will receive voting materials in time to enable you to return voting instructions to the depositary in a timely manner. Securities for which no voting instructions have been received will not be
voted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fees and Charges </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an ADS holder,
you will be required to pay the following service fees to the depositary: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><I>Service</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>Fees</I></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Issuance of ADSs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. $0.05 per ADS issued</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Cancellation of ADSs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. $0.05 per ADS canceled</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Distribution of cash dividends or other cash distributions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. $0.05 per ADS held</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Distribution of ADSs pursuant to stock dividends, free stock
distributions or exercise of rights.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. $0.05 per ADS held</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;Distribution of securities other than ADSs or rights to purchase
additional ADSs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. $0.05 per ADS held</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8194;&#8202;ADS Services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. $0.05 per ADS held on the applicable record date(s) established by the depositary</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an ADS holder you will also be responsible to pay certain fees and expenses incurred by the depositary
and certain taxes and governmental charges such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fees for the transfer and registration of ordinary shares charged by the registrar and transfer agent for the
ordinary shares in France (i.e., upon deposit and withdrawal of ordinary shares); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred for converting foreign currency into U.S. dollars; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses for cable, telex and fax transmissions and for delivery of securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">taxes and duties upon the transfer of securities (i.e., when ordinary shares are deposited or withdrawn from
deposit); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fees and expenses incurred in connection with the delivery or servicing of ordinary shares on deposit.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depositary fees payable upon the issuance and cancellation of ADSs are typically paid to the depositary by the brokers (on behalf of
their clients) receiving the newly issued ADSs from the depositary and by the brokers (on behalf of their clients) delivering the ADSs to the depositary for cancellation. The brokers in turn charge these fees to their clients. Depositary fees
payable in connection with distributions of cash or securities to ADS holders and the depositary services fee are charged by the depositary to the holders of record of ADSs as of the applicable ADS record date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary fees payable for cash distributions are generally deducted from the cash being distributed. In the case of distributions other than cash
(<I>i.e.</I>, stock dividend, rights), the depositary charges the applicable fee to the ADS record date holders concurrent with the distribution. In the case of ADSs registered in the name of the investor (whether certificated or uncertificated in
direct registration), the depositary sends invoices to the applicable record date ADS holders. In the case of ADSs held in brokerage and custodian accounts (via DTC), the depositary generally collects its fees through the systems provided by DTC
(whose nominee is the registered holder of the ADSs held in DTC) from the brokers and custodians holding ADSs in their DTC accounts. The brokers and custodians who hold their clients&#146; ADSs in DTC accounts in turn charge their clients&#146;
accounts the amount of the fees paid to the depositary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of refusal to pay the depositary fees, the depositary may, under the terms of the
deposit agreement, refuse the requested service until payment is received or may set off the amount of the depositary fees from any distribution to be made to the ADS holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note that the fees and charges you may be required to pay may vary over time and may be changed by us and by the depositary. You will receive prior notice of
such changes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary may reimburse us for certain expenses incurred by us in respect of the ADR program established pursuant to the deposit
agreement, by making available a portion of the depositary fees charged in respect of the ADR program or otherwise, upon such terms and conditions as we and the depositary may agree from time to time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendments and Termination </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may agree with the
depositary to modify the deposit agreement at any time without your consent. We undertake to give holders 30 days&#146; prior notice of any modifications that would materially prejudice any of their substantial rights under the deposit agreement. We
will not consider to be materially prejudicial to your substantial rights any modifications or supplements that are reasonably necessary for the ADSs to be registered under the Securities Act or to be eligible for book-entry settlement, in each case
without imposing or increasing the fees and charges you are required to pay. In addition, we may not be able to provide you with prior notice of any modifications or supplements that are required to accommodate compliance with applicable provisions
of law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will be bound by the modifications to the deposit agreement if you continue to hold your ADSs after the
modifications to the deposit agreement become effective. The deposit agreement cannot be amended to prevent you from withdrawing the ordinary shares represented by your ADSs (except as permitted by law). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have the right to direct the depositary to terminate the deposit agreement. Similarly, the depositary may in certain circumstances on its own initiative
terminate the deposit agreement. In either case, the depositary must give notice to the holders at least 30 days before termination. Until termination, your rights under the deposit agreement will be unaffected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After termination, the depositary will continue to collect distributions received (but will not distribute any such property until you request the
cancellation of your ADSs) and may sell the securities held on deposit. After the sale, the depositary will hold the proceeds from such sale and any other funds then held for the holders of ADSs in a
<FONT STYLE="white-space:nowrap">non-interest</FONT> bearing account. At that point, the depositary will have no further obligations to holders other than to account for the funds then held for the holders of ADSs still outstanding (after deduction
of applicable fees, taxes and expenses). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Books of Depositary </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary will maintain ADS holder records at its depositary office. You may inspect such records at such office during regular business hours but solely
for the purpose of communicating with other holders in the interest of business matters relating to the ADSs and the deposit agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary
will maintain in New York facilities to record and process the issuance, cancellation, combination, <FONT STYLE="white-space:nowrap">split-up</FONT> and transfer of ADSs. These facilities may be closed from time to time, to the extent not prohibited
by law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitations on Obligations and Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The deposit agreement limits our obligations and the depositary&#146;s obligations to you. Please note the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary are obligated only to take the actions specifically stated in the deposit agreement without
negligence or bad faith. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The depositary disclaims any liability for any failure to carry out voting instructions, for any manner in which
a vote is cast or for the effect of any vote, provided it acts in good faith and in accordance with the terms of the deposit agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The depositary disclaims any liability for any failure to determine the lawfulness or practicality of any action,
for the content of any document forwarded to you on our behalf or for the accuracy of any translation of such a document, for the investment risks associated with investing in ordinary shares, for the validity or worth of the ordinary shares, for
any tax consequences that result from the ownership of ADSs, for the credit-worthiness of any third party, for allowing any rights to lapse under the terms of the deposit agreement, for the timeliness of any of our notices or for our failure to give
notice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary will not be obligated to perform any act that is inconsistent with the terms of the deposit
agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary disclaim any liability if we or the depositary are prevented or forbidden from or subject
to any civil or criminal penalty or restraint on account of, or delayed in, doing or performing any act or thing required by the terms of the deposit agreement, by reason of any provision, present or future of any law or regulation, or by reason of
present or future provision of any provision of our Articles of Incorporation, or any provision of or governing the securities on deposit, or by reason of any act of God or war or other circumstances beyond our control. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary disclaim any liability by reason of any exercise of, or failure to exercise, any discretion
provided for in the deposit agreement or in our Articles of Incorporation or in any provisions of or governing the securities on deposit. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary further disclaim any liability for any action or inaction in reliance on the advice or
information received from legal counsel, accountants, any person presenting ordinary shares for deposit, any holder of ADSs or authorized representatives thereof, or any other person believed by either of us in good faith to be competent to give
such advice or information. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary also disclaim liability for the inability by a holder to benefit from any distribution,
offering, right or other benefit that is made available to holders of ordinary shares but is not, under the terms of the deposit agreement, made available to you. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary may rely without any liability upon any written notice, request or other document believed
to be genuine and to have been signed or presented by the proper parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and the depositary also disclaim liability for any consequential or punitive damages for any breach of the
terms of the deposit agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No disclaimer of any Securities Act liability is intended by any provision of the deposit agreement.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Pre-Release</FONT> Transactions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions of the deposit agreement, the depositary may issue to broker/dealers ADSs before receiving a deposit of ordinary shares or
release ordinary shares to broker/dealers before receiving ADSs for cancellation. These transactions are commonly referred to as <FONT STYLE="white-space:nowrap">&#147;pre-release</FONT> transactions,&#148; and are entered into between the
depositary and the applicable broker/dealer. The deposit agreement limits the aggregate size of <FONT STYLE="white-space:nowrap">pre-release</FONT> transactions (not to exceed 30% of the ordinary shares on deposit in the aggregate) and imposes a
number of conditions on such transactions (<I>i.e.</I>, the need to receive collateral, the type of collateral required, the representations required from brokers, etc.). The depositary may retain the compensation received from the <FONT
STYLE="white-space:nowrap">pre-release</FONT> transactions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will be responsible for the taxes and other governmental charges payable on the ADSs and the securities represented by the ADSs. We, the depositary and the
custodian may deduct from any distribution the taxes and governmental charges payable by holders and may sell any and all property on deposit to pay the taxes and governmental charges payable by holders. You will be liable for any deficiency if the
sale proceeds do not cover the taxes that are due. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary may refuse to issue ADSs, to deliver, transfer, split and combine ADRs or to release
securities on deposit until all taxes and charges are paid by the applicable holder. The depositary and the custodian may take reasonable administrative actions to obtain tax refunds and reduced tax withholding for any distributions on your behalf.
However, you may be required to provide to the depositary and to the custodian proof of taxpayer status and residence and such other information as the depositary and the custodian may require to fulfill legal obligations. You are required to
indemnify us, the depositary and the custodian for any claims with respect to taxes based on any tax benefit obtained for you. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency
Conversion </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The depositary will arrange for the conversion of all foreign currency received into U.S. dollars if such conversion is practical, and
it will distribute the U.S. dollars in accordance with the terms of the deposit agreement. You may have to pay fees and expenses incurred in converting foreign currency, such as fees and expenses incurred in complying with currency exchange controls
and other governmental requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the conversion of foreign currency is not practical or lawful, or if any required approvals are denied or
not obtainable at a reasonable cost or within a reasonable period, the depositary may take the following actions in its discretion: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">convert the foreign currency to the extent practical and lawful and distribute the U.S. dollars to the holders
for whom the conversion and distribution is lawful and practical; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distribute the foreign currency to holders for whom the distribution is lawful and practical; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hold the foreign currency (without liability for interest) for the applicable holders. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841346_9"></A>LIMITATIONS AFFECTING SHAREHOLDERS OF A FRENCH COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ownership of ADSs or Shares by <FONT STYLE="white-space:nowrap">Non-French</FONT> Residents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither the French Commercial Code nor our <FONT STYLE="white-space:nowrap">by-laws</FONT> presently impose any restrictions on the right of <FONT
STYLE="white-space:nowrap">non-</FONT> French residents or <FONT STYLE="white-space:nowrap">non-French</FONT> shareholders to own and vote shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Exchange Controls </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under current French foreign
exchange control regulations there are no limitations on the amount of cash payments that we may remit to residents of foreign countries. Laws and regulations concerning foreign exchange controls do, however, require that all payments or transfers
of funds made by a French resident to a <FONT STYLE="white-space:nowrap">non-resident</FONT> such as dividend payments be handled by an accredited intermediary. All registered banks and substantially all credit institutions in France are accredited
intermediaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Availability of Preferential Subscription Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with French law, our shareholders have preferential subscription rights to subscribe for new shares or other securities giving rights to acquire
additional shares on a pro rata basis, as described under the section of this prospectus titled &#147;Description of Share Capital&#151;Key Provisions of Our <FONT STYLE="white-space:nowrap">By-laws</FONT> and French Law Affecting Our Ordinary
Shares&#151;Changes in Share Capital&#151;Preferential Subscription Rights.&#148; Holders of our securities in the U.S. (which may be in the form of shares or ADSs) may not be able to exercise preferential subscription rights for their securities
unless a registration statement under the Securities Act is effective with respect to such rights or an exemption from the registration requirements imposed by the Securities Act is available. We may, from time to time, issue new shares or other
securities giving rights to acquire additional shares (such as warrants) at a time when no registration statement is in effect and no Securities Act exemption is available. If so, holders of our securities in the U.S. will be unable to exercise any
preferential subscription rights and their interests will be diluted. We are under no obligation to file any registration statement in connection with any issuance of new shares or other securities. We intend to evaluate at the time of any rights
offering the costs and potential liabilities associated with registering the rights, as well as the indirect benefits to us of enabling the exercise by holders of shares and holders of ADSs in the U.S. of the subscription rights, and any other
factors we consider appropriate at the time, and then to make a decision as to whether to register the rights. We cannot assure you that we will file a registration statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For holders of our ordinary shares in the form of ADSs, the depositary may make these rights or other distributions available to ADS holders. If the
depositary does not make the rights available to ADS holders and determines that it is impractical to sell the rights, it may allow these rights to lapse. In that case the holders will receive no value for them. The section of this prospectus titled
&#147;Description of American Depositary Shares&#151;Dividends and Distributions&#148; explains in detail the depositary&#146;s responsibility in connection with a rights offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841346_10"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell or otherwise offer our securities described herein: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through underwriters or dealers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directly to purchasers; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through a combination of any of these methods of sale. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The distribution of securities may be carried out, from time to time, in one or more transactions, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block transactions and transactions on the Nasdaq Global Select Market or any other organized market where the
securities may be traded; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its own account pursuant to a
prospectus supplement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which a broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales &#147;at the market&#148; to or through a market maker or into an existing trading market, on an exchange
or otherwise; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales in other ways not involving market makers or established trading markets, including direct sales to
purchasers. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to
you) will describe the terms of the offering of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name or names of any underwriters, dealers or agents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the method of distribution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the public offering price or purchase price and the proceeds to us from that sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expenses of the offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts or commissions to be allowed or paid to the underwriters, dealers or agents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all other items constituting underwriting compensation and the discounts and commissions to be allowed or paid to
dealers, if any; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other information regarding the distribution of the securities that we believe to be material.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Underwriters may offer and sell the securities at a fixed price or prices, which may be changed, or from time to time at market prices
prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. We may, from time to time, authorize agents acting on a best or reasonable efforts basis as our agents to solicit or receive offers to purchase
the securities upon the terms and conditions as are set forth in the applicable prospectus supplement. In connection with the sale of securities, underwriters or agents may be deemed to have received compensation from us in the form of underwriting
discounts or commissions and may also receive commissions from purchasers of securities for whom they may act as agent. Underwriters may sell securities to or through dealers, and dealers may receive compensation in the form of discounts,
concessions or commissions from the underwriters and/or commissions from the purchasers for whom they may act as agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Underwriters, dealers and agents
who participate in the distribution of securities and their controlling persons may be entitled, under agreements that may be entered into with us to indemnification by us against certain liabilities, including liabilities under the Securities Act,
or to contribution with respect to payments that the underwriters, dealers or agents and their controlling persons may be required to make in respect of those liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also make direct sales through subscription rights distributed to our existing shareholders on a pro
rata basis, which may or may not be transferable. In any distribution of subscription rights to our shareholders, if all of the underlying securities are not subscribed for, we may then sell the unsubscribed securities directly to third parties or
may engage the services of one or more underwriters, dealers or agents, including standby underwriters, to sell the unsubscribed securities to third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain persons participating in an offering may engage in over-allotment, stabilizing transactions, short-covering transactions and penalty bids in
accordance with Regulation M under the Exchange Act that stabilize, maintain or otherwise affect the price of the offered securities. If any such activities will occur, they will be described in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841346_11"></A>ENFORCEMENT OF CIVIL LIABILITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a corporation organized under the laws of France. The majority of our directors are citizens and residents of countries other than the United States,
and the majority of our assets are located outside of the United States. Accordingly, it may be difficult for investors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to obtain jurisdiction over us or our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> resident officers and
directors in U.S. courts in actions predicated on the civil liability provisions of the U.S. federal securities laws; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to enforce judgments obtained in such actions against us or our <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
resident officers and directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to bring an original action in a French court to enforce liabilities based upon the U.S. federal securities laws
against us or our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> resident officers or directors; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to enforce against us or our directors in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> courts, including
French courts, judgments of U.S. courts predicated upon the civil liability provisions of the U.S. federal securities laws. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nevertheless, a final judgment for the payment of money rendered by any federal or state court in the United States based on civil liability, whether or not
predicated solely upon the U.S. federal securities laws, would be recognized and enforced in France provided that a French judge considers that this judgment meets the French legal requirements concerning the recognition and the enforcement of
foreign judgments and is capable of being immediately enforced in the United States. A French court is therefore likely to grant the enforcement of a foreign judgment without a review of the merits of the underlying claim, only if (1)&nbsp;that
judgment resulted from legal proceedings compatible with French standards of due process, (2)&nbsp;that judgment does not contravene international public order and public policy of France and (3)&nbsp;the jurisdiction of the United States federal or
state court has been based on principles of French private international law. The French court would also require that the U.S. judgment is not tainted with fraud and is not incompatible with a judgment rendered by a French court in the same matter,
or with an earlier judgment rendered by a foreign court in the same matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, French law guarantees full compensation for the harm suffered
but is limited to the actual damages, so that the victim does not suffer or benefit from the situation. Such system excludes damages such as, but not limited to, punitive and exemplary damages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, the enforcement, by U.S. investors, of any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S.
federal securities law against us or members of our board of directors, officers or certain experts named herein who are residents of France or countries other than the United States would be subject to the above conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finally, there may be doubt as to whether a French court would impose civil liability on us, the members of our board of directors, our officers or certain
experts named herein in an original action predicated solely upon the U.S. federal securities laws brought in a court of competent jurisdiction in France against us or such members, officers or experts, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXPENSES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the expenses (other than underwriting discounts and commissions or agency fees and other items constituting underwriters&#146;
or agents&#146; compensation, if any) expected to be incurred by us in connection with a possible offering of securities registered under this registration statement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount<BR>To&nbsp;Be&nbsp;Paid</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent&#146;s fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be provided by a prospectus supplement or a Report on Form <FONT STYLE="white-space:nowrap">6-K</FONT> that
is incorporated by reference into this prospectus. </P></TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841346_12"></A>TAXATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The material U.S. federal income tax consequences relating to the purchase, ownership and disposition of any of the securities offered by this prospectus will
be set forth in the prospectus supplement pertaining to those securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841346_13"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in any prospectus supplement, Cooley LLP, Boston, Massachusetts, will be representing us in connection with any offering. Unless
otherwise indicated in any prospectus supplement, McDermott Will&nbsp;&amp; Emery AARPI will pass upon the validity of the ordinary shares, including ordinary shares in the form of ADSs, to be offered and other legal matters relating to French law,
including matters of French income tax law, in connection with any offering. Any underwriters will be advised about other issues relating to any offering by their own legal counsel. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841346_14"></A>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
consolidated financial statements as of December&nbsp;31, 2016, 2017 and 2018, and for each of the three years in the period ended December&nbsp;31, 2018, incorporated herein by reference from our Annual Report on Form
<FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2018, and the effectiveness of internal control over financial reporting as of December&nbsp;31, 2018, have been audited by Deloitte&nbsp;&amp; Associ&eacute;s, an
independent registered public accounting firm, as stated in their reports thereon, included therein, and are incorporated by reference herein (which reports: (1)&nbsp;express an unqualified opinion on the consolidated financial statements and
includes an explanatory paragraph referring to going concern and (2)&nbsp;express an unqualified opinion on the effectiveness of internal control over financial reporting). Such consolidated financial statements have been so incorporated in reliance
upon the reports of such firm given upon their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offices of Deloitte&nbsp;&amp; Associ&eacute;s are
located at 6, place de la Pyramide, 92908 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Paris-la-D&eacute;fense</FONT></FONT> Cedex, Puteaux, France. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841346_15"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">F-3</FONT> under the Securities Act with respect to the
securities described in this prospectus. This prospectus, which forms a part of the registration statement, does not contain all of the information included in the registration statement that we filed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC maintains an Internet website at www.sec.gov that contains reports, proxy and information statements and other information regarding issuers, such as
us, that file electronically with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the information reporting requirements of the Exchange Act applicable to foreign private
issuers and under those requirements we file reports with the SEC. Those reports may be inspected without charge at the locations described above. As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the
furnishing and content of proxy statements, and our officers, directors and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions contained in Section&nbsp;16 of the Exchange Act. In addition, we are not
be required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as United States companies whose securities are registered under the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841346_16"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; into this prospectus and any accompanying prospectus supplement the information we have filed with
the SEC. This means that we can disclose important information by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be a part of this prospectus, and information that we file
later with the SEC will also be deemed to be incorporated by reference into this prospectus and to be a part hereof from the date of filing of such documents and will automatically update and supersede previously filed information, including
information contained in this document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We incorporate by reference into this prospectus and any accompanying prospectus supplement the following
documents that we have filed with the SEC: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519094568/d676474d20f.htm">Form
 <FONT STYLE="white-space:nowrap">20-F</FONT></A> for the fiscal year ended December&nbsp;31, 2018, filed with the SEC on April&nbsp;1, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">6-K</FONT> furnished to the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519001156/d672661d6k.htm">January&nbsp;3,
 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519037995/d671794d6k.htm">February&nbsp;13, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519048310/d713123d6k.htm">February&nbsp;
22, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519064105/d702858d6k.htm">March&nbsp;5, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519097939/d698055d6k.htm">April&nbsp;
4, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519100905/d581756d6k.htm">April&nbsp;9, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519144274/d687176d6k.htm">May&nbsp;
10, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519145975/d701620d6k.htm">May&nbsp;14, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519157095/d714491d6k.htm">May&nbsp;
24, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519163521/d749236d6k.htm">June&nbsp;3, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519181889/d600200d6k.htm">June&nbsp;
26, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519209920/d784121d6k.htm">August&nbsp;1, 2019</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312519215368/d780374d6k.htm">August&nbsp;7, 2019</A>;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our ordinary shares contained in our Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1613780/000119312514375129/d798615d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A>, filed with the SEC on October&nbsp;17, 2014. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also incorporating by reference
all subsequent annual reports on Form <FONT STYLE="white-space:nowrap">20-F</FONT> that we file with the SEC and those of our current reports on Form <FONT STYLE="white-space:nowrap">6-K</FONT> that we furnish to the SEC that we specifically
identify in such form or in any applicable prospectus supplement as being incorporated by reference into this prospectus or such prospectus supplement after the date hereof and prior to the completion of an offering of securities under this
prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will furnish without charge to each person, including any beneficial owner, to whom a prospectus is delivered, upon written or oral
request, a copy of any or all of the documents incorporated by reference in this prospectus, including exhibits to these documents. You should direct any requests for documents, either in writing to Corporate Secretary, c/o DBV Technologies S.A., <FONT
STYLE="white-space:nowrap">177-181</FONT> Avenue Pierre Brossolette, 92120 Montrouge, France or by telephone at +33 1 55 42 78 78. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You also may access
these filings on our website at <FONT STYLE="white-space:nowrap">www.dbv-technologies.com.</FONT> We do not incorporate the information on our website into this prospectus or any supplement to this prospectus and you should not consider any
information on, or that can be accessed through, our website as part of this prospectus or any supplement to this prospectus (other than those filings with the SEC that we specifically incorporate by reference into this prospectus or any supplement
to this prospectus). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any statement contained in a document incorporated or deemed to be incorporated by reference in this prospectus or any prospectus
supplement will be deemed modified, superseded or replaced for purposes of this prospectus or any prospectus supplement to the extent that a statement contained in any other subsequently filed document that also is or is deemed to be incorporated by
reference in this prospectus or any prospectus supplement modifies, supersedes or replaces such statement. Any statement that is modified or superseded will not constitute a part of this prospectus or prospectus supplement, except as modified or
superseded. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Commission Position on Indemnification for Securities Act Liabilities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the
foregoing provisions, or otherwise, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>$125,000,000 Ordinary Shares
</B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>(including in the form of American Depositary Shares) </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g841346g31k50.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:100pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Goldman
Sachs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Citigroup </B></P>
<P STYLE="margin-top:100pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g841346g15e30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g841346g15e30.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1H64&AO=&]S:&]P(#,N,  X0DE-! 0
M     #(< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   @  ' )0  Y4:6UO
M=&AY($%R;F]L9#A"24T$)0      $!WYGAB%F#1L6=HG@KU#^ZLX0DE-!#H
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M8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M     $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"
M<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M  !2<VQT56YT1B-0>&Q <)HY8         IV96-T;W)$871A8F]O; $
M4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M         %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O
M='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!2
M96-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#
M[0      $ /      0 " \     !  (X0DE-!"8       X
M/X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M   )           ! #A"24TG$       "@ !          (X0DE- _4
M $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $
M6@    8       $ -0    $ +0    8       $X0DE- _@      '   /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z   .$))300(       0     0   D    )
M #A"24T$'@      !      X0DE-!!H      S4    &              +_
M   &BP         !                          $             !HL
M  +_                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  +_     %)G:'1L;VYG   &BP    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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M)^V/\:?AU+_V#;_[RIAUC_&B&@-'4HC3]3;Q_P"PR&["_P :,&#U68T_3_\
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MZO4?5<TG,:QSBQCQ7C. DN:+MP>Y_IM^G[_^#_XM<J.4DM%/9C$RPV/VI87
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MS?O"A<YOHV>YOT7=QX+A%*G^?J_KL_ZIJ6BG_]D .$))300A      !5
M 0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(
M     4I-30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0
M  $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L
M @    \   "PAVD !     $   #     [  HB(8  "<0 "B(A@  )Q!!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C$P.C X(#$R.C,T.C4X
M %1I;6]T:'D@07)N;VQD     Z !  ,    !__\  * "  0    !   &BZ #
M  0    !   "_P         & 0,  P    $ !@   1H !0    $   $Z 1L
M!0    $   %" 2@  P    $  @   @$ !     $   %* @( !     $
M         $@    !    2     $X0DE- _T       @          /_A 4Q-
M30 J    "  ( 1(  P    $      1H !0    $   !N 1L !0    $   !V
M 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    \
M  "PAVD !     $   #     [    \     !   #P     %!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*0 R,#$Y.C$P.C X(#$R.C,T.C4X %1I;6]T
M:'D@07)N;VQD     Z !  ,    !__\  * "  0    !   &BZ #  0    !
M   "_P         & 0,  P    $ !@   1H !0    $   $Z 1L !0    $
M  %" 2@  P    $  @   @$ !     $   %* @( !     $
M \     !   #P     '_X3]+:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.
M5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B
M('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@
M,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL
M;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT
M87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*
M(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,3DM,3 M,#A4
M,#<Z,3$Z-# K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP
M.D-R96%T;W)4;V]L/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]X
M;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#$Y
M+3$P+3 X5#$R.C,T.C4X*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @
M(" @/'AM<#I-971A9&%T841A=&4^,C Q.2TQ,"TP.%0Q,CHS-#HU."LP-3HS
M,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^
M"B @(" @(" @(#QP9&8Z4')O9'5C97(^36EC<F]S;V9TPJX@5V]R9" R,#$P
M/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@
M(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D9CI397$^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D^5&EM;W1H>2!!<FYO;&0\+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^
M"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS
M.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S
M;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(CX*(" @
M(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HR1$8T.#5&,#DY13E%
M.3$Q.#4S0D,W-T0Y,S0P-44V,CPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @
M(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HR-T8W,44S-#DY13E%.3$Q
M.#4S0D,W-T0Y,S0P-44V,CPO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @
M/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C(W1C<Q13,T.3E%
M.44Y,3$X-3-"0S<W1#DS-# U138R/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT
M240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F
M.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN
M<W1A;F-E240^>&UP+FEI9#HR-T8W,44S-#DY13E%.3$Q.#4S0D,W-T0Y,S0P
M-44V,CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.G=H96X^,C Q.2TQ,"TP.%0Q,CHS,CHS,RLP-3HS,#PO<W1%=G0Z=VAE
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E
M;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T
M.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED
M.C)#1C0X-48P.3E%.44Y,3$X-3-"0S<W1#DS-# U138R/"]S=$5V=#II;G-T
M86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$Y+3$P
M+3 X5#$R.C,T.C4X*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N
M9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE
M=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D
M(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G
M92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN
M<W1A;F-E240^>&UP+FEI9#HR1$8T.#5&,#DY13E%.3$Q.#4S0D,W-T0Y,S0P
M-44V,CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.G=H96X^,C Q.2TQ,"TP.%0Q,CHS-#HU."LP-3HS,#PO<W1%=G0Z=VAE
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E
M;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T
M.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @
M(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HR0T8T
M.#5&,#DY13E%.3$Q.#4S0D,W-T0Y,S0P-44V,CPO<W12968Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HR-T8W
M,44S-#DY13E%.3$Q.#4S0D,W-T0Y,S0P-44V,CPO<W12968Z9&]C=6UE;G1)
M1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N
M9&ED.C(W1C<Q13,T.3E%.44Y,3$X-3-"0S<W1#DS-# U138R/"]S=%)E9CIO
M<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R
M;VT^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H
M;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @
M(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-
M;V1E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\
M+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M/#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_;
M $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 14"70,!$0 "$0$#$0'_Q  ?
M  $  @(# 0$! 0          !@<%" 0)"@," 0O_Q !?$   !0,!  L,! D*
M! 0""P #! 4&!P ! @@)$1(3%!495UB7UA87&!I5DY:8U-77V%EWE=,*(2(W
M.%2VM](C,34V4U9R=;.U)#)!>"4S49$F=B<T4F%T@;*TT?#Q_\0 '0$! 0 #
M 0$! 0$           ,! @0%!@<("?_$ %H1  $# @$%"0D-! D"!@$% 0$
M @,$$1(%$R%3DQ05,5%2DM'2TP86(C)!5%61E",S5F%Q<Y6AH['4X>(7&+/!
M!S1"0X&BLM7P)&(()35R=+1U)D1CPO&"_]H # ,!  (1 Q$ /P#W\41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B+H[U.O_5PDK6L 2&5*;#$FMZ?D5)AAL)2(Z5-FFM/
MQC1M&"W(ZL13;I)IK\%0G^>?JVRW82WIP'IN34E@D%52X>>:9PBYSZ>>KI-9
MNF\E%)F2U4]JCC5%TZR M)"T\9%OIXF97/1\Y!=0*\HNU +J#&%1(I-3V.N!
MGR@;9+R"VXJ:Y<',ZK88F2*1P])D\IB%I+4GJKR 75#^M.=VW/(RZMR M&K0
M\GQ7KV$C*TC-M<;X"5'+4$=S>@H-OJ"1NB+@4K,?(91&-J:<74"*@'Q)6M\>
M'M/JHPCD_JDR.9$ SUB-LRAO!*3V>[3FIN!D8PBM+.S=L69),H1590:S2-Q\
M'P==@D)7D@]DOE4E)>6)%Q5MW;*%!^H!YLL92?LMM>2XJ94&,41$;BN]63!,
MT3_+FI%Q1+,9][G&PAFG>SM-D5H;8CZ?'<IEB:BZS)..W,M)R<HN&]S)%$XS
M?>N=7T?Z@@'B[-0!"?RVG/3F6BMS'\WTD2B7>BY ,<9R8OM6,.X^S3=#B >9
MUV*SA45$L:.H3H!/$LDL*Y'>@2*X8Q=VN-Y/.Z9-)";VZMM;9$HH@QU"-K-\
M-MB.Z$6]I!(V?<E,Z[;%)$0(@E.7DC"1R*YP@0VTU=TW8Y]=*JI)33<R+;N8
M%>4D+4&]$%.597D5L2,RG*7:I!CGY,9=M-RTQ(7/.4H;60$,F U)':,ENDB4
MQ3GK=PD7BB2,N)\>@IKP0#*D&S"+KR-S/LD3>:J))4<-2?UY-3M,+1T[C-%S
MM(PXSJOJI?&FDO.2MJ4R2'8-F]3IAO3$;9>GLBE#I 49)BX:?82F,2 *9ADB
M+8TW+TM'-1<2L1HH\\8Z?DQUHXSME!^2--*(@R&1<.G"55<J6<RP:BA =<9.
M5LNUOL0R\6: H&T'"0'&G-[,BUE'C!-.D7=2'?&X>%\+WRPOAC?#*^66=\L=
MJVYO?+*]\LKWMM7OEE>^5_Y[WO>]$7[HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
M1$HB41*(E$2B)1%I!JMV033[HU<#3;4RBO3!3>:.>7$:S6;6"Z!<BGG<2!BY
MH7)2([P-PC*VX#MB)NL-O+=6_FKJIZ.:I:YT6&S38XG6TD7XBN2IK8*4M;,7
M O!+<+<6@&Q^]:H\N?H8_6)=ZO0NT%=&]57Q1\_\ES;\47*DV9Z4Y<_0Q^L2
M[U>A=H*;U5?%'S_R3?BBY4FS/2G+GZ&/UB7>KT+M!3>JKXH^?^2;\47*DV9Z
M4Y<_0Q^L2[U>A=H*;U5?%'S_ ,DWXHN5)LSTIRY^AC]8EWJ]"[04WJJ^*/G_
M ))OQ1<J39GI3ES]#'ZQ+O5Z%V@IO55\4?/_ "3?BBY4FS/2G+GZ&/UB7>KT
M+M!3>JKXH^?^2;\47*DV9Z4Y<_0Q^L2[U>A=H*;U5?%'S_R3?BBY4FS/2LHM
M[-OHD;ZRJH2@/+-CZ,HG$L[8%@A"A6-$3 A8>P0G'^.^!V%#RW&>U;=8[5]J
MVW6K<F53VM>W-V< 1X=M!T\2V=E:D8YS'&2[20? )TC1QK%\N?H8_6)=ZO0N
MT%;;U5?%'S_R6N_%%RI-F>E.7/T,?K$N]7H7:"F]57Q1\_\ )-^*+E2;,]*<
MN?H8_6)=ZO0NT%-ZJOBCY_Y)OQ1<J39GI3ES]#'ZQ+O5Z%V@IO55\4?/_)-^
M*+E2;,]*<N?H8_6)=ZO0NT%-ZJOBCY_Y)OQ1<J39GI3ES]#'ZQ+O5Z%V@IO5
M5\4?/_)-^*+E2;,]*<N?H8_6)=ZO0NT%-ZJOBCY_Y)OQ1<J39GI662MFUT3+
M/&7 AY8OQ4DG5DWOK!!#VB1"P=S%P_\ Q^^[%M83'<!_BW7X_P =MJL')=4+
M7$>D@#P_*?\ !;-RK2.O8R>"TN/@'@'#Y5B>7/T,?K$N]7H7:"L[U5?%'S_R
M6N_%%RI-F>E.7/T,?K$N]7H7:"F]57Q1\_\ )-^*+E2;,]*<N?H8_6)=ZO0N
MT%-ZJOBCY_Y)OQ1<J39GI3ES]#'ZQ+O5Z%V@IO55\4?/_)-^*+E2;,]*<N?H
M8_6)=ZO0NT%-ZJOBCY_Y)OQ1<J39GI3ES]#'ZQ+O5Z%V@IO55\4?/_)-^*+E
M2;,]*<N?H8_6)=ZO0NT%-ZJOBCY_Y)OQ1<J39GI3ES]#'ZQ+O5Z%V@IO55\4
M?/\ R3?BBY4FS/2LJ/LVNB4NB)K@$'ECB]54UA)*7LP0KC7-H99$-GK"!<?_
M ) =@5]/WK/=7WS*XV.UCO6WEJ,F51<YEH[M#7'P_(XN \G_ &GZEL<JT@:U
MY,F%SG-'@'A8&EVB_P#WA8KES]#'ZQ+O5Z%V@K;>JKXH^?\ DM=^*+E2;,]*
M<N?H8_6)=ZO0NT%-ZJOBCY_Y)OQ1<J39GI3ES]#'ZQ+O5Z%V@IO55\4?/_)-
M^*+E2;,]*<N?H8_6)=ZO0NT%-ZJOBCY_Y)OQ1<J39GI3ES]#'ZQ+O5Z%V@IO
M55\4?/\ R3?BBY4FS/2G+GZ&/UB7>KT+M!3>JKXH^?\ DF_%%RI-F>E.7/T,
M?K$N]7H7:"F]57Q1\_\ )-^*+E2;,]*<N?H8_6)=ZO0NT%-ZJOBCY_Y)OQ1<
MJ39GI657-FVT2MY5.(RB/+%CI$3$,>P+!!%"MEF$&-CN!./\=U;<"8_CVK?C
MV[?]*U;DRJ<T. CL>#P_R6SLK4C'%KC)<:#X!/\ -8KES]#'ZQ+O5Z%V@K;>
MJKXH^?\ DM=^*+E2;,]*<N?H8_6)=ZO0NT%-ZJOBCY_Y)OQ1<J39GI3ES]#'
MZQ+O5Z%V@IO55\4?/_)-^*+E2;,]*<N?H8_6)=ZO0NT%-ZJOBCY_Y)OQ1<J3
M9GI3ES]#'ZQ+O5Z%V@IO55\4?/\ R3?BBY4FS/2G+GZ&/UB7>KT+M!3>JKXH
M^?\ DF_%%RI-F>E.7/T,?K$N]7H7:"F]57Q1\_\ )-^*+E2;,]*RZ+LVFB9>
M,FBB>/+%Q2:0MK8V_,$(/'@* DG%E0OCEQ]ENA;$B(]P0]JV^BVP#V\=UMVU
M=DRJ:+D1VQ-;X_E<X-'DXR%LW*U(XD R:&N<? / UI<?+Q K$<N?H8_6)=ZO
M0NT%;;U5?%'S_P EKOQ1<J39GI3ES]#'ZQ+O5Z%V@IO55\4?/_)-^*+E2;,]
M*<N?H8_6)=ZO0NT%-ZJOBCY_Y)OQ1<J39GI3ES]#'ZQ+O5Z%V@IO55\4?/\
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M"Z%U2@[-I-[5D,=M2_I5+L@=LQ:F2#(D5"B/U.D5LXEM#SMU>O.Q5[.!OD&
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M6@.DP V<;>%,/%!N[1%PBPN2+7:5T&C8&EV)QM$9+7:+D-@=XQ%F:92+.TD
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MA:2;MN16)& VPLSA)\5E%)72TV.VA-2X$I<?-QV&U<_%*$Z5<E<85&()Y%+
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M + A!DE088<MB%OHF.3-L/"UITDZ1>Y+<!)OPW;X)OPCA3/2\MW  +:+ .Q
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M&SAU"/JPR\>1CF1C(0,TF'%LP.KFB(X8A8PI#"G1@\S F0E]1%&&X1&P-!Q
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MWM:VV!M@VV@$$ Z;%ML-KWM:PM;@\B9V2Y=B.(AP)T D.\:_'B\M^%<%XO\
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M5-4"2G.*G%/"US)7%K62.>TR.,EWN=B]T/\ :(!%M-]#-"861891:4RO(<P
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M*;'6#95RNE-(*#=,*8:R7UWE;CI/"C=%!!%%+&X2MSCFR9R649N5@+I2 #G
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MV)W<Y'ES;69V"XHI*0OS3@[W24O=*TAWCN:;/)O=V(BP=88W:S&YV"334-G
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MC89]T%T_NF)\DDF$N<"VV'0/"*JZN8YSO<Y,#\XYWN@Q-=)'FP(_!PM:UI(
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MF=3#)NQ@Z95%48X;-#VMW4]')3T+Z4/CSCFS 2M86B\I>0]PN27-+N,"P
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M"IF$Z)':3>EW26HQ9'2RK )[GD-!F8213[1)&=T%@MY,VT1M,=;($C&0(JH
M16@U()-L:,)I)5/ @)AN4W<L]L;W0U8ED NV-T.;#R/[./.OL3Y+BU^$@:5N
MS+#2X"2' P\+@_$6_'AP"_QV-^*_ O5@T'>UI :S>>[(<"2ZF@[$@@OMIR(1
MT!11UM%5"X9M/4DX\6SS ,E31<7 4(0/*]KVRVK[65KVM\J]CXWNC>TL>QQ:
MYKA8M<#8@CXE[+7!P#FD%I%P1I!!\H4CK592B)1%1\^_U49WUX:?OWTL:K0>
M,_YF?^$]1G\5GST'\5BO"HJR41*(E$2B)1$HB410R,/T@IE^J2 /VMU$U9WO
M$7SDWW0J+??Y?FX?OF5&Z_YM=VFV.T2=T4ZFE6%&\N1*>U XJ*=8_N-/KE<)
M1BR4OE!<<<C"8-'91U$92.*!:V^<3,=5(B6R+'A[5%674*-LL,KP:R7F_P"<
M4E*5W(MPG ,W,.-'0KA1^@)Y+4'EK6E]KQJGF6M#;E7TJ1&Y#,)--KNI0D=X
MFFLLKB 9,(N+;<MQTF02+YS_ +,E(#1%2%AHQ>73@V!/#2+NUB(3L29 4Y$A
M)YZ5-6,D$%=X+Z.R5](B]'17Q$*2Z'@5;*DMS$TFXQG-@IL<3 4NWW83_FE6
MTD;*2_T=[O=L!1RA2:@MR1)"/+;N-2JFDRZ='B#J%@&#"Y:+B[4A8B3=Q'#*
M<BKG:^+N42BF?2$48NM/=0,J)8V4(I?J&U::OH\U@3@C1:T#\@P1IDAR)ILE
M)K$D:/N#FV&NL74NY'TFD54XN%)6/RRXU>+F*D1$F-% 7FC8R*X@WQB0 ,II
MNQ%#DC9DLAB$!W7HC8J>O31-+4C4%!1YF-.3-09[M?<&,,.2&(KID<9H"P"W
ME:;RY5=9[L566\,SC34QTQ'--A1)N@(BYC)V8!3/)T;+4G0JRXZ0)$2H->/=
M'>9C)YOM5BSM'^N9:;)USJJW'+5*ISC#?^BH=EV2+"#)1VTK-;,BX#*R3S15
M(BV&V/W6G)NKAVS1D^6['++;:*S=+<B1NU$!PJBJ^2#=GO39&LP*6#DXP2TL
M%<24YR.U70TYU)Y),+#'$TZBY)^0R8(=,$79S1$HB41:M:QY$?L7PC9R1IQY
MD[U&7=.C#*!M<@RE-SCIDGZ@XQC=R%VV4D8XGL6[@,MMU*P",8=)TJC$U$0N
M;-C88 ;=$6H2!KTEMBJJ['LYQ:TD-?BB/!%257TM2BS$"Y9PA1(2E0@KXQ>U
MA7M(*VUC5E5,8SB7(L:S^2"#\+.NS=NKM]MG!P2+EQ[LC+LD)4(V3(=:HK<3
M,XT3GHKE)+61U#CB4=5&H?2F@Y,5)$C<$)P)(3F@C%W'1UU3:Q\)!<MD\ @;
M4T_;-$7WC;9!%N:7_IK3V$0B@BQY*4&8FR2?/OT98.)CA?FG(6:RC";AM.2
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M41>.O\(GTA:G=3VK2&S^GR#Y"ETFT-.J24<YED(0ZP$AF5>2I(&3 %#,*]K
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MQY65#JFJDR()X^;4E P:'%&.&,Q.IM?D=CS(R>B9(6AI>W-M>6@ !I< "6@
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M>I8U(V++9%%Y.*JZ-HZG123#V&0A0\59AL0N8PP$S"RR"SMEM96L('GA>_\
M]K&]O^E#E7)P-C60 CA!> ?45@4=4X7$$A!X#99+DFMDGZ%D^>A)S^*F^N3?
M/:?:!9W%5ZB3U)R36R3]"R?/0DY_%3?7)OGM/M FXJO42>I3N,MAAV2>2GTW
M&3?2U(S#"7C^!4R\9%2[M5F-TICCD*;55U9-Y9;R5*EPQ!,2Y0 VHGA;!DDX
MD;.C@@"3ERSDV*-S]U1R81<,B<'O<?( !QG1<V X20%LV@JW.#<RYMS;$[0T
M?&3IT?X%>]38ZMCKAG8[(7+1['Q8%P2 X02!^6I9/$02[A?[B+ Y[6&.U<45
M):*,*.:!:K7",# )988<T:&/K:@JJI[X/*.49LHS&20X8VW$40-VQM/JNXV&
M-]KN/$  /HZ6ECI8\+-+C8O>>%Q'W-']EO -)TDDGL%KSUTI1$HBH^??ZJ,[
MZ\-/W[Z6-5H/&?\ ,S_PGJ,_BL^>@_BL5X5%62B)1$HB41*(E$2B*&1A^D%,
MOU20!^UNHFK.]XB^<F^Z%1;[_+\W#]\RM!R?TL8_P ?Z.%15E@J(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%3Z-^?V1_J?A7]M)]JI]XC^
M=F_T0*0]_D^:A_USJX*DJI1$HB41*(E$2B)1%3VGK\P\-?5@QOV;3JM4>_S?
M./\ O*C3^\0_-L^X*X:BK)1$HB41*(E$2B*F9E_Y8L^N9A_ZJA5X.&7YB7[E
M&;^Z^>9_-7-4%9*(E$2B)1$HB41*(J80/T@I5^J2"_VMG^K.]XB^<F^Z%0;_
M %B;YJ#_ %3JYZBKI1$HB41*(E$2B)1%3.GK\S3$_P M-_[LH56?WU_R_P @
MI0>],^3^95S5)52B)1$HB41*(E$5'S[_ %49WUX:?OWTL:K0>,_YF?\ A/49
M_%9\]!_%8KPJ*LE$2B)1$HB41*(E$4,C#](*9?JD@#]K=1-6=[Q%\Y-]T*BW
MW^7YN'[YE:#D_I8Q_@ _T<*BK+!41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B+PP?A38H@>K[3SN!,\-O3:%M[C/+';_P#I/?O\^U>VW7W'
M<L :6IN+_P#4#^&Q?.Y8_K$?S(_UO7G,28GE=>C!WS2CLUT*$4,)P-UJ/%_E
MRH^3:;[D=F)K-NHI]1OE8/%05,"8^0)</?,L,=YN/O5C);?OHS)"V5D)<P2R
M-<YD>C$YK/&('$+_ /+%>6&/+'/#26-(#G6T NX!?C*^F44R+A#@,]B)^]Q>
M:DPU$)1>$6$_ P;?I!K%'FH)!1&R.663 *<WE%,.J"F"1S3"6:HF%3!L,T?*
M@BXSD6>S']X(Q,1AT8"XL!O:VEP( O?03Y%G [!G+>!CP7N/& #B+<.@$:>#
M2%].]))/>7\(+)-W$57D_O.!.'-83\!S$@XM3NU'1BR+D=LLF BC<R /'50(
MADF%,SI H8-AFSI8$1G8L_N?^]S6>PX= CQX+DVL"7< O<@$\ 3-NS>=MX&/
M-WN+XL.*UN'0.$\&D*K^$&/[<;SN?\55L.(>H+1.$&/[<;SN?\5+#B'J"*3L
MQI/F1G.D,J/VXZ'L\%\<0JAM9II:FX'"L&02XQP4!,1TH$TH'A@BA8P9$#+%
MQ,L"X PV5K!AYY6T>Z.-I?(6,8WQG/(:T7( N38#20/E*RUKG$-:"YQX  23
M\@"C'"#']N-YW/\ BK>PXAZ@L+9V2-'FJ&(HA:T[R/%ZZUHK>(S3+H;E.+;;
M,#[Z_&X>=[(Q66VGKQQUM>SO:R8><#:S<Z&CAK:07R/)V1@OF'GGRQU=)-*Z
M".1KY6XB6AKK> X-?A<6ACL#B&NPN.$Z#95?!*Q@D>PM:ZUB2+^$,3;MOB%Q
MI%P+C@5;MV%9E=D52!.#:8;M6(BBE1;:/(DA$B8V;8:2H[CH2:VT]54;YXAA
MFE4Z.7+@ A6%S#R,ELC%@<#(&0E730,EC@<]C9I0XQQFV)X8+N('Q 'U&W M
M1&\L=(&DL98.=;0"XV )^,KC%(HD<[#J[/0"9G>+6[([9B93<0BJ1!SL_':V
MW0[49%*)8IO%5/[I 9ZT>/'B9,<@EVQ( J!DL.JIH9D98A,V#^]=&Z4##HP,
M<UI)-K#PG  7N=) L#9@<6&2W@!S6$W'C.#B !PG0TWXM"E4<Z<)YEQCJ<@Q
MFPW$^$%,DAEQ%B6;5N-W*L2*_P!!>;H;37;31)"C.9S'S" P'2JG>(DH^$E%
M" 8BD(5L=)[_ *R5%/%((I'-8XQOFNX6:(V.8QSG//@M&)[0+D7)T<!66Q2/
M;B8TN&-K+#2XN<'. #>$Z&DFPT#A5$\(,?VXWG<_XJO8<0]04TX08_MQO.Y_
MQ4L.(>H(G"#']N-YW/\ BI8<0]01.$&/[<;SN?\ %2PXAZ@B<(,?VXWG<_XJ
M6'$/4$3A!C^W&\[G_%2PXAZ@B<(,?VXWG<_XJ6'$/4$3A!C^W&\[G_%2PXAZ
M@B<(,?VXWG<_XJ6'$/4$3A!C^W&\[G_%2PXAZ@B<(,?VXWG<_P"*EAQ#U!$X
M08_MQO.Y_P 5+#B'J")P@Q_;C>=S_BI8<0]01.$&/[<;SN?\5+#B'J"+T+;$
M"8,H>GV=WIA9?B=$)O+)MR?JR#%&4W8T8]<"2RP ("TGM@#A:@;U)3HY+$DY
M4<:<2MBUD%*9)P0NO.(=F$"GS66P'5-/'X,I,>*.C\5KY&F0FHJW&S=S0-N0
MTGPG&3Q68R?6R?HBE=X3!BPOGX2UAP>Y0@7.>D-KFV@!ITNPV[? 05!L+;=1
MV^B-J&W)#<;#N1FL5S#@JT([&'":PEJ1]0GV><[FLD^2M;DG(YU?4T1N<,Q.
M$3#E5 U);46V4=$B/OQ;AS7$ET[9I U[VW$^5)VD 00:+QT,9#0YUM. $ /+
M(H_0X"+!L9C82&G3'1QN!)DETV?4/%]%[Z3<EN*1_!14\OF'%+:8[&=*^,Y%
M95EJ"H)EE2.DUR7W/BJ!#N'9%=D;7,P!3R='S?7BI9Q10QE$,=6/C(C7+H(0
M#A.(S.C#))]U<][6X6B&>>$ MB;ALW)V36\!D<WP)G@V&)Y=X <^; 'O8:TF
M[C)'&\F\CKZ:JK/D:",4;3X1LW#X5FQX[(5MK[5-'1#$B3>T9MD"Q-764_+!
MO3#LJ$RHA?( -EM@#(48I&FQ^1JGYCIJ@8-&LV>8; ZEA;@2$5.+LJ9\)CP/
M<X'P1DAKO"AR5 [27NL 9<HRD8@ ,>(#A<0V#'@N!\:1LC[$C1)6R 6PC39E
M*S2#<X;7%P 3)E5=6SQO*KQ>$A+ 2O<TDQ'J!U$1"24L5# UB>O9M;'1L;J'
MC_XM<[95#P(R._4S>CF:P6R/*!=0<!S(>)\-'O3&1BVF6GIIBW"1;PLI92=8
M"V'3%&;BV@$-%I\DZ9'%^G1'+-&#H(/@TE*.&]_'</+8D8C[GS+7.H2V=&5,
MFK"3IA2,02@^:;<!9@O8MX.7T\L$ U6Z.!EQ7)6N*3T0P3(X'4X OP'!1,73
MS0K=)$$F3==#F^#CF9/*>'1494G:;XW C%%0Q.!)!)N0+@/+G1/%.G#&8V^3
M3%1Q'R C0^I>.+@'_;;.<=%(&K*$8-M'8YE(4D%-5I;@*!):/C&4^*4H0P?,
M+VR+;(JX!Q0[J<EJYWC1T,AA*.6:J3<QH(C=0)NLPN.B/LN.B5[GW#B(JB>$
M:93X(;DW)S1XL8%F22#P2P$V+ QD@:"P 6(!?%$_^P--ZRK<>%Q-W,8=-SPX
M\3HL>E9IBPGM,HD)TE2RS)2D2[J8377#YM)FC9'IH;N9(:\X3,I[UB+&VBN*
M+%4T5N)9\H(5.M9!1#026I(P+:;;NV-VEY<8X9(HL,CP Z')L#KV@@%_=*V:
MYQ$&X>YPQ!Q>]F-!L '/:]]V-)(DJY!ISDAX64T>BP.C"!H(PM?W'Z3-8B<_
MD_!ER0\T9Q+*6Z2\9)T\%R:,Q8JG.9C&;F677'4$I!U<.KCJ(1H1306[W2AX
MFB;E-)Y\(J?4%E*7-QY=32&,XF,+069W,$E\T$ PALE00T-8Z0G%@T%H(N "
MU=D4P<+.<'6.#."S622:<38A<EP9;#?C!%R0;;4Z>OS-,3_+3?\ NRA7-/[Z
M_P"7^06\'O3/D_F5<U254HB41*(E$2B)1%1\^_U49WUX:?OWTL:K0>,_YF?^
M$]1G\5GST'\5BO"HJR41*(E$2B)1$HB410R,/T@IE^J2 /VMU$U9WO$7SDWW
M0J+??Y?FX?OF5H.3^EC'^ #_ $<*BK+!41*(E$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B+PN_A3WZ7^GC_ +;0OWGOVON.Y;^JU/\ \@?PVKYW
M+']8C^9'^MZU#9>R!Z,F7IV:VDBT&R@N14WF9&JX['6:74DF>EZ9QIY@&9YM
M,.J,PC0C=()"BBQFKQ.Q'>,Z%UQ)[#1&\G#))#%S.'@78_)]8^H=5YZ,2N?*
MUK+$B*',3PPX9-!)!D$CV!K07N<<1PM46U,#8FPYMY8&L+C<#&_.1ODNS@TA
MI8UQ<2&@  8BMOWGLPVF)UJI1#"?FK9.+I;:U/#L"?@XNB^TH00]9LE")U)H
M@PW'Y>8"R"VV^PX*CM2AAKJ1)\IRVT"[@-JR"$&5-B(Y3D;D>I:,6;I3=U-G
M(,[)FYV112A^=DS.)SI)WB5X++/M8V(#C8UT1T8IM EPR8&8XW2/86AC<X
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M+VJ;ST^LF];.HGBL>C3I :F_M"*_AK3OIK=12\V7M4WGI]9-ZV=1/%8]&G2
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M. D'Y)^QRPJF'8]#!67@;:,79*3H;$?K)I,6FNM3>JC7',ZBI1%/IHK@EV8
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M>TQX8X\$()BC(<Y@F(TU+VD^ZS7T@RXF@6:&8&M:!IVG%=SL3S9[M <8Q_=
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MIW*3-SOM[JJ [:TQPZEVU_0F";7-V7ZU44#-B718C9(A.5T$H5R3S5P2PD9
MFLPL>-3]KXY&+N\#?=O*U\MO>L-JU[8[5]K;O29T.<?>)Q-^'.V\@\F!3A;-
MFF6E:-'!FOC/_>K=[E)FYWV]U5 =M:GCAU+MK^A4P3:YNR_6G<I,W.^WNJH#
MMK3'#J7;7]"8)M<W9?K3N4F;G?;W54!VUICAU+MK^A,$VN;LOUIW*3-SOM[J
MJ [:TQPZEVU_0F";7-V7ZT[E)FYWV]U5 =M:8X=2[:_H3!-KF[+]:=RDS<[[
M>ZJ@.VM,<.I=M?T)@FUS=E^M.Y29N=]O=50';6F.'4NVOZ$P3:YNR_6J9G)L
M2X$V&ED<E9!-AY3-!0888<9 E;AFA9?9@9,U?.SO&WS H:R",B%MSC8U@%D7
MN*#82XN%8718G6B</<IO[V]QFGW'B>4>7R*,S9L+;RM/NT/]U;3G66_MJYNY
M29N=]O=50';6I8X=2[:_H5L$VN;LOUIW*3-SOM[JJ [:TQPZEVU_0F";7-V7
MZT[E)FYWV]U5 =M:8X=2[:_H3!-KF[+]:=RDS<[[>ZJ@.VM,<.I=M?T)@FUS
M=E^M.Y29N=]O=50';6F.'4NVOZ$P3:YNR_6G<I,W.^WNJH#MK3'#J7;7]"8)
MM<W9?K3N4F;G?;W54!VUICAU+MK^A,$VN;LOUIW*3-SOM[JJ [:TQPZEVU_0
MF";7-V7ZUR((3G0FSI-@+K<I)T'LXN@(0 Z1;V#;" *W=&H3'$KD3P5%:PV>
M(N(HMS-S&%\K"V#WJU@[99;2%IAB+6EHSDV@NQ:;0^6P^Y:Q!PFFQN#CFX=(
M;A\LWDN?O5LOUT-EN+Z,3<+B0D$V[5DJV&J565=/2S#F<HJ,H+03>;X!XP *
MLK@B.B+*M@DIV)D_FF)"F?Q+W*D#0H7.NA0!I2K&C^67&WF,_6D\5EH7M@Z"
M+87DU=$01NZ)UM 4JJ9IA@R"3.E'6Q7FVE B*)B<3EYKKB2? +'DXR &19AP
MO1I-,^T$MS.)(0E&0'-=ELDDIG02AATNS%N.)WW;R(&+ECD?5NY=I.9=X$!N
MAKIJ&I&K8[V6$O8B^S>=C:=F*SFVEM/6\6ZX55IKF2<8P,62W*ABX K"(<OA
M^(%0311, S9?+\L'/*V.6U?\5$6 .RS%::Z'"QU&3(_(/1HLV\BNMH'7FW"K
MH;$?8BBE\GVX4 =2#5D5FV'+C@W<ZD4+(EA010[GMV'GC8BK _K"TKIB4&OF
MM0D1<0#(@SD*N J^D ^@'F^7C]V2L,MIRV0.F4M12@XV8KQ>^1XB;,%NYMMJ
MRI82Y8H)G8BV(*FBYXL6.DQPS)0V ":*F0<[" F"Y@/$4 <(3&]\<PQ0L\1
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M)LG6PPH\6QTE.F<V 7<J:R6P17P!X]F<88%9*HY,%2"%&*L04L*)@;P%QS$
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M>#_#7-Z@>:,>T4W1-K')F(N0/KZ4\'^&N;U \T8]HINB;6.3,1<@?7TIX/\
M#7-Z@>:,>T4W1-K')F(N0/KZ53,YP9$A%KM,4HPT, 0:9H))"9X!F-O,J?E]
MEDS@%]L>_P"08*CB@B?]=QGEM7M?\=5AGE+G7>XVBF(^41/L5&:&+"SP![]#
MQZUGQJYO!_AKF]0/-&/:*ENB;6.5LQ%R!]?2G@_PUS>H'FC'M%-T3:QR9B+D
M#Z^E/!_AKF]0/-&/:*;HFUCDS$7('U]*>#_#7-Z@>:,>T4W1-K')F(N0/KZ4
M\'^&N;U \T8]HINB;6.3,1<@?7TIX/\ #7-Z@>:,>T4W1-K')F(N0/KZ4\'^
M&N;U \T8]HINB;6.3,1<@?7TIX/\-<WJ!YHQ[13=$VL<F8BY ^OI7(@AFM=D
MSI-B:U$4FAD3,70$='+$L<\0Q363HU" 9#Y6$SSON[A !87VKVMN<,?Q5M(Y
MSX8G.)<<Y-I/R0K2-C63S!HL,W#P?+,LKJ$FYHP@J1R8>A1>R3)2EQ@PHFK*
M02)&DQN.R1<#J>S3KM&-*1 5-;ZVZ"Z4RBQ\@ JF^ZIU-HEDGXDSAM0(<ZZ%
MJ:Q-D9T[O-.?3G4%%48K%9*0EN#NJ=6*:9S6VVK/J<V6GO(HVVBHNEPIK#6"
M4".M_-]WKQ%,35*/C95Q&K)=DY>*I1%EI+V0S2]&@S5'.R(BK3:5Y9,Q*['N
MD'RUV7'2F2AJ7YJ.K+B<QK(NCJ*6GH4-.!&4P6R=6E%,<!Y/3CQ, Q8<(,BR
MB5KVTSBKAAL.F26ZQG&)(*\P4-$7U0N(H+(J([&LQK+(X*=8WW,$C;M>K5;P
MI5V715%'6G C)*Z63E%2*%A"+F.76O$K0GN0X%<I)<03$1Q:A3')TG+R]%+<
MC1F,5P)+_62BF=[HI+29&6,"1.-W!FNF6K'2^F-[$5,,K2@1(FA398BY2/KK
MTG+RBQ49)F)(-K,DNTPQ6<C<0O$!84745=9YBF$HXE&6Z"H(.03R2EELW..$
MNE)]UE"<!'$W<=!6,21%MM1$HB41*(E$5:RO*S3AEJ$WH]AC!9 -OB,F#F;
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M9X+K15T%ONE967NN-EA=U+K3HR8J9<Q)BRW$,L]GDEL-UJ"*5(H2(<+ K0"
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M#! %#7'WVSAKO_+X'ROW VGC@K'S OKX:BI$<[FTHS<L%/3E\L<;9;O>QH<
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M&R$%&%$RR$$$$RRSSSRRRRROE>]ZZ1EW(30&MRODH    5U(  -   EL !H
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MR@X'3PBE!PMO,7.9VO5^>+]W2B)1$HB414SIZ_,TQ/\ +3?^[*%5G]]?\O\
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M,:"R&(14R=Q  .&\11A21804T"2/BA8E!K0B#$^SY?>9N&-G!FG7_O3IMP<
M^-2F-1A;>.'WZ'@E>=.=9;AA&B_">$#2 >!7-QYJ(YLH:Z\'K\OU1M3\N;9,
M[95O4ZN#;2=@G'FHCFRAKKP>OR_4M3\N;9,[9+U.K@VTG8)QYJ(YLH:Z\'K\
MOU+4_+FV3.V2]3JX-M)V"<>:B.;*&NO!Z_+]2U/RYMDSMDO4ZN#;2=@G'FHC
MFRAKKP>OR_4M3\N;9,[9+U.K@VTG8)QYJ(YLH:Z\'K\OU+4_+FV3.V2]3JX-
MM)V"<>:B.;*&NO!Z_+]2U/RYMDSMDO4ZN#;2=@G'FHCFRAKKP>OR_4M3\N;9
M,[9+U.K@VTG8+FP(;>IR<YM$?*"UV\IXQ? 6!4HU78JN\B*1LY]0>6)@=05F
M:R1RYK(?(</(H&FF0L0@PA;'<LA<@0=I<&9BP%Q&<F\9H:>"'R!SA]?^"Q$7
MF:7.-:TYN'0QQ>+7F\I8P_X6/RJ^7)_2QC_ !_HX5SKH6"HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$71ULD6H&88-U#-_"*7N?9V+EAEI
MY+EB1%'.<89)+WDVR=<3C5./W#X+91.VQWC>MUO^6^;O<X;G].[A\BY+RID^
ML?E"D94OBK,$9>Z5N%KH8B0,V]@TD Z;E?SM_3-W8=TG<SEC)$.0LJ2Y/BJL
MFR2U#(X::4221U4C&.)J()2"&DCP2 ?*"M!_#]U?\]J[]B,_L[7VW>AW-^BH
M=I4=LOQO]J_](/PEJ?9<G?@T\/W5_P ]J[]B,_L[3O0[F_14.TJ.V3]J_P#2
M#\):GV7)WX-/#]U?\]J[]B,_L[3O0[F_14.TJ.V3]J_](/PEJ?9<G?@T\/W5
M_P ]J[]B,_L[3O0[F_14.TJ.V3]J_P#2#\):GV7)WX-/#]U?\]J[]B,_L[3O
M0[F_14.TJ.V3]J_](/PEJ?9<G?@T\/W5_P ]J[]B,_L[3O0[F_14.TJ.V3]J
M_P#2#\):GV7)WX-/#]U?\]J[]B,_L[3O0[F_14.TJ.V3]J_](/PEJ?9<G?@U
MW8Z(-<")J.10&4\Q2:),R(1OF=)X[@L0>I$KC_*KS?"OEM8' P[6%6T7#;R*
MY;L^2MDG9"!D/R[NJ[E9<BRFJI0Z7)DK_!=I<^E>XZ(IB!XA.B*4^-H8[P[%
M_P#27]&?])E-W84S<FY2='3=T5-%>2,69%E*)@\*JI&^21HTU-.-+#>6.\1(
MBVKT]?F'AKZL&-^S:=7R51[_ #?./^\K]5I_>(?FV?<%<-15DHB41*(E$2B)
M1%3,R_\ +%GUS,/_ %5"KP<,OS$OW*,W]U\\S^:N:H*R41*(E$2B)1$HB414
MP@?I!2K]4D%_M;/]6=[Q%\Y-]T*@W^L3?-0?ZIU<]15THB41*(E$2B)1$HBI
MG3U^9IB?Y:;_ -V4*K/[Z_Y?Y!2@]Z9\G\RKFJ2JE$2B)1$HB41*(J/GW^JC
M.^O#3]^^EC5:#QG_ #,_\)ZC/XK/GH/XK%>%15DHB41*(E$2B)1$HBAD8?I!
M3+]4D ?M;J)JSO>(OG)ONA46^_R_-P_?,M?MD4CUQ2-$F2<UAW[9:;[V:CP)
MIK!:IE[BN,RWB:B8(MEUM0A(,8J2TREQ1$)$5TL0=Z8(%D(3-FARB87/J1&*
MLM#-26FO5YJ8(Z!VN H&].B\!ISD\MJ#<<?.%X*#:@B7UED0=@DY,T1KR2V5
M%PN9G.<B^245+BLX7"D@Y)Q@ZLV6"9PP$H%CR_%8?S_)0AW*6RY(S>5E)!<L
MFKRVO/?7!DP4),C?3** @KK(GI*:>AEA/L97:Y(R!I]E2%2SJ?4GR)PX*121
M_%OX!OMI"G TY5+*I&"=3.R&:F):DIIM6:WFW2J5JE;[56$IHQYIV=!.+M/A
M.4-5S7<KKP'68D'/,A95$QDPZCDX_EM>?,E$;D3<D8;\TG^F)I$BFX+XV9)X
M$'T 43I<BH"RV^W SS*JW=,;[>9$!/TMRNY&RP#"IWD6FSU)OB:DVW'K0Q.
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MHB41*(E$2B)1%;<&,N4GY*320X:#5,9 Q5"Z@BJ:68%(YM_,B+@,(OG%,/\
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MQ+^E#^CC+/=QE3)M3DNLR73,H,GN@E%?+5QO<^6HED:8Q3T=2"T!MB7.:;\
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M^D/-OFH8^#E,ZW40_:]JF9?YS/\ 8=BG>D=?2'FWS4,?!RF=;J(?M>U3,O\
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MN^G+F(@ G?&IN0V]AX_DN;?*5D/"XU/\_LL>FZ[[96.]W(/H?)WLD/46>_\
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M9HZ.0PC<HS$+LL/(PX"Y[#)$^:HCFD,SS%IU=WA'JXJ["KC,F&2TF; Y](C
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MQY0M #-WTREHAQ=.I)//"[VN#8,B;7UH<++ /$3+)0&L+GGCB%B'G==)8-W
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CW+1:P:.-==+#)%C=+.Z=S\(!<P,+0POT:";W+B?)_CY/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g841346g31k50.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g841346g31k50.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2+Z4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  (#P     $  CA"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             ,@   "K          $                          0
M            JP   ,@                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   ,@     4F=H=&QO;F<   "K    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   #(
M     %)G:'1L;VYG    JP    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $     SA"24T$#      8@P    $   ")    H    9P
M 0&    89P 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ H ") P$B  (1 0,1 ?_=  0 "?_$ 3\   $% 0$! 0$!          ,
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MU5U8LJ<'L=PX*K1E8'5*75P':2^I_P!(>?\ YFQ9EE>3T3)%M1-F':8<T_\
M4N_X3_1O_P (A0.E<,NR;KQ#T"2A5;7=6VVH[F/$M(4TQ<I))))2DDDDE/\
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M1J%NQ\"RZ-99BY5W3+C,$NJ/CW='_&,_2?\ ;BVEB=9'V;/Q,UNFH:_X-/\
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M &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
M( !# %, -@    $ .$))300B      %^34T *@    @ # $   ,    ! *L
M  $!  ,    ! ,@   $"  ,    #    G@$&  ,    !  (   $2  ,    !
M  $   $5  ,    !  ,   $:  4    !    I $;  4    !    K $H  ,
M   !  (   $Q  (    >    M $R  (    4    TH=I  0    !    Z
M 2  "  (  @ #T)    G$  /0D   "<0061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD ,C Q.3HQ,#HP." P.#HR,SHU-      $D   !P    0P,C(Q
MH $  P    '__P  H ( !     $   "KH , !     $   #(          8!
M P #     0 &   !&@ %     0   6X!&P %     0   78!*  #     0 "
M   " 0 $     0   7X" @ $     0              2     $   !(
M 3A"24T#_0      "           _^$!@$U- "H    (  P!   #     0"K
M   ! 0 #     0#(   ! @ #     P   )X!!@ #     0 "   !$@ #
M 0     !%0 #     0 #   !&@ %     0   *0!&P %     0   *P!*  #
M     0 "   !,0 "    '@   +0!,@ "    %    -*':0 $     0   .@
M  $@  @ "  (   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I #(P,3DZ,3 Z,#@@,#@Z,C,Z-30     !)    <    $,#(R
M,: !  ,    !__\  * "  0    !    JZ #  0    !    R          &
M 0,  P    $ !@   1H !0    $   %N 1L !0    $   %V 2@  P    $
M @   @$ !     $   %^ @( !     $              \     !   #P
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M]4IO2+Q^!"#W" <B%9L[>34KU(V8[II"\KDG(!)>1LC)SUQ^@J9N9DLK5G
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MFY'/Z\9^=6A:IM6.FE*:4II2FE*\]^EM5^GZ35_G\OC,=S^[CW///[/KK/\
M9;G_ &>?_P &3_TUI?M+3O\ ;[+_ /=0?_Z5VC62CWX"9B_9O"@'(BU<HN
M/S'T3GXUB9'3\:.G]I67_$"MB.:&7^2EBE_ZN1'_ /*37-Y\<_Q_;_9KK66F
ME*X4DT+(1S]@8>"O63IF8>.>"N4#HB/'GG@#Z[*VUE;^BP;]#FN&&Y2ON"/U
M&*K.V%OS1%[R]378>FZ,DQD$T##\Y/A$H^CG8\?B',BQ ?'R^.?KXM_B<>9;
MV%PO* ,A(' \Q$=>?F5?Y#'SJOZ,VV:ZC;AL*<=_2S+]/WA\_P"_'TWK-W%4
MS)B?(Z9.$2MVC-1?C@J9X28%V!#&#R'*,DX4*'Y$./T =<^'@+BPOK0D9RQ
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M:6-%W;T.4L4#ZI6YIETP*RLGH (=SN,F&QBPDZ!"<&%L()+ F/!NTY@UQ>>
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M K3];4+/PQ2@ G5.V(8KQJ7GR(N61UR%#D/O.PWX:@M$O197T;.?NI?NI.N
M&(VL?[+ $_+]*E=3MOM-JP7^43UICJ2.HZ$\CVK'^RW,2-SHY:%,..VTTM/V
MZ:2QN%WL(!N&ZX <W>91H<3-G < )."<@ :VO$.GFVNOM,8^XN><CG$G&03V
MR/4.>_Y5KZ3>":'R'.)8N-I(R4)])['@G&/D*FUJO5,4TI32E-*5^*ZZ+5%5
MPY5(@W03.LLLH8")I))E[CG.8> *4I0$1$?P = "2 !DG@ =23T ^M"0 2>
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MT_0(G;MGK\NE2T7\%W7YAYFI>-(99CR2L5Y+CW!,SG)^?Y]:]7%]'.QQJ"B
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M/P_^&GGWM]=RBSO=2L%\Q[F1R4DT_3G7.%5=QNKO*JJ*P#K&LCF1^R/IQ5#
MK-ED/+#>/O.:'I0>"JY+[^#I:JW)SMH9-RF!7LK\XE>SCE(RIC=Z3$J#<ZGK
M5_QG\0;K7)'L=*:6RT=#LP#LGO0O ><H?1'QE(5. ,;RS#B^?"?X&:9X.AAU
MKQ(D&L>*I )=[CS;/2F<9,=HL@'FW."!+=R*6R"L01"VZT@
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MFZC&O,MJ^/N+HKNC('J$HRUS6U3=?CO=50F]DJSI-C96**2-QICE8/BE=D#
M)3 )#" NHUP8HG92"0&263'L.)'!%$B^0>)_"^H>&+YK:Z4O;R%C:7:C[JYC
MX([>F1<XDC.&4CH1@U]3_#KXC:'\1=&34--E6*^A54U/2Y&'VFQG(Y!7_20.
M>8ITRCJ<$APRB*V>\-VS =\3SCAY-5M!"]4?2T:R3$4(-=TH;WC55HCZ??79
M$IQ+Z( 9-F)SMRE30!#MWM,OX-4MCIFH%3)M"1.W!DQC!WDG$R #!(]0' SG
M,[?6DMC.+RS]$>2611Z48]<KP/+;G.,E<\#&,3(P=N'IN;84J2:C>+M*2 $F
M:PZ4)ZH")0*JNR]7Y7K!7D>T2]QR (IK$[BB(U_4M*NM-D]0+P[O1.F0,]5#
M8Y4CY]>HZ5+6=_#>)@<2 8=#[X&<>ZG/M\JQ+F#9%2;JN[G:"Z)1K N8RQX]
M-$#UATX'R)P:I%]Q$F.;DQSL06;\_*1@0#G,._8>([JU BN!]IA'&3CSE4XS
MZB/7TQAN3W;' UKK1X9<M;GR'[@?R9YSG _ ?8J. 3@<G. V]/WSXJ_F$%*3
MMAB&W"38K:0BK<S,@GP4A6[:9([DV2)2E "(D(V$H#P4H!SQ*-<>&;WURQQP
M2$Y.(W@;..KF+"-[YR<GY]= 0ZS;#;&TCJO"^N.4?(A6#,!^AYP1TQRSWS?O
M*A[-&N3L8<QNSW1*=$M3<<  G%9^U60)]>0,!2B _,40\:?9O"R'>TZ.,_A\
M]ST!.=J8<YZ8Z\<UV\[6B0!'(.V?+0=NIW#'_"OK';3=P.6I)O(YJO#M@P3.
M"@)24P-A?H$-^L6+B6RQHB.$Y1$#$!5H!.1$4CF$2CUEUS2[)2NFVJL_0,L2
M1Q\=V8KYS9[9W]^GI-%TR]NGW7DQ"]<%MQ'0>E =H) ]UX]^E3QQEAS&V#8-
M<E>9(-%?;@>:M,NH@I+/BI !CG>/SE3*W:E,4#E:-B(-"B!3BF=;E4U9O+^\
MU.0&5B3^Y#&&V*3[+DDM@8RQR0.>,BIFWM+:R0^6 HZM(Y&>![\ #'90!U[U
M";<)N7E\FR7^1K!Q'DH276".F)N-!0KB6!03IJQD6H7M,C&F#@7[\PID62 R
M0'!N*HJV/2=(CM$.HZEMC$0\R.-R,+@9#..[']U>QQW.!$7^H/<-]ELPS;B5
M:1>K=057V'])N01GM4IMNN#(; U,<+R:K92URS9-[;9U4Y2MVR3<#J)Q;58_
M:"4;&E$RBBIQ 7+@ZKE0WI@@DWA=5U.;5;D!5;R$.RWB _$6.TL5R29'.,#G
M (4<Y)D+*TBTZ!Y)756VEYI6("(BY)&]NBJ!EV)P3S53V\[?!=\_7$^UG:8+
M^5;3#L8*RVR %9-]9%_5.D]AX)Z0R8-8!$I#?%)?N(5RB"A$%BMA,L;UWP?X
M+L]#M/\ XF\5&.!H%$\%K<;=ENG&V6:,\O<'(\N'G:2"1NX'R1\4_BUJWC+5
M&^'7PW$]R+J0VE_J=EN$MX^XK+:VDP(\NT4 _:;G]],JAV98SUV/[%*?M7KI
M+!,$:6+,$XR*G.V0R1%$8-JL"2BE?KHG*)F[,BA"^]>%$J\BJ0!4-[=)!,E&
M\:>-KOQ/<-!$7M])@<F"V!VF=@3BXN"O+.<G8A.V,$X!8LQ]B^$OPBTWX>V(
MO;P17_B>\C_CE^5#K:(X4M96)892,,H\V7\<SCD[%118)JB5[132E-*4TI32
ME-*4TI32E=7,PL58HF0@IV.:2T/*M5F,C&OD2+M'C1P42*H+HJ )#D,0>/(<
M@( 8HE, "'>&66WE2>"1HI8W62.1&*NC@Y#*<\8//ZC%:]U:V][;S6EY!%<V
MUQ&T4\$R!XI8W&&5E;(((/U'4'(S6O-N6VFY9V*9%+N;VNO9!>A,GHNIN"3]
M5VK7&;A3N>1L\S3 H2U-<B(IG5-RJPY14.*0HE=I^]^'?%.F>-M./AOQ+'$M
M^\6R"=L+]ID&=DD#DXBO$&#_ $9%5E .=K?%'CSX;^(_A!KG_P P/A]-,^C0
MS"6\LN9#81R,3+#>1J!]ITMB<!CEH"5R5"[Q:1M)WL8NW:50D:<64%D-%@1*
MTT&361/[DPHE*[=P8K&_SK$JF$Y@*(>Z;D'M<)<%,IKS/Q7X-U+PM<EB&N-/
M9R;>^B!PHSZ5GQ_)3#CN%;JIZ"OH7X9?%G0?B-IZ(&CL->BB3[?I$L@W,^T>
M9+9%B#<6Q.2,#S%&=Z\;CXW+^RYVC*J7;!\D>!ETEC/?@!G:C-,BX"*AC0SU
M(.]N)A\ U6Y3-W=H&[1X#7L?$0:,6VI(9HSZ?-VY.#_K!T8#'XA_QS5[N])8
M-YUF=C@Y";B,?-6'(Y_=^?!%>!K>[W,6)WB58S13'4H1F8&QWZ[<\7,F*3^L
M5T/,9)#V\B95,P<  !QR!@UN2Z!87Z^=IMPJEOW =Z9QG)'XT&2!@YY(QFL$
M>JW5J1'>1,PR1N*[6&.^?PL, YYSFI)P.^#",ND07[R;@%QX]1*1C.Y(G)>1
M[7#=90J@ /("($+^?'&H:7P[J4;$*B2XR/NVZ_/! /\ ?WYJ136+-NI=.<>I
M?E\C]>WUQSCU#C=_@-!(52W,KC@!$4F[%V=;^!#ID ?/C]8/.L*Z%J;-M^S$
M>Y8J .W)SQ^A[CKTRG5+$?Z;)]@K9_P _O\ K6&KCO\ J%'HJHTNMS=@?#R5
M%:2(G%,"G\ !E2@HLY.F81X $P X_7C4A;^%[IV7[1+'$IZ[26;![\@+V[]^
M/G6I+K<"\1([DC@MA5S['!)]\8ZXXK!AV^Y[=BY(D\25J5%.IR<#IN(B#*EW
M=P=R1_Y_,*]@_=B( W4[0^@ASJ1SHVAJ2G\9N0,+RKOD#!Y_#&ISUSGVK2(U
M'4R ?NHNN,;4QG@\C+GCCMFIN8QPSB[;55Y&POY!B@X:,3NK%=I]5NU*@W2)
MWK)H**]I&3,#!R1%,167.)2")SB4FJ_=7M_K5Q';QQNY=PL%K"&8LQX' Y9L
M8Y(P #]:D2-.T*SFO;RXAM;>WC:2XO+EUC2.-1EB7; 4?(<L<#U'%4\[H=YV
M2-YUX)M@VI1LL>JRKDS2=LC<JS-Y:6R"@@Z6<.2#_F2FM *59THKVN)$.Q,W
M!54FJ_LGAKP?IWA"S/B7Q1+&+F%0\-N=K1VSL/2BJ?Y>\(R% ],9R1RI=?CW
MX@_%/7?BEJX^'_PX@N&T^XD,=[?(&CDU&-?Y0O(.;338P=[NV&FP%)&X1M9O
MLOV24C:G5$W"A6MBRC,-4OTFMIT2B#4QR%%6'@!.0%&L6D?DIE!X7=B BJ($
MX3UYMXO\8WOBBZ(RT&G1.?L]J"?5SQ-/SAI2/R3H*]^^%GPHTGX=::K$1WOB
M"YC7]H:D5!V$@9M;/(#1VZ$8W</*?4_&!4Y=4RO6Z:4II2FE*:4II2FE*:4I
MI2FE*X[MJV?-5V;QNB[:.DCMW+9RF15!=!4.Q5-5,X&(HF8@F Q#%$#!X'7*
MLR,KH2K*P964D,K9R"".00>XZ5CECCFC>*5$DBD5DDCD 9'1AAE=2"&4J2""
M,$<&J1=UG3$FHNQK9JV?/3U6T,'!IEQCYE(*17<_*H=91Y2I$3E2CW!^X0^"
M.U48Y7@"-5F8\IJ^R^&/B5%);#1?%L8NK20+$M^Z+*0FTKLO$(+2(/3]\BF7
MJ6#G!'R?\1?@!=6U^WBSX8ROIVI0N;E]%AG-MF;=N>729LA89#D_Q61UA;\,
M31_A/D<&=5JYXRD1QCO"HUE;S,,JFP=VEI"_#+/']O:F!K-67OL"/"E#E0TA
M'F1652$JI6[XY^\=S6OAA9ZC'^TO"5];/#*OF+:O,'MWX)/V:X7>5YP!'(#@
MYRR 8J*\)?PC-5\/SKH'Q.T?4([FW=8)=2CM?L]_!^Z&U&QF,*R?TFF@(9E]
M024L#5M%&SAMLW'QA&M0O>/,A$>(@96NKO6 V%%(P=W#NKRA6\^T#D!+RO'I
M$,)3=AS@ B/E-_H>OZ"Y-[87]CM; G\M_LY(Y]%S'N@? ]7$C8X! '3Z;T#Q
MMX-\7Q*="U_2=49ADVJ7,:WJ C'WEA,4NX^3M]<*@G.">_736T' $VJ=8]'1
MCU#B(C\'DI2*2+SY^5NR=HHAQ_5 2<  _3P :Q1Z]JB+@7)8=#O1')^I=2?\
MY[U/-I=BW^A _LLR#]%(']W_  KSK?9#@)%0#*P,PZ3#SZ*MDF2$_8 ^B[3.
M8/K]3_@'//&LQ\2:KMVB6,9ZD0QY/YD8_P ^PK&-'L>\;$#H#))_ZOR_R,9%
MBL,8&Q6U4L!*O4:ZUCB^LO8K NW C,@#QWN):;7,1%/GZF57*7D"^>>.-1KW
M5-080B6YN7<X6&$,Y?GH(XER3GC 4\UVDCTK3(7NKAK6S@B :2YNI8XHHP.A
M>:=@B#GJS#KC-12SEU0-L6'6CF/JD^GERS(E42:Q&/U6[N!16)R!0>VL!^"%
M;E'];X0I++E /F0*!@/JX:)\-?$NKNCW-LVE6I(+SWZLDVWOLM3B8L./Y41+
MSG=V/COC#^$#\/\ PQ%+%87Z^)=14%4M=&99K17P=OG:B/XH$X.?LSW+\8*+
MUJL8J.]7JAV%$ZZ1\?8,;/3'(Z40?QM'8ID4[#>S*)0>7:=(D8?(*JMD5"B1
M=Q'$$I#>D;O!GPUMR ?VAKK18959'O6+#C=GT64!(Y](8@\"3K7@ 7XL?P@;
M]696T/P?')E9666#28U!ZQ+CS=5N]AQG>R*3AVA&U3>!MEVGXJVM5(("AQ8.
M)M\DC^DMRDBD6L%B<I<B!G3@"E*V:)G,<6T>S(BT0[A,"0J&.<WB_B/Q1JGB
M:Z,]_+B%&/V>RC)%O;*>RKD[G(_%(V6;IP,"OK7P#\.?#GP]TQ;+1[??=R(H
MO]5G :]OI%).Z20<)&"3LAC"QJ/W=Q),G-5VK]32E-*4TI32E-*4TI32E-*4
MTI32E-*4XUQ@>V?KS2L+9@V[86SU&A&Y7Q[7[9Z29DF4HY:^UL$8!N?]66!B
M9M,,2@8>X44'A6ZH\ NBJ7Y=3.DZ_K&AR&32]0N+0,0TD2-NMY2/];;N&B<]
MMQ3< 3@BJKXG\$^%?&-N+?Q'HEEJ052L4\L>R\@SG^0O(BES$,G.Q90C'\2,
M.*JLR7T7*,^77D,0Y7L%76%05FL/;V+><:HGY[R E.1A8U^@FB<I02]2.>K]
MO!CKG53(<?3=.^,%\BK%JNEV]TO"M+:R/ 2O<M!)YL;LPY.)(@2!C )!^==?
M_@JZ1,[3^&?$E]IS EH;34H8[N)&/*D7< @F4(0 NZ&5MN,L64$X='I\=1FA
M?S2@[BI-2-1Y*W1K.9+]74/1 0$A09.U8M @\  "GVB0/  8>-2Y\=_#V] >
M]T",2MPQN-'L)F [X=/-8\\XS[XQ5<_^2_QPT;$>C^.+AX!^Y8>)]:LT P,8
MAD:",=,8 (]\@5]?Y'O58DQ]H^SY>&Z!_!E5L_68J8%\?T@1TV==0O \=HE-
M]/(#H/%OPOBY70K)SUP-!M]W? )>)5]^^.!W-=#\,?X15P/*E\9:NB-D,\GC
M*^Q[=(+PL003\Q^>*[*,Z1&?K^_0?YOW"L7!.\#F4(^M5^FFX<\&$HV$\:S%
M4Q. [BOU0   .1\AK%)\5="T]"FBZ R']WT6UA$V!Z<B 3$C)8E3&/[^-B#^
M#3XSUJ=)O%GC9)%.2Y6?4-7N4)!!*B],,18C&&\XXY/7@SPPMTM]KN)EVDI-
M03_+$^U,FJF\R"HV?0R*Y #YVU6:MV\0H3NY,1.7+,&3'@2J]Q2"6DZS\2_$
MVK(T,<T>F0,,%+%2LS+[-=.6F^1\HP@C(P <5Z]X4_@]?#SPT8Y[JRE\1WD9
M5A+K12:U5USZDTZ-$M2,\@7*W)!P0<@&K%6;-G'M4&+!JV8LFJ1$&K-F@DV:
MMD4P J:*#=$I$D4B% "D33(4A0  * !KS]F=V9Y':1W)9G=BS,3U)9B2?S)/
MSKW&**.&-(H8TBBC4)'%$BQQQHHPJHB@*JJ. J@ #@"N3KBN]-*4TI32E-*4
MTI32E-*4TI32E-*4TI32E8%W/[A*CM3P)D[<+?&,O)U#%=:=6B>8P222\NY8
M-#ID438I+J))'7'U [2G4*'@?.MJRM)+ZZAM(BHDG<(I;.W)]\9K!<W"6L$E
MQ("4B4LVWDX'L.]8,Z?W4 Q)U%<1S69,.P=M@:Y!VQW3W32X-&K.1/(LVK=V
MJJDFT<.4S-Q3<D IA.!NX!#CQK9U72KC2+A;:Y:-I&02#RR2H4G R2!SQ6"P
MOXM0A,\(95#%,.,'(QGIGCGBO2;[=[.,]@&!'FX7+4199NGL;57*DNRJ;9L[
MEQ?V91VDR5(BZ7;)"@F=H?UC>IW% Q>TIM=-+TVXU:[%I;%!(8Y),N2!MC&3
MT!.22,5VOKV*P@-Q,&*!E4[!DY;@<?6O8[/MTE%WH;=\>;D\:QTY$TO)#>;<
MPK"R((MIEN2"L4M6G0/46ZJZ)#'>P[A1+L5-RB9,P\&$2ACU"QFTV\FLIRIE
MA*ABF2OK177!./W6&>.O>N]G=1WMM'<Q!A'+N*AOQ>EV0Y_-34F-:=;--*4T
MI32E-*4TI32E-*4TI32E-*4TI32E-*4'GCQ]?PY^FE*?N_\ W_XAI_C2FE*J
MXZU/CI;;T1_]C4Y_]YKJ<\-_SYIO_:H_\:C-9_FR\_ZES^@S59GV5'SL)R,/
MYYVGO[H6+U,>.?YUBYS_ !=?_,?I4;X7&-/?_KW_ ,%K,'VGK_9:6+_CCB#_
M +[-?X_QQK%X(YUZ,>]M<_W*I!'T(%9?$W\UO\IH2/\ O?\ +/\ GFI"_9_/
M]DEM+$?QB\E#_P#-^_ '']G[?WZT_%O_ .(-1_MPY_\  B_S_D5G\/\ \TVG
MTE__ )I*N5U7*F::4II2FE*:4II2FE*:4II2FE*:4II2FE*:4J&&]W?IMVV!
M8H=94SY;2122XJM*I48T@/K?=YDJ8G2B*Y$%.51PJ;CN</%SH1[! IW#UT@D
M0QM2&FZ7>:K/Y%I'N(P9')Q'$N<;G8XP.P R2<8!Z5IWM];V$7FW#8'15'XG
M/LH]_K@#N:U#;_\ :5>HON,N#ZO[*=L]7KL 5PL2,34IMJRY?5T"G$J*T@ZC
MI&+K,<JHF9,ZC%.(D/14'M3D7!!Y'T*+P7H]G$'U/4)#)QGUQP0ANX *L[CV
M.]?F.U5.3Q)J$[[;*UC"G.W*O,Y^NTJ%..Q^N:^D-U_>L5MFE(^6W7[6X&QT
M-5PF:22LF*KEB^9.U >]4L7:XZ0=PD<IZ(*"4\E69%,PE+Y( &[N'\*>';V,
MC3K]A/T79<1S*6ST:,J&;CL'4]^>!7 U[5[4@W5H&0D<O&\+$'L&R4'']4]O
M< VR[ENIQMQZD71NWJVW$$LO"7:OX5DR9"Q39#(M[?37JQF?WIDTCG;S$$X5
M[@CYV,479KE#TE_;/B+M$8"TT6]T7Q%ID=PJLCW2&*9,F.50><9P58=T8 C!
MZC!,M<ZE;ZCI%X\!(=8"9(CPZ$CGWR.P89'Y\5TGV5'_ *A&1O\ CM/?_AHO
M7?QSD:K%_P!F3&#GN?T^F./\./"_&GMT(\YN0>^!_GWK,'VGG_9:6/\ XX8@
M_P"^S7 ?LY'@.?PYYU@\$'&O1'C_ */<=>.JJ/\ C63Q-_-3_P#70YX^9_3G
MN<^W?-8&Z?74@VX=.GHC;2[UFZPJ+V"6A\HIT?&M?!)[=+N_2R]?0%&*8F43
M3:L$5#![R8D5&T<T(!O47]3M(;9U?2+[6?$U_%;1$1AH3+._$<2F"(Y8XR2<
MX"KDGL*UM.U&WT[1+629LLPE\N(?C<^=(,8_=Z9.[H/?K4 9#KR=8[=M)R#O
M9+LX91E'1<* Q4@\87/+%F]#N'T3/K L_BZXH)TQ3.JBSK@ D<3%*\5* #J5
M'A;P[8!!J>IYF/XE,T<*@]\*-SD#L2>>. :TCKNKW9_B5GA.^(I)6![>L$)D
MCL%./F.O0Q7VA+JR;2+='1V^+:I R-67<)@^:3N.;=B"Y"B8Q2'&+GQDI*M"
MHF4PJ$:.ZV8SHY2)@\;E,8X96\(Z!J"$Z5J#AP."LL5Q$#@D;DVI)SM;+!\
M=C@ ]1K^K6; 7UH-FX @QO$YSSPY)0<<XVD_2MKS81U&-N'41Q>&0L&V-0DO
M%%;(7G'5@*DQNM'E%TBG]K+1Y554G+-01,#.8C%GD4\[#E1="JFJF2@ZKI-[
MI$YAND&#S%*AS'*/=2<8XZJV&'<5:K#4;?4(_,@8Y&-\;<.A/N.X]F'I/8U,
M/(+JXL:+<GN/&,5*7QE6)QY38N<,NE#R=G;1KE>$C9-9LHDN@Q?R*;=HY71.
M"C=)8RP=W9VC'Q>69(Q*66(NGF,H]00L Q&>,@'(!ZFMN0N$<Q@,X4E0> 6
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MX6UU=65+'4 LMW;!9K:5L R",YW$G'WJ]<C&1DD<51-=TL6!^TV8,=O-F.5
M20IDXX'] ] #G!QCKQ<!]E1Y'83D81^O^7:>^G_N:+U7O'>#JT6/]F4_JQ_S
M]<U,^%^-/;_KF_P'3Y&LP_:>.?\ DM+'Q_VWXA_#GZO)H/X?7\P_+D.=:W@G
M^?8O^SW'Y9"@']<5D\39_94GMYT.[YC?_P"K'/;Z5K^] _I;([_)A#<#N>=2
MMIVX;>7@T'&] D';GX79K&#QQ;GT&5,>"HU2'?6!27F$&IDUI"1DVZ!U/2%0
M26WQ7KITD-:6 6.[O,33R@>I4P(PWOO94PN>%"YQDY-?T#3?MY\^ZRUO;_=Q
M1G.&)&]E]MH9LG'4DJ3Q6_W5ZI6:1!1U7IU?AZO7(=LFTBX* C6D5%,&R10(
M1)JR9)(MTB@4H=W:3N,(=QQ$PB(^3L[R,SR.TCLQ)9R68D\\DDD]:ORJJ (H
M"J!@*H   P.   *\?F'"^+,_4*=QCF.C5W(-%L;-9E*U^R1R#]J<JR9DP<-3
MJE%9@^1*8PMG[)1!XW./<BN0>><EO<SVLJSV\KPRH05=&*G@YP<=5/=3D'N*
MZ30Q3QM%,BR(PP589'_O['L:T!-TF'\F?9\.ICCW*^%)>9?[?KZ\6GJXS?.'
M"R<Q0G,@5G<L96<R0(MY![7T5TW$4Z4*519(\>[*4KANN8/5K*XA\7:++!<*
MBW< V,0!E9=I,4\?7:LA&UAP <CIBJ'=0R:!J44L+'[,YRJ=C'D!XVY 8H"6
M7.>@.0>:_H+8WOM?RE0:9DBJ.R/:W>:S#6B%<$,4X'83+%%\@!C$$2BHD5;T
M5@*(@55,Y0'QKR>:*2"5X9!AXG:-Q[%20>W?';L:OT<BRQI*ARLBJZGY,,C_
M !K1EZKU)L?2>ZT.&M^>.HU9OC/,UF3R<[9,BBW9.IE1,E3SY2CBF!$2C/Q,
MT:QI@I\B![:4R!>Y@42>GZ!(FO>&[G2)>9[:,PKG&0/Y2UFR23Z641GW*'KG
M%4?5D;2=9AU"-?NI6\PJ.-S#TSQYZ#>&W <8W9'3C>FHUTKF1Z74L@T^21F*
MG>*W"6VM2K<0,C(P5AC6TM%/"<"/ .&3M%02B/<03"0W!BB&O+Y(VBD>)QAX
MW9''LRL58?D0:O*.LB+(ARKJ&4CH589!_,&HT;]-T\#LPVF9JW#SBS?W%'J+
MW]$V"PEYF+Q+$&+J,85(3%,N16:<MG+Q-,?5"-:OE2?T6MS2[%]2O[:S0'[V
M0;R/W8UYD;OT4''&,D5K7UTME:S7+<^6GI7CU.>%';J2,\] >E:O7V6[:[/Y
M OVX_J,9307EI><EI;&6.9N6*==Y(V6?=I6C+=M277+WJ+ F[@ZZWD$3\*#(
MVADKR9,W%X\<WJ0I::- <+&JS2J#@*BJ([9"!Q^Z[XQQZ*J_A>V>66ZU&;DL
MS1QDCJS8:5L\]!L4$<D%A@8.=T77G%7.FE*:4II2FE*KFZNUFEJCTQ]\4S"*
MJH2!MNV084BR B55)K9XP:S(J$.' D,2.EW9@. @)..X! 0#4MH*"36M,4]/
MMD+8/0F-O,4?/)4#!R#T(P34?JK,NFWI7\7V>4#C.-RE<G@],]:I3^R742 C
M]J.X[)*#=O\ I+9\XL:D_<\%%T2'J--B9..;B/ZR:*CNUR"HE 0*H<A1$!],
MHA9_'\K'4+. GTI:>8 .!NED8,1CK_)CGG . :A?"B 6MS)P6:<(3WPB+CGV
M]1[#WYK;%U0JM5-*55[UH:/"WWI@;QHR;0162B,13-LCS+E Q&TU5UFTS$N@
MY_5.@]:I*%,'D!#D-37AQVBUO32A()N40XY.U\JPY]U)'O@\5&:R@?3+P''$
M+,,C/*\@_D1D?.JQ_LJ/_4)R/_QVGOW?ZFB_IX#G]_X_D&IOQW_.\?3_ *,O
M3V#'_/3Y]ZC?"V?V>^?]>V/IM7YG].U9@^T]#QTL['YX_P"?#$ #^WE[->/H
M/U'C]WUU@\$Y_;L>#C^+7'_E!_QQ67Q-G]EMC_7PY'7(R>/UP?RJ2?0/IT'4
M.E#M0&&;((K6BOW"W3KA$"@+^;E,@VILLX7$O@ZS=@PCXP3CY%*/2 WS%'6G
MXK=GU_4 W2-XXUR2<*(D/?W+$_GTK9T)%32K3;^\KN<<Y+2/S^F/ITJX?5=Q
M4O32E:P_VJ>@UZ?V&4:\/T$/C]"S173P;KM*5SZ=A:NX60:E5\&,@=!T*YT?
M)!41(IV]Q"B%V\"R.NK21 MLFMG# <@;?6"?TQ^=5GQ2BFP1R!N29<''9@0?
MRYSCW[581T+K7+6[I<;57<RJHNYBJ:XKR*RQC'4491$FZ0:F,<WS'^[-V@81
M'Y0 .> #41XHC6+7+\*  TN_ Z98 G'_ -N/SJ0T1BVEVA8DD1[>?ZI(']U>
M Z^VS0^\'IYY("N0YI7*.!UD\W8X(W2,K(.U:PW<(W2OM 2 7#A2>I#J<29L
M"#V.IUI!G, F;)B7-X4U+]G:O"78""[!M9LG"J)"#'(W8!) I+?NH6QUK'KU
MF;NP?:"98#Y\>!DDJ#N4>^Y"<#NV!46/LRF] ,];-7^W>U3!7=_VRRA8:);N
M%BF>/,6SG\\KK@A3&,X62A)121B%5C\)MVRT.T3*4" &MWQKIGV/4OM4:X@O
M5WY X$X_'G &-P*L!WPQ]R=7PU>_:+,V[L/,M3L"]_*_=/N<$X^7 R:@!]J
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M&V\R&.X+B,N6VNX" Y9. ,XQGCWKU&^W!V^[/^WJW0&<X+83C"'@4(R;K6<
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..1KM2-51%]E48 _2O_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
